<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004322.pub2" GROUP_ID="COLOCA" ID="688102111810204788" MERGED_FROM="" MODIFIED="2012-07-09 11:21:12 +0100" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Dear Editors;&lt;/p&gt;&lt;p&gt;Hope you will enjoy reading our article.&lt;/p&gt;&lt;p&gt;Figure 1.4. regarding Bleeding Scores, two studies (Belcaro 2010) and (La Torre 2004) had a Mean Value and Standard Deviation which were both zero (0). These were values which were presented to us in the studies. Unfortunatley the software was not able to computerize these values and so the outcome was non-estimatable. Perhaps you could advise us ?&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-07-09 12:17:47 +0200" NOTES_MODIFIED_BY="Henning Keinke Andersen" REVIEW_NO="150" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2012-07-06 15:14:26 +0200" MODIFIED_BY="Henning Keinke Andersen">
<TITLE MODIFIED="2010-11-15 21:55:22 +0100" MODIFIED_BY="Nirmal Perera">Phlebotonics for haemorrhoids</TITLE>
<CONTACT>
<PERSON ID="42567338409615470280101004144716" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Nirmal</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Perera</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Doctor</POSITION>
<EMAIL_1>perera.nirmal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Medicine</DEPARTMENT>
<ORGANISATION>Addenbrookes Hospital</ORGANISATION>
<ADDRESS_1>Hills road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cambridge</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>07862715124 (+44)</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-07-06 15:14:26 +0200" MODIFIED_BY="Henning Keinke Andersen">
<PERSON ID="42567338409615470280101004144716" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Nirmal</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Perera</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Doctor</POSITION>
<EMAIL_1>perera.nirmal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Medicine</DEPARTMENT>
<ORGANISATION>Addenbrookes Hospital</ORGANISATION>
<ADDRESS_1>Hills road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cambridge</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>07862715124 (+44)</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="36247086114749079201101004145125" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Danae</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Liolitsa</LAST_NAME>
<SUFFIX/>
<POSITION>Dr (MBBS, PhD)</POSITION>
<EMAIL_1>dliolitsa@aol.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Barts and The London NHS Trust</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="81254047862732695247110817104458" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Satheesh</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Iype</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>satheeshiype@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Ipswich Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ipswich</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="36387270972746134643110524130332" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anna</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Croxford</LAST_NAME>
<SUFFIX/>
<POSITION>General Surgeon</POSITION>
<EMAIL_1>dr.anna.croxford@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Queen Elizabeth's Hospital</ORGANISATION>
<ADDRESS_1>Gayton Road, Kings Lynn</ADDRESS_1>
<ADDRESS_2/>
<CITY>Norfolk</CITY>
<ZIP>PE30 4ET</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="00569214986061446851110524130114" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Muhammed</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Yassin</LAST_NAME>
<SUFFIX/>
<POSITION>General Surgeon</POSITION>
<EMAIL_1>mgyassinali@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Queen Elizabeth's Hospital</ORGANISATION>
<ADDRESS_1>Gayton Road, Kings Lynn</ADDRESS_1>
<ADDRESS_2/>
<CITY>Norfolk</CITY>
<ZIP>PE30 4ET</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="84074954421425804733101004145516" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lang</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Doctor</POSITION>
<EMAIL_1>peter.lang03@imperial.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of General Surgery</DEPARTMENT>
<ORGANISATION>Brighton and Sussex University Hospitals</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Brighton</CITY>
<ZIP>BN2 5BE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="21738031539462427756101004144943" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Obioha</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ukaegbu</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Doctor</POSITION>
<EMAIL_1>ukaegbuobioha@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Medicine</DEPARTMENT>
<ORGANISATION>North Middlesex Hospital</ORGANISATION>
<ADDRESS_1>Sterling way</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="98379399472857671780120118104916" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Christopher</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>van Issum</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>vanissu0@me.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Faculte de Medecine</DEPARTMENT>
<ORGANISATION>Universite de Geneve</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Geneve</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-07-05 15:07:27 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="7" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="1" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2012-03-21 11:18:51 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-21 11:18:51 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>For editors</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-12-14 11:21:10 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-12-14 11:21:10 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-10-26 01:04:22 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-10-26 01:04:13 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-10-26 01:04:13 +0200" MODIFIED_BY="[Empty name]">
<NAME>Ipswich Hospital Library, NHS</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-10-26 01:04:22 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-02-20 19:57:04 +0100" MODIFIED_BY="[Empty name]">
<NAME>Kings Lynn Hospital Library NHS trust</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-07-09 12:15:01 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-07-06 15:18:40 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-10-27 02:23:29 +0200" MODIFIED_BY="[Empty name]">Phlebotonics for haemorrhoids</TITLE>
<SUMMARY_BODY MODIFIED="2012-07-06 15:18:40 +0200" MODIFIED_BY="[Empty name]">
<P>Haemorrhoids are among the most common benign anorectal pathologies which usually manifest with the common symptoms and signs of bleeding, pain, pruritus, swelling and discharge. The prevalence can vary from 4.4% in the general population to 36.4% in general practice. However their true prevalence will inevitably be underestimated due to the under-reporting of these symptoms. Medical and conservative management with high-fibre diets, stool softeners and laxatives are the preferred treatments for grade I-II haemorrhoids whereas surgical procedures such as haemorrhoidectomy are reserved for the more severe forms of haemorrhoids.  Phlebotonics are a heterogeneous class of drugs used to treat haemorrhoidal disease in the less severe stages of first and second-degree haemorrhoids, and during the thrombosis episodes. Although their true mechanism of action has not been well established, they are associated with strengthening of blood vessel walls, increasing venous tone, lymphatic drainage and normalizing capillary permeability. We considered twenty four studies for inclusion in this review. This review identified twenty randomised controlled trials enrolling a total of (2334) participants which compared an intervention using phlebotonics with a control intervention. Of these twenty studies, one study compared phlebotonics with a medical intervention and another with rubber band ligation. Of the remaining four trials, we identified two trials which compared phlebotonics with each other, one trial which compared phlebotonics with herbal therapy and one trial which compared phlebotonics with infrared photocoagulation. The trials obtained did not show any significant adverse events or side-effects from the use of phlebotonics. The studies demonstrated a beneficial effect of phlebotonics in treating the symptoms and signs of haemorrhoidal disease as well as symptom relief post-haemorrhoidectomy.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-07-05 15:48:02 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-07-05 15:48:02 +0200" MODIFIED_BY="[Empty name]">
<P>Haemorrhoids are variceal dilatations of the anal and perianal venous plexus and often develop secondary to the persistently elevated venous pressure within the haemorrhoidal plexus (<A HREF="Kumar 2005">Kumar 2005</A>). Phlebotonics are a heterogenous class of drugs consisting of plant extracts (i.e. flavonoids) and synthetic compounds (i.e. calcium dobesilate). Although their precise mechanism of action has not been fully established, they are known to improve venous tone, stabilize capillary permeability and increase lymphatic drainage. They have been used to treat a variety of conditions including chronic venous insufficiency, lymphoedema and haemorrhoids.</P>
<P>Numerous trials assessing the effect of phlebotonics in treating the symptoms and signs of haemorrhoidal disease suggest that there is a potential benefit.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-01-28 21:03:58 +0100" MODIFIED_BY="[Empty name]">
<P>The aim of this review was to investigate the efficacy of phlebotonics in alleviating the signs, symptoms and severity of haemorrhoidal disease and verify their effect post-haemorrhoidectomy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-03-21 11:20:00 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library 2011 issue 9 , MEDLINE (1950 to September 2011) and EMBASE (1974 to September 2011).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-07-02 00:52:56 +0200" MODIFIED_BY="[Empty name]">
<P>Only randomised controlled trials evaluating the use of phlebotonics in treating haemorrhoidal disease were used. No cross-over or cluster-randomized trials were included for analysis and any trial which had a quasi-random method of allocation was excluded.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-02-12 14:07:48 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted the data and analysed the eligibility of the data for inclusion. Disagreements were resolved by meaningful discussion.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-07-05 14:46:33 +0200" MODIFIED_BY="[Empty name]">
<P>We considered twenty-four studies for inclusion in the final analysis. Twenty of these studies (enrolling a total of 2344 participants) evaluated the use of phlebotonics versus a control intervention. One of these twenty studies evaluated the use of phlebotonics with a medical intervention and another study with rubber band ligation.</P>
<P>The remaining four studies included two which compared different forms of phlebotonics with each other, one study which evaluated phlebotonics with a medical intervention and one study which compared the use of phlebotonics with infrared photocoagulation. Eight studies were excluded for various reasons including poor methodological quality.</P>
<P>Phlebotonics demonstrated a statistically significant beneficial effect for the outcomes of  pruritus (OR 0.23; 95% CI 0.07 to 0.79) (P=0.02), bleeding (OR 0.12; 95% CI 0.04 to 0.37) (P=0.0002), bleeding post-haemorrhoidectomy (OR 0.18; 95% 0.06 to 0.58)(P=0.004), discharge and leakage (OR 0.12; 95% CI 0.04 to 0.42) (P=0.0008) and overall symptom improvement (OR 15.99 95% CI 5.97 to 42.84) (P&lt; 0.00001), in comparison with a control intervention. Although beneficial they did not show a statistically significant effect compared with a control intervention for pain (OR 0.11; 95% CI 0.01 to 1.11) (P=0.06), pain scores post-haemorrhoidectomy (SMD -1.04; 95% CI -3.21 to 1.12 ) (P= 0.35) or post-operative analgesic consumption (OR 0.54; 95% CI 0.30 to 0.99)(P=0.05).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-06-25 16:35:21 +0200" MODIFIED_BY="[Empty name]">
<P>The evidence suggests that there is a potential benefit in using phlebotonics in treating haemorrhoidal disease as well as a benefit in alleviating post-haemorrhoidectomy symptoms. Outcomes such as bleeding and overall symptom improvement show a statistically significant beneficial effect and there were few concerns regarding their overall safety from the evidence presented in the clinical trials.</P>
<P>However methodological limitations were encountered. In order to enhance our conclusion further, more robust clinical trials which take into account these limitations will need to be performed in the future.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-07-09 12:14:22 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-07-06 15:19:02 +0200" MODIFIED_BY="[Empty name]">
<P>Haemorrhoids are among the most common anorectal pathologies blamed for many anorectal complaints by both patients and medical practitioners alike. Although ambiguity often arises when defining haemorrhoids, for the purposes of this review haemorrhoids refer specifically to the pathological presence of circular venous type cushions present in and around the anal canal. They consist of a vascular circular-like cushion and are found within the subepithelial space of the anal canal. Haemorrhoids consist of connective tissue cushions surrounded by arteriovenous communications between terminal branches of the superior rectal arteries and the inferior, superior and middle rectal veins <U>(</U>
<LINK REF="REF-Thomson-1975" TYPE="REFERENCE">Thomson 1975</LINK>
<U>).</U> Due to their rich vascular supply, highly sensitive location and their tendency to engorge or prolapse, haemorrhoids are subsequently a common cause for many symptomatic anorectal complaints (<LINK REF="REF-Billingham-2004" TYPE="REFERENCE">Billingham 2004</LINK>).</P>
<P>The classical position of haemorrhoids corresponds to three positions which are the right anterior, right posterior and the left lateral areas of the anal canal. Haemorrhoids may be external or internal. External haemorrhoids are covered with skin and internal haemorrhoids are covered with anal mucous membranes. The majority of symptoms and signs which patients present with, arise from internal haemorrhoids. The grading system used by Banov et al. to classify internal haemorrhoids is one of the most common grading systems used by clinicians and is used to guide therapeutic practice (<LINK REF="REF-Banov-1985" TYPE="REFERENCE">Banov 1985</LINK>). Internal haemorrhoids can be divided into four categories depending on the degree of prolapse (the protrusion of the haemorrhoid through the anus). First-grade: protrude into the anal canal but do not prolapse; second-grade: prolapse but spontaneously reduce; third-grade: prolapse and require manual reduction; fourth-grade: irreducible prolapse.</P>
<P>This medical problem is one of the most common gastrointestinal conditions with a prevalence varying from 4.4% in the general population to 36.4% in general practice (<LINK REF="REF-Abramowitz-2001" TYPE="REFERENCE">Abramowitz 2001</LINK>). Haemorrhoids occur equally in both men and women. The prevalence is higher in the Caucasian population with a greater incidence in higher socioeconomic groups and a peak incidence between the ages of 45-65 years <U>(</U>
<LINK REF="REF-Johanson-1990" TYPE="REFERENCE">Johanson 1990</LINK>).</P>
<P>The symptoms derived from structural changes of the normal anatomic padding constitute symptomatic haemorrhoids known as "piles". The majority of symptoms are derived from enlarged internal haemorrhoids and are generally associated with chronic straining either due to constipation, diarrhoea or prolonged periods trying to defecate. It is also common during pregnancy and childbirth (<LINK REF="REF-Beck-1998" TYPE="REFERENCE">Beck 1998</LINK>). Common symptoms and signs are rectal bleeding, prolapse, pruritus (itching), pain and less frequently soiling or mucoid discharge. Rectal bleeding (the most common presenting sign) is classically bright red as there is a high blood oxygen content within the arteriovenous anastomosis. This bleeding is usually described as bright red spotting on the toilet tissue or dripping in the toilet bowl and normally occurs at the end of defecation, separately from the stool. External haemorrhoids may be asymptomatic or associated with discomfort or with acute extreme pain in the event of a local thrombosis (formation of a clot). It should be noted that despite the common prevalence of haemorrhoids it is important to exclude other gastrointestinal conditions such as colonic carcinoma particularly in the elderly which can often present with rectal bleeding.</P>
<P>Medical and conservative management in the primary care setting are the mainstay of treatment for grade one internal and non-thrombosed external haemorrhoids. This consists of high-fibre diets, adequate fluid intake, stool softeners, topical and systemic analgesics, proper anal hygiene and in some cases a short course of topical steroid cream. High-fibre diets in particular, help reduce the severity and duration of symptoms (<LINK REF="REF-Moesgaard-1982" TYPE="REFERENCE">Moesgaard 1982</LINK>). Grade two haemorrhoids are generally treated with non-surgical procedures such as rubber-band ligation (<LINK REF="REF-Johanson-1992" TYPE="REFERENCE">Johanson 1992</LINK>), injection sclerotherapy or cryosurgery. Surgical haemorrhoidectomy is generally reserved for those with grade three, grade four or grade two haemorrhoids with failed non-surgical management. Currently, it is estimated that approximately 5-10% of patients with haemorrhoids will eventually require treatment with haemorrhoidectomy while the rest can be managed conservatively. It should be noted that surgical management does pose significant risks such as post-operative urinary retention which can occur in approximately 20 percent of patients (<LINK REF="REF-Bleday-1992" TYPE="REFERENCE">Bleday 1992</LINK>) and therefore conservative management where appropriate, using drugs such as phlebotonics or lifestyle changes is ideal.<BR/>
</P>
<P>Phlebotonics are a heterogeneous class of drugs mainly used to treat chronic venous insufficiency (the inability of veins to transport blood towards the heart) (<LINK REF="REF-Martinez-2005" TYPE="REFERENCE">Martinez 2005</LINK>) and haemorrhoids (<LINK REF="REF-Quijano-2005" TYPE="REFERENCE">Quijano 2005</LINK>). They are generally used in the less severe stages of haemorrhoids, first and second-grade haemorrhoids and during the thrombosis episodes. Although their true mechanism of action has not been well established, they are generally associated with strengthening of blood vessel walls, increasing venous tone, lymphatic drainage and normalising capillary permeability (<LINK REF="REF-Beck-2011" TYPE="REFERENCE">Beck 2011</LINK>). Most of these drugs are natural products extracted from plants (flavonoids, sapsonides, etc), but synthetic products are also used (calcium dobesilate i.e.). The true benefits and efficacy of these drugs are still not clear. The main adverse effects of flavonoids are gastrointestinal symptoms, however some case-control studies have shown an associated risk of agranulocytosis (severe reduction of white blood cells which in some cases can be life threatening) for calcium dobesilate (<LINK REF="REF-Ibanez-2000" TYPE="REFERENCE">Ibanez 2000</LINK>).There have been numerous examples in the literature as well as randomised controlled trials where classes of phlebotonics have been evaluated for their effectiveness in the treatment of haemorrhoids. So far no rigorous evaluation has been performed assessing the effectiveness and safety of phlebotonics in the treatment of haemorrhoids or their benefit post-haemorrhoidectomy. For this reason it was a necessity to perform a review.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-06-07 14:39:46 +0200" MODIFIED_BY="[Empty name]">
<P>The main objective of this review was to determine the efficacy and safety of phlebotonics in improving the symptoms and signs of haemorrhoids as well as to determine their effect post-haemorrhoidectomy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-07-09 12:00:36 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-07-09 11:54:58 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-07-27 20:52:41 +0200" MODIFIED_BY="[Empty name]">
<P>All published and unpublished parallel group double-blinded randomised controlled trials (RCTs) were eligible for inclusion in this review. Randomised controlled trials published as abstracts or as letters were also included in the primary analysis. However, in order to explore the potential bias resulting from their inclusion, a secondary sensitivity analysis was also conducted. Quasi-random studies were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-03-21 11:27:03 +0100" MODIFIED_BY="[Empty name]">
<P>1) Patients of both genders and all ages receiving phlebotonics for first-, second-, third- and fourth-grade haemorrhoids, symptomatic or asymptomatic, will be eligible as well as patients who received phlebotonics post-haemorrhoidectomy.</P>
<P>2) Pregnant women or women with haemorrhoids after delivery will be eligible.</P>
<P>3) Patients of both genders and all ages receiving phlebotonics with thrombosed haemorrhoids will be eligible.<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-07-09 11:54:58 +0200" MODIFIED_BY="[Empty name]">
<P>We intended to obtain studies involving the use of phlebotonics administered orally or topically at any dose in the following comparisons. However we envisaged that the majority of the comparisons would involve phlebotonics and control interventions.</P>
<P>-Phlebotonic versus phlebotonic, comparing different classes of phlebotonics (e.g flavonoids vs non-flavonoids),</P>
<P>-Phlebotonic versus placebo,</P>
<P>-Phlebotonic versus conservative management (lifestyle intervention, high fibre diet),</P>
<P>-Phlebotonic versus medical intervention,</P>
<P>-Phlebotonic versus surgical intervention,</P>
<P>-Lifestyle changes (fibre) or topical treatment plus phlebotonics versus lifestyle changes (fibre) or topical treatment (fibre) plus placebo,</P>
<P>-Lifestyle changes (fibre) or topical treatment plus phlebotonics versus lifestyle changes(fibre) or topical treatment,</P>
<P>-Non-operative or surgical treatment plus phlebotonics versus non-operative or surgical treatment plus placebo,</P>
<P>-Non-operative or surgical treatment plus phlebotonics versus non-operative or surgical treatment.</P>
<P>Phlebotonics are a class of drugs which will include:</P>
<P>1) Natural products:<BR/>-Bioflavonoids: Quercetin, rutin, hesperidin, rutosides (troxerutin, buckwheat herb extract, ruscus aculeatus), diosmin, hidrosmin, ginko biloba; saponosides: escin (horse chestnut seed extract),<BR/>2) Synthetic products: calcium dobesilate, naftazone, aminaftone, chromocarbe,<BR/>3) Others: iquinosa, flunarizine, sulfomucopoly-saccharide.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-05-26 19:51:08 +0200" MODIFIED_BY="[Empty name]">
<P>The main outcome measures assessed were related to symptom control, relief and relapse rates of symptomatic haemorrhoids. Attempts at contacting authors were made if data from studies was ambiguous or insufficient.</P>
<P>The outcome measures were categorized into primary and secondary.</P>
<P>1) Primary outcome measures included the most frequent symptoms of haemorrhoids. These were;</P>
<P>i) Measurements of bleeding,</P>
<P>ii) Measurements of pain,</P>
<P>iii) Measurements of pruritis.</P>
<P>2) Secondary outcome measures included the following;</P>
<P>i) Analgesic consumption,</P>
<P>ii) Discharge or leakage,</P>
<P>iii) Overall symptom improvement,</P>
<P>iv) Compliance,</P>
<P>v) Any adverse events (side-effects)</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-07-01 15:15:03 +0200" MODIFIED_BY="[Empty name]">
<P>The search strategy advocated by Cochrane colorectal cancer group (CCCG) was adopted. The databases used were primarily the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE. The databases CINAHL, AMED, the British Nursing Index (BNI) and Health Business Elite were also used but resulted in no additional search results being obtained. The search strategies used when searching the MEDLINE and EMBASE databases are outlined below;</P>
<P>
<B>MEDLINE</B>
</P>
<P>1 hemorrhoid*</P>
<P>2 exp HEMORRHOID/</P>
<P>3 haemorrhoid*</P>
<P>4 hemorhoid*</P>
<P>5 hemorroid*</P>
<P>6 haemorroid*</P>
<P>7 haemorhoid*</P>
<P>8 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7</P>
<P>9 phlebotonic*</P>
<P>10 flavonoid*</P>
<P>11 bioflavonoid*</P>
<P>12 escin OR quercetin OR rutin OR hesperidin OR rutoside* OR diosmin OR hidrosmin OR saponosides</P>
<P>13 calcium AND dobesilate</P>
<P>14 diosmin OR naftazone OR aminaftone OR chromocarbe OR daflon OR naphtha OR venotoni* OR hydroxyethylrutoside dobesilate OR naftazone.</P>
<P>15 9 OR 10 OR 11 OR 12 OR 13 OR 14</P>
<P>16 8 AND 15</P>
<P>
<B>The Cochrane Controlled Trials Register and Embase</B>
</P>
<P>1 hemorrhoid*</P>
<P>2 exp HEMORRHOID/</P>
<P>3 haemorrhoid*</P>
<P>4 hemorhoid*</P>
<P>5 hemorroid*</P>
<P>6 haemorroid*</P>
<P>7 haemoroid*</P>
<P>8 hemoroid*</P>
<P>9 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8</P>
<P>10 phlebotonic*</P>
<P>11 flavonoid*</P>
<P>12 exp FLAVONOID/</P>
<P>13 bioflavonoid*</P>
<P>14 quercetin OR rutin OR hesperidin OR rutoside* OR diosmin OR hidrosmin OR saponosides OR escin</P>
<P>15 calcium AND dobesilate</P>
<P>16 diosmin OR daflon OR naphtha OR venotoni* OR dobesilate OR naftazone OR aminaftone OR chromocarbe OR hydroxyethylrutoside</P>
<P>17 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16</P>
<P>18 9 AND 17</P>
<P>These electronic databases were explored vigorously using the broad search strategies such as those described above to identify all the randomised controlled trials available evaluating the efficacy of phlebotonics for haemorrhoids. All searches were run from the earliest date available (1950 for MEDLINE, 1974 for EMBASE, 1981 for CINAHL and 1985 for AMED). A final search of MEDLINE, EMBASE, AMED and CINAHL was undertaken three months before publication. Free Internet search engines such as Google Scholar, Intute and Turning Research Into Practice (TRIP) databases were also used but revealed no useful study data. All journals were included and retrieved into the final analysis. Non-English language journals were retrieved and were subsequently translated.</P>
<P>In order to minimize publication bias, a grey literature search was performed. The Healthcare Management Information Consortium (HMIC) of the Department of Health Library (UK), the King's Fund health charity database, OpenSIGLE and the National Technical Information Service (NTIS) was used to search for all relevant grey literature such as conference abstracts.</P>
<P>Attempts at contacting pharmaceutical companies and editors of general medical, general practice, gastroenterology and general surgery journals were made for information on any papers on phlebotonics and haemorrhoids undergoing peer-review.</P>
<P>It is acknowledged that some completed trials are never published. In order to minimize bias, it was a necessity to search for unpublished trials. Ongoing trials were searched mainly from the following databases;</P>
<UL>
<LI>Meta Register of Controlled Trials (mRCT); http://www.controlled-trials.com</LI>
<LI>US NIH register; http://clinicaltrials.gov</LI>
<LI>Register of the Center for Clinical Trials and Evidence-Based Healthcare; http://trialscentral.org</LI>
<LI>The Association of the British Pharmaceutical Industry (ABPI); Trials database - www.cmrinteract.com/clintrial/</LI>
</UL>
<P>Other national and international trial registers were searched for, if appropriate. Particular pharmaceutical or biotech industry trials registers were searched for and the Clinical Trial Results web site (www.clinicaltrialresults.org/) were searched for various slide presentations reporting the results of relevant clinical trials related to phlebotonics and haemorrhoids.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-07-09 12:00:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>1) Selection of Studies:</B>
</P>
<P>Two reviewers (NP and DL) were involved in the selection of studies. Once all the papers were collected, one reviewer determined the eligibility of the studies and excluded papers from the initial searches unrelated to haemorrhoids in humans. This decision was based on account of the title, abstract and content. The second reviewer independently scrutinized the studies excluded from this selection process. Disagreements were addressed by meaningful discussion and where necessary the remaining reviewers were contacted for further assistance.</P>
<P>Afterwards the full text of potentially relevant reports were retrieved in order so that they could be examined by the two reviewers (for compliance with the pre-stated eligibility criteria). These two reviewers examined the full text reports independently, disagreements were addressed and the remaining reviewers were contacted if a resolution could not be found. Where appropriate, it was necessary to liaise with investigators to request further information such as incomplete results data.</P>
<P>All potentially relevant trial reports were scrutinized for multiple publications of the same data. It was necessary to compare criteria such as similar author names, locations, settings and similar interventions in order to avoid duplicate publications.</P>
<P>Those trials searched for but classified as not eligible are displayed in a table together with the reason for their exclusion.</P>
<P>
<B>2) Data Collection:</B>
</P>
<P>Data was collected and recorded onto specially designed forms by two reviewers. These data collection forms were piloted and tested using a representative sample of collected studies and were modified pending further changes necessary. Data collection involved two reviewers and was proof-read by the remaining reviewers. Disagreements arose when collecting data, and the remaining reviewers were consulted where necessary. Attempts at contacting study authors where data was insufficient were also made.</P>
<P>The specialized data collection forms were paper forms. Data extracted contained key characteristics of each trial (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>
<U>)</U> with the following subheadings;</P>
<P>i) Eligibility; whether this trial was eligible and reason for exclusion,</P>
<P>ii) Study methods; study design, total study duration, sequence generation, allocation sequence concealment, blinding and bias,</P>
<P>iii) Participants; age, sex, nationality total number and degree of haemorrhoids,</P>
<P>iv) Interventions; the specific intervention which took place and their intervention detail,</P>
<P>v) Outcomes; the outcome definition and the unit of interest. The details and prevalence of individual symptoms before and after treatment (making note of any improvements), haemorrhoidal symptom scores, global assessments of symptoms and where possible patient satisfaction scores post treatment. Where measurement scales were used it was noted whether or not they were standard scales and whether they were validated,</P>
<P>vi) Results; Number of participants. For each outcome of interest - sample size, missing participants, summary data for each intervention group (e.g. 2×2 table for dichotomous data; means and SDs for continuous data),</P>
<P>vii) Miscellaneous; Key conclusions of the study authors - miscellaneous comments from the study authors and references to other relevant studies.<BR/>
</P>
<P>
<B>3) Assessment of bias and study quality</B>:</P>
<P>The studies selected were assessed for whether the study correctly avoids bias. Bias specifically refers to a systematic error or deviation from the truth in results or inferences (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). Methodological quality however refers to the extent to which the authors have carried out their work to the highest possible standard (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>). It was recommended by the Cochrane collaboration that the level of bias was to be assessed rather than the study quality <U>(</U>
<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>
<U>)</U>. In order to assess the risk of bias a two part domain-based tool was used. A pre-designed form was created with seven specific domains. This addressed 'sequence generation', 'allocation concealment', 'blinding', 'incomplete outcome data', 'selective outcome reporting' and 'other issues and sources of bias'. Within each entry of the domain, Part One involved a description of what happened in that study. Part Two involved a judgement relating to the risk of bias for that entry. The answers 'yes', 'unclear' or 'no' were allocated for each of part two. These corresponded to 'low risk of bias', 'unclear risk of bias' or 'no risk of bias', respectively. This assessment for each study was performed by two reviewers (NP and AC) with the remaining reviewers participating if disagreements arose. Pre-set criteria for allocating an answer such as 'yes, no or unclear' were already defined (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). If the data reported in each trial was insufficient, the judgement allocated was &#8216;Unclear' risk of bias.</P>
<P>Using RevMan5, a 'Risk of bias graph' was generated illustrating the proportion of studies with each judgement (Yes, No or Unclear). A 'Risk of bias summary figure' was then generated to draw conclusions about the overall risk of bias.</P>
<P>A comprehensive description of the assessment of the risk of bias tool is shown below;</P>
<P>
<B>Assessment of Risk of Bias</B>
</P>
<P>Assessments of risk of bias were performed using the Cochrane collaboration risk of bias tool. The following outline is shown below:</P>
<P>i) Sequence Generation; assessed as yes, no or unclear:</P>
<P>Yes; When the allocation described to generate the sequence was described in sufficient detail,</P>
<P>Unclear; When it was not or incompletely described,</P>
<P>No; When the sequence was not generated or a quasi-random method of allocation was described.</P>
<P>ii) Allocation concealment; assessed as yes, no or unclear:</P>
<P>Yes; When the study described sufficient concealment of the allocation,</P>
<P>Unclear; When it was not described or incompletely described,</P>
<P>No; When it was clear that the allocation of participants to the trial had been broken.</P>
<P>iii) Blinding of participants; assessed as yes, no or unclear:</P>
<P>Yes; When blinding took place either as single or double blinded,</P>
<P>Unclear; When it was not clearly described,</P>
<P>No; When it was an unblinded study.</P>
<P>iv) Incomplete data outcome; assessed as yes, no or unclear:</P>
<P>Yes; When the study described the completeness of data for each outcome stated including attrition and exclusion and these did not include a significant number of exclusions,</P>
<P>Unclear; When it was not or incompletely described,</P>
<P>No; When there were significant exclusions.</P>
<P>v) Free of selective outcome reporting; assessed as yes, no or unclear:</P>
<P>Yes; When the studies primary and secondary outcomes of interest have been reported,</P>
<P>Unclear; Insufficient information to report if all the outcome measures have been reported,</P>
<P>No; When missing outcomes are not reported.</P>
<P>vi) Other sources of bias; assessed as yes, no or unclear:</P>
<P>Other sources of bias which we considered were funding agencies especially pharmaceutical. Papers which did not state the source of funding were deemed as 'Unclear'.</P>
<P>Other sources of bias that we considered were baseline imbalance.</P>
<P>
<B>4) Addressing reporting bias</B>
</P>
<P>In order to detect the degree of reporting bias, a funnel plot was constructed detecting the intervention effects against the study size and precision. It is acknowledged that if reporting bias does occur, the funnel plot will have an asymmetrical appearance with the degree of asymmetry resembling the degree of bias. Funnel plots of effect estimates against their standard error of the intervention effects were plotted using RevMan 5.</P>
<P>When interpreting a funnel plot, asymmetry was acknowledged, as a variety of other factors could be contributing other than reporting bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). A visual assessment of funnel plot asymmetry was performed, however for an objective determination statistical tests were considered. The approach used by <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK> for dichotomous data corresponds to a linear regression of the log odds ratio on its standard error, weighted by the inverse of the variance of the log odds ratio. If continuous data were present, a simple statistical test involving the linear regression of the intervention effect estimates on their standard errors was considered.</P>
<P>
<B>5) Presenting results and Summary of Findings</B>
</P>
<P>In order to present results in a systematic and concise format a variety of tables and figures were used which included the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table, 'Forest plots' and 'Summary of findings'.</P>
<P>The 'Characteristics of included studies' table presented information on individual studies. They contained the following subheadings; i) Methods ii) Participants iii) Intervention iv) Outcomes. The 'Methods' section detailed the study design, stating whether randomizations occurred and the duration of study. The 'Participants' section included details of the participants such as the settings, degree of haemorrhoids, age, sex and nationality. The 'Interventions' section listed the various intervention groups including the details of phlebotonics used, dose, frequency, mode of administration, side-effects and duration. The 'Outcomes' section included the outcomes of interventions and time-points measured in the study.</P>
<P>Forest plots were generated using the RevMan 5 software. Data was entered into RevMan5 by two reviewers.</P>
<P>A 'Summary of findings' table was produced using the GRADEprofiler and the RevMan 5 software. The standard template for this table is recommended by the Cochrane collaboration (<LINK REF="REF-Schunemann-2008" TYPE="REFERENCE">Schunemann 2008</LINK>). The following subheadings were used:</P>
<P>i) List of all important outcomes ii) Illustrative comparative risks iii) Absolute and relative magnitude of effect iv) Numbers of participants and studies addressing outcomes v) Quality of evidence rating (<LINK REF="REF-GRADE-Working-Group-2004" TYPE="REFERENCE">GRADE Working Group 2004</LINK>) vi) Additional comments.</P>
<P>
<B>6) Data analysis and drawing conclusions:</B>
</P>
<P>For the purposes of this review, a meta-analysis combining the statistical analysis of multiple studies was performed using RevMan 5. The meta-analysis was used as well as the statistical power to enhance the statistical precision.</P>
<P>
<B>Measure of treatment effect </B>
</P>
<P>The meta-analysis performed involved a two-part process. The first part of the meta-analysis involved calculating a summary statistic for the study. For dichotomous data we calculated the estimate for the treatment of effect using the odds ratio.</P>
<P>For continuous data the mean and the standard deviations were recorded. Where necessary the standard deviations were calculated from the standard errors or from the upper and lower limits of the confidence intervals provided. The two main summary statistics which were used were the Mean Difference (MD) and the Standardized Mean Difference (SMD). The SMD was used as a summary statistic where for example the outcome measure of interest is the relief of haemorrhoidal symptoms but the studies use different global assessment scales to measure the effect. The SMD expresses the size of the intervention effect in each study relative to the variability observed in that study.</P>
<P>SMD = (difference in mean outcome between groups)/(Standard deviation of outcome among participants)</P>
<P>The second stage of the meta-analysis involved pooling together the data and calculating the weighted average of the effects of the intervention estimated in the individual studies. The weighted average was defined as;</P>
<P>Weighted average = (sum of (estimate x weight))/(sum of weights)</P>
<P>For the meta-analysis of dichotomous data, four specific types of methods were considered depending on the result of the studies obtained. These were 'Mantel-Haenszel', 'Peto', or 'Inverse Variance' for fixed-effect meta-analysis or 'DerSimonian and Laird' for random effects meta-analysis. The Mantel-Haenszel (<LINK REF="REF-Mantel-1959" TYPE="REFERENCE">Mantel 1959</LINK>; <LINK REF="REF-Greenland-1985" TYPE="REFERENCE">Greenland 1985</LINK>) was used if the data present was sparse or the study size was small. The Peto's odds ratio method was used to pool relevant odds ratios together.</P>
<P>
<B>Unit of analysis</B>
</P>
<P>Only randomised controlled trials were included for analysis in this review. No trials were cross-over or cluster-randomized controlled trials.</P>
<P>
<B>Missing data</B>
</P>
<P>It was considerably difficult to contact investigators regarding missing data. Many contact details of the authors were not included in studies. We considered incomplete data to have been addressed if 85% or more participants had been included in the final analysis. If less than 85% were included but steps were taken to ensure that these did not bias the results, this was deemed satisfactory.</P>
<P>If the above were not clear, we intended to calculate the statistics on an intention-to-treat analysis (ITT) basis. Where summary statistics were not available, we intended to calculate these summary statistics (e.g. standard deviations) from the available data supplied.</P>
<P>
<B>Assessment of heterogeneity </B>
</P>
<P>The degree of heterogeneity was assessed using the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). It should be noted that a Chi <SUP>2</SUP> test is poor at detecting the true heterogeneity among studies. A statistically significant result indicates heterogeneity while a non-significant result is certainly no evidence for non-heterogeneity.</P>
<P>An I<SUP>2</SUP> statistic expresses the proportion of  total variation across studies that is due to heterogeneity as supposed to chance. Values for I<SUP>2</SUP> lie between 0% and 100%. For the purpose of this review we categorized significant heterogeneity as an I<SUP>2</SUP> value &gt;50% whereas non-significant heterogeneity as an I<SUP>2</SUP> value &lt;50%. If significant heterogeneity occurred (I<SUP>2</SUP>&gt;50%) a random-effects model was used whereas if low heterogeneity occurred (I<SUP>2</SUP>&lt;50%) a fixed-effect model was used.</P>
<P>
<B>Assessment of reporting bias</B>
</P>
<P>Attempts to gain further information were sought from trial authors however practically this was not possible since a large proportion of the trials had been carried out many years ago.</P>
<P>A funnel plot constructed of the effect estimates against their standard error (for overall symptoms improvements) suggests that there is publication bias resulting in asymmetry. However there were too few trials to perform Egger's regression test. </P>
<P>
<B>Data synthesis</B>
</P>
<P>Data was analysed using a fixed-effect model for cases of low heterogeneity (I<SUP>2</SUP>&lt;50 %) and a random-effects model for high heterogeneity between studies (I<SUP>2</SUP>&gt;50%).</P>
<P>
<B>Subgroup analysis and assessment of heterogeneity</B>
</P>
<P>Various factors considered as possible causes for heterogeneity were differing formulations of phlebotonic and differing characteristics of the study populations (such as age or gender). Further investigations into subgroup analysis will be carried out in the future when sufficient studies are available.</P>
<P>A random methods meta-analysis was performed to incorporate heterogeneity among studies. A meta-analysis within the subgroups was also performed. RevMan 5 was used to perform the sub-group analysis.</P>
<P>
<B>Sensitivity Analysis</B>
</P>
<P>We had planned to perform a secondary sensitivity analysis as per protocol, based on the presence and absence of randomised controlled trials (RCT's) published as letters and abstracts. This was not possible as there were no further RCT's published as letters and abstracts which were not already included in the meta-analysis.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-07-09 12:13:55 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-07-09 12:07:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Description of Studies</B>
</P>
<P>
<B>See ; </B>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>
</P>
<P>
<B>Results Of Search</B>
</P>
<P>Two review authors (NP and DL) screened the results of the search. A total of seventy-four results detailing randomised controlled trials were obtained, (MEDLINE =19; EMBASE= 23; CENTRAL = 32). After the removal of duplicates thirty-two studies were obtained of which twenty-four were included and eight were excluded. No trials were found through pharmaceutical companies.</P>
<P>
<B>Included Studies</B>
</P>
<P>We identified twenty-four studies for inclusion in this review. Even though we intended to obtain studies involving the use of phlebotonics administered orally or topically at any dose in the comparisons listed under 'Types of Intervention', the majority of the included studies reported phlebotonics versus control interventions.<BR/>The majority of studies were performed in high income countries (20 out of 24). Seven of the trials were performed in Italy (<LINK REF="STD-Annoni-1986" TYPE="STUDY">Annoni 1986</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Cospite-1992" TYPE="STUDY">Cospite 1992</LINK>; <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>; <LINK REF="STD-Squadrito-2000" TYPE="STUDY">Squadrito 2000</LINK>). Three studies were performed in France (<LINK REF="STD-Godeberge-1994" TYPE="STUDY">Godeberge 1994</LINK>; <LINK REF="STD-Chauvenet-1994" TYPE="STUDY">Chauvenet 1994</LINK>; <LINK REF="STD-Debien-1996" TYPE="STUDY">Debien 1996</LINK>).Two of the studies were performed in Singapore (<LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>; <LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>), two in China (<LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>) and two in Turkey (<LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>; <LINK REF="STD-Mentes-2001" TYPE="STUDY">Mentes 2001</LINK>). Each of the following countries had one study each: Germany (<LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>), Greece (<LINK REF="STD-Dimitroulopoulos-2005" TYPE="STUDY">Dimitroulopoulos 2005</LINK>), India (<LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>) and Slovenia (<LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>). Four studies came from low income countries: Thailand (<LINK REF="STD-Thanapongsathorn-1992" TYPE="STUDY">Thanapongsathorn 1992</LINK> and <LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>), Indonesia (<LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>) and Venezuala (<LINK REF="STD-Sarabia-2001" TYPE="STUDY">Sarabia 2001</LINK>). As noted the majority of trials were performed in continental Europe and Asia reflecting the increased use of phlebotonics in these regions.</P>
<P>
<B>Participants </B>
</P>
<P>The majority of studies included in this review involved both male and female adult participants. The only exception was one study, (<LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>), which only included pregnant women. One study, (<LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>), specifically included participants under the age of fifty and another (<LINK REF="STD-Squadrito-2000" TYPE="STUDY">Squadrito 2000</LINK>) specifically included only participants over the age of thirty.</P>
<P>
<B>Interventions </B>
</P>
<P>Of the twenty-four trials included in this review, twenty trials evaluated the use of phlebotonic versus a control intervention. Of these twenty, four studies (<LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>; <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>; <LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>) evaluated the use of phlebotonics and controls post-haemorrhoidectomy. One study (<LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>) specifically evaluated the use of phlebotonics with controls in pregnant women. Another study (<LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>) also evaluated the use of phlebotonics versus control versus rubber band ligation and another study (<LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>) also evaluated the use of phlebotonics with control and medical intervention (C.quadrangularis).</P>
<P>The remaining four studies included two studies which evaluated the use of phlebotonics versus phlebotonics (<LINK REF="STD-Cospite-1992" TYPE="STUDY">Cospite 1992</LINK>; <LINK REF="STD-Sarabia-2001" TYPE="STUDY">Sarabia 2001</LINK>). Another which evaluated phlebotonics versus Infrared photocoagulation (<LINK REF="STD-Dimitroulopoulos-2005" TYPE="STUDY">Dimitroulopoulos 2005</LINK>) and one study evaluated phlebotonics with a medical intervention (<LINK REF="STD-Debien-1996" TYPE="STUDY">Debien 1996</LINK>).</P>
<P>Different formulations of phlebotonics were also used. The most commonly used preparations were Micronized Purified Flavonoid Fraction (MPFF) which were used in thirteen studies (<LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>; <LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>; <LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>, <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>; <LINK REF="STD-Godeberge-1994" TYPE="STUDY">Godeberge 1994</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>; <LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>; <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>; <LINK REF="STD-Dimitroulopoulos-2005" TYPE="STUDY">Dimitroulopoulos 2005</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-Sarabia-2001" TYPE="STUDY">Sarabia 2001</LINK>; <LINK REF="STD-Thanapongsathorn-1992" TYPE="STUDY">Thanapongsathorn 1992</LINK>; <LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>). Two studies used Diosmin (<LINK REF="STD-Chauvenet-1994" TYPE="STUDY">Chauvenet 1994</LINK>; <LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>) with a control intervention. Cospite's study (<LINK REF="STD-Cospite-1992" TYPE="STUDY">Cospite 1992</LINK>) compared Daflon (an MPFF of Diosmin) with Diosmin.Troxerutin-carbazochrome was used in three studies (<LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Squadrito-2000" TYPE="STUDY">Squadrito 2000</LINK>) and Calcium Dobesilate in two studies (<LINK REF="STD-Mentes-2001" TYPE="STUDY">Mentes 2001</LINK>; <LINK REF="STD-Sarabia-2001" TYPE="STUDY">Sarabia 2001</LINK>). Two studies (<LINK REF="STD-Annoni-1986" TYPE="STUDY">Annoni 1986</LINK>; <LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>) used hydroxyethylrutoside. Belcaro's study (<LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>) used Pycnogel<SUP>R </SUP>which is a flavonoid medication derived from a French maritime pine bark.</P>
<P>
<B>Disease verification</B>
</P>
<P>The included studies evaluated the use of phlebotonics for either symptomatic acute on chronic haemorrhoidal disease, chronic haemorrhoidal disease or symptom improvement post-haemorrhoidectomy. All studies with the exception of two (<LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>; <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>) stated explicit exclusion criteria.</P>
<P>The following studies evaluated the effect of phlebotonics post-haemorrhoidectomy (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>; <LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>; <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>). They all stated appropriate inclusion criteria with all patients being eligible for surgery.</P>
<P>The majority of studies evaluated the use of phlebotonics for acute haemorrhoidal disease (<LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>; <LINK REF="STD-Cospite-1992" TYPE="STUDY">Cospite 1992</LINK>; <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>; <LINK REF="STD-Debien-1996" TYPE="STUDY">Debien 1996</LINK>; <LINK REF="STD-Chauvenet-1994" TYPE="STUDY">Chauvenet 1994</LINK>; <LINK REF="STD-Dimitroulopoulos-2005" TYPE="STUDY">Dimitroulopoulos 2005</LINK>; <LINK REF="STD-Godeberge-1994" TYPE="STUDY">Godeberge 1994</LINK>; <LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>; <LINK REF="STD-Mentes-2001" TYPE="STUDY">Mentes 2001</LINK>; <LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>; <LINK REF="STD-Sarabia-2001" TYPE="STUDY">Sarabia 2001</LINK>; <LINK REF="STD-Squadrito-2000" TYPE="STUDY">Squadrito 2000</LINK>; <LINK REF="STD-Thanapongsathorn-1992" TYPE="STUDY">Thanapongsathorn 1992</LINK>). These studies all stated explicit inclusion criteria and screening of these patients were often based on symptoms, signs, clinical examination and pre-stated inclusion criteria. Studies of <LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>; <LINK REF="STD-Annoni-1986" TYPE="STUDY">Annoni 1986</LINK> included patients with chronic haemorrhoidal disease states. For further details of individual specific inclusion criteria please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>
<B>Excluded Studies</B>
</P>
<P>We excluded eight studies on the following grounds;</P>
<P>1) One study did not describe a randomised controlled clinical trial (<LINK REF="STD-Garner-2002" TYPE="STUDY">Garner 2002</LINK>)</P>
<P>2) Two studies described poor methods of randomizations (<LINK REF="STD-Mlakar-2008" TYPE="STUDY">Mlakar 2008</LINK>; <LINK REF="STD-Sandhu-2004" TYPE="STUDY">Sandhu 2004</LINK>) and one study poor methodology (<LINK REF="STD-Marsicano-1995" TYPE="STUDY">Marsicano 1995</LINK>).</P>
<P>3) Three studies upon closer evaluation into the literature did not use phlebotonics (<LINK REF="STD-Smith-1998" TYPE="STUDY">Smith 1998</LINK>; <LINK REF="STD-Tan-2006" TYPE="STUDY">Tan 2006</LINK> and <LINK REF="STD-Quijano-2005" TYPE="STUDY">Quijano 2005</LINK>)</P>
<P>4) (<LINK REF="STD-Kubchandani-2001" TYPE="STUDY">Kubchandani 2001</LINK>) was a conference abstract describing various randomised controlled trials already included in the meta-analysis.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-07-09 12:10:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Allocation concealment</B>
</P>
<P>Allocation concealment was only adequately described in two studies (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>) . In twenty-two studies, allocation concealment was deemed 'unclear'.</P>
<P>
<B>Blinding</B>
</P>
<P>All of the studies described, with the exception of three (<LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>; <LINK REF="STD-Debien-1996" TYPE="STUDY">Debien 1996</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>), stated adequate methods of blinding (either as double or single-blinded) and it was unlikely that blinding was broken.</P>
<P>
<B>Incomplete data outcome</B>
</P>
<P>One study (<LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>) reported incomplete data outcome which was significant to induce a plausible effect size. In one study (<LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>) it was unclear as to whether incomplete data outcomes had been properly addressed. In the remaining twenty-two studies, incomplete data outcome was deemed to have been appropriately addressed.</P>
<P>
<B>Selective reporting</B>
</P>
<P>In two studies (<LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>) both described a situation in which selective reporting was present and not adequately addressed. In three studies (<LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>; <LINK REF="STD-Annoni-1986" TYPE="STUDY">Annoni 1986</LINK>; <LINK REF="STD-Godeberge-1994" TYPE="STUDY">Godeberge 1994</LINK>) it was unclear as to whether or not there was selective reporting. The remaining nineteen studies adequately showed a low risk of selective reporting.</P>
<P>
<B>Other potential source of bias </B>
</P>
<P>In thirteen studies it was unclear whether any other<I> </I>sources of bias were present, (<LINK REF="STD-Annoni-1986" TYPE="STUDY">Annoni 1986</LINK>; <LINK REF="STD-Cospite-1992" TYPE="STUDY">Cospite 1992</LINK>; <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>; <LINK REF="STD-Debien-1996" TYPE="STUDY">Debien 1996</LINK>; <LINK REF="STD-Godeberge-1994" TYPE="STUDY">Godeberge 1994</LINK>; <LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>; <LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>; <LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>; <LINK REF="STD-Sarabia-2001" TYPE="STUDY">Sarabia 2001</LINK>; <LINK REF="STD-Squadrito-2000" TYPE="STUDY">Squadrito 2000</LINK>; <LINK REF="STD-Thanapongsathorn-1992" TYPE="STUDY">Thanapongsathorn 1992</LINK>; <LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>). This was largely due to the lack of vital information such as sources of funding. Nine studies were deemed clear of other sources of bias (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>; <LINK REF="STD-Chauvenet-1994" TYPE="STUDY">Chauvenet 1994</LINK>; <LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>; <LINK REF="STD-Dimitroulopoulos-2005" TYPE="STUDY">Dimitroulopoulos 2005</LINK>; <LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>). In two studies (<LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Mentes-2001" TYPE="STUDY">Mentes 2001</LINK>), other sources of bias were present. In Basile's study the research was sponsored by a pharmaceutical company and Mentes' study had very poor compliance amongst the participants which resulted in the randomizations stopping prematurely amongst the control group.</P>
<P>
<B>Sequence Generation </B>
</P>
<P>Any study which had a quasi-random method of sequence generation was excluded. For the twenty-four studies that were included for analysis in this review, eleven described an adequate sequence generation (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Annoni-1986" TYPE="STUDY">Annoni 1986</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>; <LINK REF="STD-Dimitroulopoulos-2005" TYPE="STUDY">Dimitroulopoulos 2005</LINK>; <LINK REF="STD-Debien-1996" TYPE="STUDY">Debien 1996</LINK>; <LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>; <LINK REF="STD-Mentes-2001" TYPE="STUDY">Mentes 2001</LINK>; <LINK REF="STD-Squadrito-2000" TYPE="STUDY">Squadrito 2000</LINK>). In thirteen studies the method of sequence generation was unclear (<LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>; <LINK REF="STD-Chauvenet-1994" TYPE="STUDY">Chauvenet 1994</LINK>; <LINK REF="STD-Cospite-1992" TYPE="STUDY">Cospite 1992</LINK>; <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>; <LINK REF="STD-Godeberge-1994" TYPE="STUDY">Godeberge 1994</LINK>; <LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>; <LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>; <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>; <LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>; <LINK REF="STD-Sarabia-2001" TYPE="STUDY">Sarabia 2001</LINK>; <LINK REF="STD-Thanapongsathorn-1992" TYPE="STUDY">Thanapongsathorn 1992</LINK>; <LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-07-09 12:13:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>i) Primary Outcomes</B>
</P>
<P>
<B>Pain </B>
</P>
<P>A variety of methods were used to measure pain. These were pain and pain scores post-haemorrhoidectomy.</P>
<P>Two studies (<LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>) recorded the number of participants who reported pain (dichotomous variable see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The use of phlebotonics was associated with a beneficial but not statistically significant effect for pain (OR 0.11; 95% CI 0.01 to 1.11)(P=0.06) but this was also associated with associated significant heterogeneity (I<SUP>2</SUP>= 85%).</P>
<P>The following studies (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Squadrito-2000" TYPE="STUDY">Squadrito 2000</LINK>; <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>; <LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK> ) all reported pain scores, however the results could only be pooled from two studies (<LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK> ) due to the different formatting of results (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). These two studies specifically involved post-haemorrhoidectomy patients.</P>
<P>Although several studies (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Squadrito-2000" TYPE="STUDY">Squadrito 2000</LINK>) could not be pooled due to the different formatting of results and lack of essential study data, they demonstrated the beneficial use of phlebotonics in treating symptomatic haemorrhoids. Belcaro's (<LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>) study compared phlebotonics with a control and this demonstrated a beneficial effect in using phlebotonics for haemorrhoids. However this could not be pooled into a meta-analysis since it did not involve post-haemorrhoidectomy patients and was simply an isolated comparison with symptomatic haemorrhoids.</P>
<P>The use of phlebotonics was associated with a beneficial but not statistically significant effect for pain scores post-haemorrhoidectomy (SMD -1.04; 95% CI -3.21 to 1.12) (P=0.35) with significant statistical heterogeneity (I<SUP>2</SUP>= 96%).</P>
<P>
<B>Bleeding</B>
</P>
<P>Different methods were used to measure bleeding. Bleeding (dichotomous variable) and bleeding post-haemorrhoidectomy were the different parameters used.</P>
<P>Several studies reported the number of patients who experienced bleeding as an outcome measure (<LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>; <LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>) and these were pooled into a forest plot (see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Two of the studies (<LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>) were pooled together and they demonstrated the statistically significant beneficial effect of phlebotonics in treating symptomatic haemorrhoids (OR 0.12; 95% CI 0.04 to 0.37)( P=0.0002) with no statistical heterogeneity (I<SUP>2</SUP>=0%). Two studies (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK>) were pooled together (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) as these compared bleeding post-haemorrhoidectomy with week 2 taken as a common end-point. Phlebotonics also demonstrated a statistically significant effect in alleviating bleeding post-haemorrhoidectomy (OR 0.18; 95% CI 0.06 to 0.58)(P=0.004) with no statistical heterogeneity I<SUP>2</SUP>= 0%.</P>
<P>Four studies reported bleeding scores (<LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>; <LINK REF="STD-La-Torre-2004" TYPE="STUDY">La Torre 2004</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>). Basile's studies (<LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>) could not be pooled into a forest plot due to lack of essential study data available and different formatting of results however they both demonstrated a significant beneficial effect in using phlebotonics. Belcaro's study and La Torre's study both had zero outcomes for their continuous data and therefore these results could not be pooled into a forest plot.</P>
<P>
<B>Pruritis</B>
</P>
<P>Pruritus symptom scores were also reported in two studies, (<LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>). These could not be pooled together due to the formatting of results presented and lack of essential data needed to calculate values such as the standard deviations. Two studies however reported the number of patients experiencing pruritus (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>) and these were pooled together (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).There was a significant beneficial effect in using phlebotonic medication for pruritis (OR 0.23; 95% CI 0.07 to 0.79) (P= 0.02) and there was no statistical heterogeneity between the trials (I<SUP>2</SUP>=0%).</P>
<P>
<B>ii) Secondary Outcome</B>
</P>
<P>
<B>Discharge or Leakage</B>
</P>
<P>Two studies (<LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>) reported the number of patients who experienced discharge or leakage (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The studies showed that phlebotonics had a statistically significant beneficial effect for discharge or leakage (OR 0.12; 95% CI 0.04 to 0.42)(P=0.0008) with no statistical heterogeneity (I<SUP>2</SUP>=0%).</P>
<P>Two studies (<LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>) both reported symptom scores of discharge on a VAS scale, however due to missing data and the formatting of results presented, they could not be pooled together in the meta-analysis. They did however demonstrate the beneficial use of phlebotonics. A ba-bai-ke-re's study (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>) demonstrated the beneficial use of phlebotonics in improving discharge and leakage, however since this was an isolated study involving post-haemorrhoidectomy patients this could not be pooled with other studies.</P>
<P>
<B>Overall symptom improvement (positive outcome)</B>
</P>
<P>Five studies could be pooled together (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>) which assessed the overall symptom improvement comparing phlebotonics with controls. Four studies (<LINK REF="STD-Annoni-1986" TYPE="STUDY">Annoni 1986</LINK>; <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>; <LINK REF="STD-Mentes-2001" TYPE="STUDY">Mentes 2001</LINK>; <LINK REF="STD-Thanapongsathorn-1992" TYPE="STUDY">Thanapongsathorn 1992</LINK>) were pooled together into a subgroup. One study (<LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>) assessed the improvement in symptoms dealing with pregnant women only and this was pooled into a subgroup analysis. Overall, there is a statistically significant beneficial effect in using phlebotonic medication (OR 15.99; 95% CI 5.97 to 42.84) (P&lt;0.00001). There was however significant statistical heterogeneity between studies (I<SUP>2</SUP>= 39). The subgroup analysis also revealed that this effect was statistically significant for pregnant women (P&lt;0.00001) and non-pregnant women (P&lt;0.00001) with minimal statistical heterogeneity within the subgroup (I<SUP>2</SUP>=0%).</P>
<P>Two studies (<LINK REF="STD-Godeberge-1994" TYPE="STUDY">Godeberge 1994</LINK>; <LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>) assessed the improvement for each individual symptom but not the global symptom improvement and for this reason this data could not be pooled into the meta-analysis. Godeberge's study demonstrated that phlebotonics had a beneficial effect in symptom improvement compared with a control intervention. The Panpimanmas study however did not show any difference for symptom improvement between a phlebotonic or control intervention.</P>
<P>
<B>Post-operative analgesic consumption</B>
</P>
<P>Three studies (<LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>) only evaluated post-operative haemorrhoidectomy patients and recorded the number of patients who required analgesic consumption (with day 2 taken as a common end-point). The three studies were pooled together (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). One study (<LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>), records the total number of analgesic consumption of Tramadol and Naproxen in both control and treatment groups, however these results could not be pooled with any other data for the purposes of the meta-analysis. Phlebotonics were associated with less analgesic consumption (OR 0.54; 95% CI 0.30 to 0.99)(P=0.05) and no statistical heterogeneity (I<SUP>2</SUP>= 0%). This is a reflection of their beneficial effect in alleviating pain caused post-operatively.</P>
<P>
<B>Adverse events (side-effects)</B>
</P>
<P>Seven studies reported the number of adverse events which took place (<LINK REF="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TYPE="STUDY">A ba-bai-ke-re 2011</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>; <LINK REF="STD-Belcaro-2010" TYPE="STUDY">Belcaro 2010</LINK>; <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>; <LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>; <LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>). Overall the number of adverse events which took place as a result of taking phlebotonics were few and often consisted of mild gastro-intestinal side-effects. The results demonstrate that there is no difference between the two groups (phlebotonics and control) with regards to this outcome measure (RD -0.00; 95% CI -0.04 to 0.04)(I<SUP>2</SUP>=0%), see <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>.</P>
<P>
<B>Non-Compliance</B>
</P>
<P>Only three studies mentioned non-compliance for those patients who completed their respective study. This demonstrated no significant difference between phlebotonic and control groups (RD 0.00; 95% CI -0.04 to 0.05)(I<SUP>2</SUP>=35%), see <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-07-09 12:14:22 +0200" MODIFIED_BY="[Empty name]">
<P>The evidence suggests that there is a potential benefit in using phlebotonics for symptomatic haemorrhoids as well as for symptom relief post-haemorrhoidectomy. In this discussion we aim to justify this argument, explore heterogeneity and address the main limitations encountered in this review.</P>
<P>The majority of the data supports the hypothesis that phlebotonics alleviate the symptoms of haemorrhoidal disease and post-haemorrhoidectomy. Outcomes such as bleeding (P=0.0002 ), bleeding post-haemorrhoidectomy (0.004), pruritus (P=0.02), discharge and leakage (P=0.0008) and overall symptom improvement (P &lt;0.00001) indicate a statistically significant beneficial effect. Other outcomes such as pain (P=0.06), pain scores (P=0.35) and post-operative analgesic consumption (P=0.05) indicate that there are beneficial effects, but they were not statistically significant. Evidence from the trials suggests there were no issues regarding adverse events of phlebotonics or patient compliance. The majority of data demonstrates the beneficial use of phlebotonics with some outcomes being statistically significant and because of this, we recommend their use. However limitations were encountered and these need to be taken into consideration.</P>
<P>Among the limitations, many trials used subjective clinical parameters such as symptom scales. These scales could not be objectively defined and varied widely between studies and the resulting self-assessment scales were therefore subjective. Several trials (<LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>; <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK>; <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>; <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK>) used a linear visual analogue scale which required the patients to assess their own symptoms and other studies used a patients' self-evaluation scale. These methods of assessments would have resulted in a subjective interpretation of the scales used by different patients. However despite this, there were also more objective quantitative measurements of assessment. These included dichotomous variables such as the presence of bleeding, pruritus, discharge or leakage. This would have resulted in a higher quality of results.</P>
<P>Other major methodological limitations encountered related to issues regarding dietary and lifestyle measures. Haemorrhoidal disease is more likely to occur as a result of low-fibre diets, poor nutrition, lack of exercise, obesity and poor lifestyle intervention (<LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>). Although dietary advice was given in some cases, the individual diet of patients in the majority of trials could not be rigorously controlled, thus leading to bias in the results obtained. Several trials (<LINK REF="STD-Mentes-2001" TYPE="STUDY">Mentes 2001</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>) clearly state that although dietary advice was given, there was no feasible method of ensuring that strict compliance was adhered to and this would have undoubtedly been the case in the majority of studies, thus leading to bias. Even the geographical location would have had an effect on the diet with Misra's study (<LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>) suggesting that the high-fibre diets used by the North Indian subcontinent was beneficial in treating haemorrhoids. Misra's study then subsequently made the conclusion that micronized purified flavonoid fraction (MPFF) had a positive effect above and beyond the good dietary intervention received by the North Indian community.</P>
<P>There was also little similarity in the overall summary estimates used by investigators to describe the incidence, severity and duration of haemorrhoidal disease symptoms. Consequently for some outcomes, it was not possible to pool all of the data together. Most investigators required their participants to record the clinical severity of symptoms and signs and used similar scales to estimate this. Continuous outcome measures included the use of the linear visual analogue scales (VAS scales), whereas other trials used a symptom severity scale which rated symptoms on a scale (e.g. none, mild, moderate or severe). Several trials used dichotomous results to report the presence or absence of a particular sign such as bleeding. For several studies, it was not possible to use the data since essential values such as the standard deviation, standard error of the mean or confidence intervals were not provided and could not be calculated from the available data. Attempts were made to contact the authors involved to provide the missing data, but in many cases this was not possible due to the lack of contact information available.</P>
<P>The majority of studies compared phlebotonics with a control intervention. Very few trials compared these with surgical or medical interventions and because of this, a conclusion could not be made with regard to these outcomes. Only two studies compared phlebotonics with other herbal medical therapies<I>. </I>The study by Panpimanmas (<LINK REF="STD-Panpimanmas-2010" TYPE="STUDY">Panpimanmas 2010</LINK>) compared MPFF with a placebo as well as Cissus quadrangularis. Cissus quadrangularis is a herbal extract found mainly in Asia. This study concluded that C.quandragularis and Daflon showed no difference in the treatment of acute haemorrhoids. Debien's study (<LINK REF="STD-Debien-1996" TYPE="STUDY">Debien 1996</LINK>
<I>) c</I>ompared phlebotonics with Gingko biloba herbal extract. Because the comparisons involved two entirely different substances it was decided not to pool these outcomes together into a forest plot.</P>
<P>Only two studies obtained compared phlebotonic drugs with procedures such as rubber band ligation (<LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>) and infrared photocoagulation (<LINK REF="STD-Dimitroulopoulos-2005" TYPE="STUDY">Dimitroulopoulos 2005</LINK>). These two studies used different procedures and because of this it was inappropriate to pool these comparisons into a meta-analysis. Ho's study concluded that although the addition of MPFF to fibre supplements accelerates the relief of bleeding from non-prolapsed internal haemorrhoids, no statistically significant advantage could be found over rubber band ligation. The study by Dimitroulopoulos compared the effect of a treatment combining IRP and oral MPFF versus each treatment alone on bleeding cessation in patients with acute internal haemorrhoids. The study demonstrated no statistical difference between the IRP group and the MPFF group. However five days of treatment combining oral MPFF with local application of IRP was beneficial in reducing the bleeding of internal haemorrhoids.</P>
<P>Statistical heterogeneity between studies was encountered and several reasons for this are identified. One of the key factors was the dose of phlebotonics. Different formulations were used and subsequently the therapeutic regime greatly varied between the studies. Another factor resulting in statistical heterogeneity were the different study populations used. Some trials were carried out in mainland Europe whereas others in Asia. The dietary requirements and lifestyles of these two groups would have differed greatly with populations in Asia receiving a high-fibre diet and a more active lifestyle than their European counterparts (<LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK>). This would have subsequently resulted in a different response rate of haemorrhoids to the treatment provided depending on their geographical location.</P>
<P>
<B>Summary of main results</B>
</P>
<P>Studies reporting the effect of phlebotonics for haemorrhoidal disease suggest that there is a potential benefit in their use. Several outcomes suggest that there is a statistically significant beneficial effect whereas other outcomes, although beneficial were not statistically significant. There was however some significant statistical heterogeneity between trials and methodological limitations were encountered.</P>
<P>There is limited data comparing the effects of phlebotonics with medical treatment or procedures such as rubber band ligation and sclerotherapy.</P>
<P>
<B>Potential biases in the review process</B>
</P>
<P>All trials assessed the effect of phlebotonics in treating haemorrhoidal disease. For several trials there was missing data and many results could not be pooled together. Although these were addressed in the final discussion, they would have inevitably led to bias in the meta-analysis.</P>
<P>There was also the potential to miss trials or grey literature, which mentioned haemorrhoidal symptoms (under the spectrum of anorectal pathologies) as secondary outcome measures. These would have been less well-publicised trials. Conducting a thoroughly comprehensive search and identifying the relevance of each paper would have largely avoided this.</P>
<P>
<B>Agreements and disagreements with other studies or reviews</B>
</P>
<P>There have been no previous meta-analyses evaluating the effectiveness of phlebotonic medications as a whole in their treatment of haemorrhoidal disease. However, there have been review articles evaluating the effectiveness of flavonoids in the treatment of haemorrhoids. One meta-analysis (<LINK REF="REF-Alonso_x002d_Coello-2006" TYPE="REFERENCE">Alonso-Coello 2006</LINK>) mentioned that flavonoids seemed to have a beneficial effect in the symptomatic treatment of haemorrhoids. However, the authors also mentioned that flaws in the study design existed and these weakened any inferences of the effect of phlebotonics on symptomatic haemorrhoids. The review article also used fewer outcome measures to evaluate the effect of the medications. A review article (<LINK REF="REF-Hain-2011" TYPE="REFERENCE">Hain 2011</LINK>) made a very similar conclusion in that the true effect of flavonoid medications were still unknown.</P>
<P>Whilst we greatly appreciate the arguments presented in these reviews, the scope of our review is slightly different in that we evaluated phlebotonics as a whole group (flavonoids and non-flavonoid medications) and thus included more studies. These previous reviews presented a rigorous evaluation of flavonoids only. We have however presented data which supports the beneficial use of phlebotonics with more trials included. We also evaluated more outcome measures. To enhance our conclusion further we certainly recommend more rigorous trials to be carried out in the future taking into account various methodological limitations.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-07-05 16:24:07 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-07-05 16:24:07 +0200" MODIFIED_BY="[Empty name]">
<P>The evidence presented in this review suggests that there is a benefit in using phlebotonics for symptomatic haemorrhoids as well as symptom alleviation post-haemorrhoidectomy and there is little concern regarding their overall safety from the trials presented. Adverse events from the studies mainly consisted of mild isolated gastro-intestinal disturbances. We do therefore recommend the use of phlebotonics in treating haemorrhoidal disease as there is a proven benefit. However although there is a beneficial effect, not all of the pooled data is statistically significant. The methodological quality is largely moderate with associated risk of bias in included studies (see <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK> and <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>) and some of the confidence intervals were wide with statistical heterogeneity. The funnel plot constructed (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>) also indicates that there is some publication bias present.</P>
<P>None of the trials examined the use of phlebotonics for thrombosed haemorrhoids and very limited data exists examining their role in pregnant women or the more severe stages of haemorrhoidal disease. We therefore cannot recommend their use in these specific subgroups of patients.</P>
<P>In summary, we recommend the use of phlebotonics for haemorrhoids in clinical practice. However, more robust clinical trials are needed to further support our conclusion and to make further recommendations with regards to specific sub-groups of patients and other medical and surgical treatment options.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-07-01 15:50:33 +0200" MODIFIED_BY="[Empty name]">
<P>There is a greater prevalence of haemorrhoids among the Caucasian adult male and female population (age groups of 45-60 years). The numerous trials obtained mainly compared the use of phlebotonics with control interventions for the less severe stages of haemorrhoidal disease. This review demonstrates the benefit in using phlebotonics for haemorrhoids and a conclusion can be made with regards to this. To further support this conclusion, we outline several recommendations for a future research agenda. We suggest the use of similar end-points for outcome measures so that more data can be pooled appropriately. We recommend that investigators succinctly describe their methods of randomizations and allocation concealment so that the methodological quality of the trials is greater. Although phlebotonics are a heterogenous class of drugs, we recommend that future studies use similar or identical agents as well as therapeutic regimes in studies which have already taken place. This will inevitably minimize the statistical heterogeneity between trials.</P>
<P>There are very few trials which evaluate the use of phlebotonics and procedures such as rubber band ligation or sclerotherapy. We recommend that more future trials evaluate these comparisons. We also recommend that more trials investigate the effect of phlebotonics with thrombosed haemorrhoids.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-10-25 23:44:23 +0200" MODIFIED_BY="[Empty name]">
<P>We would like to thank Mr Muhammed Iqbal Bhatti for his expert guidance in helping us in the content of this review. Also Dr Martina Muscat for reviewing the final draft.</P>
<P>Mr Abdel Omer, consultant general surgeon with a specialist interest in anorectal pathologies was also advising as a content expert.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-07-23 20:02:56 +0200" MODIFIED_BY="[Empty name]">
<P>No conflicts of interest are present and no declarations of interest are present.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-03-04 15:22:55 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Nirmal Perera (NP) and Dr Danae Liolitsa (DL) were involved in the data search, exclusion of studies and data extraction. NP and Dr Anna Croxford (AC) were involved independently in completing a systematic critical review in included studies. Dr Peter Lang (PL) and Dr Obioha Ukaegbu (OU) were involved in the grey literature search as well as the attempt to contact authors of studies where statistical data was insufficient. Mr Muhammed Iqbal Bhatti (MIB), Mr Mohammed Yassin (MY) and Mr Satheesh Iype (SI) were senior general surgeons involved as content experts.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-05-07 11:36:58 +0200" MODIFIED_BY="[Empty name]">
<P>We mainly addressed the outcome measures regarding symptom control, relief and relapse rates which were originally addressed in the protocol. We ensured that these were the main focus of our outcome measures. The symptoms of haemorrhoids were more specifically defined in the final review and we decided to separate them into primary and secondary categories based on their clinical importance. We defined the primary symptoms as bleeding, pain and pruritus and secondary outcomes were measures of discharge, overall symptom improvement and analgesic consumption.</P>
<P>The outcome measure regarding the adverse events reported just isolated events. The general consensus is that phlebotonics are a safe class of drug and due to the sparse nature of the adverse events, it was inappropriate to pool this outcome into a meta-analysis.</P>
<P>We originally predefined the sub-groups according to the following categories: 'thrombosed haemorrhoids, pregnant women, methodological quality and use of a validated questionnaire'. However, none of the studies reported using phlebotonics in thrombosed haemorrhoids, so this category could not be placed as a subgroup. The majority of the studies were also of a similar methodological quality and so a sub-group analysis could not be performed in this case. In many cases there were also too few trials per outcome measure to perform a subgroup meta-analysis. We did however included the 'pregnant women' into a subgroup meta-analysis.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-07-09 12:15:01 +0200" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-07-05 16:48:22 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-07-05 15:58:16 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-07-05 15:58:16 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" MODIFIED="2012-05-07 11:55:11 +0200" MODIFIED_BY="[Empty name]" NAME="A ba-bai-ke-re 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-05-07 11:55:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ba-bai-ke-re MM, Huang HG, Re WN, Fan K, Chu H, Ai EH, et al</AU>
<TI>How we can improve patients' comfort after Milligan-Morgan open haemorrhoidectomy</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>11</NO>
<PG>1448-56</PG>
<IDENTIFIERS MODIFIED="2011-06-29 02:04:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-29 02:04:47 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Annoni-1986" MODIFIED="2012-07-05 15:58:16 +0200" MODIFIED_BY="[Empty name]" NAME="Annoni 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-07-05 15:57:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Annoni F, Boccasanta P</AU>
<TI>Treatments of acute symptoms of haemorrhoidal disease with O-(B-hydroxyethyl)-rutosides at high oral doses</TI>
<TO>Trattamenti dei sintomi acuti della malattia emorroidaria con O-(B-idrossietil)-rutosidea ad alte dosi per via oral</TO>
<SO>Minerva Medica</SO>
<YR>1986</YR>
<VL>77</VL>
<NO>37</NO>
<PG>1663-8</PG>
<IDENTIFIERS MODIFIED="2012-07-05 15:57:58 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-05 15:58:16 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basile-2001" MODIFIED="2012-05-07 11:55:47 +0200" MODIFIED_BY="[Empty name]" NAME="Basile 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-07 11:55:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basile M, Gidaro S, Pacella M, Biffignandi PM, Gidaro G</AU>
<TI>Parenteral Troxerutin and Carbazochrome Combination in the Treatment of Post-hemorrhoidectomy Status: A Randomized, Double-blind, Placebo-controlled, Phase IV Study</TI>
<SO>Current Medical Research And Opinion</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>4</NO>
<PG>256-61</PG>
<IDENTIFIERS MODIFIED="2011-07-23 22:57:53 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 22:57:53 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basile-2002" MODIFIED="2012-05-07 11:56:03 +0200" MODIFIED_BY="[Empty name]" NAME="Basile 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-05-07 11:56:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basile M, Gidaro S, Pacella M, Biffignandi PM, Gidaro G</AU>
<TI>Troxerutin-Carbazochrome Combination Versus Placebo in the Treatment of Posthemorrhoidectomy Symptoms; A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study</TI>
<SO>Current Therapeutic Research</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>9</NO>
<PG>527-35</PG>
<IDENTIFIERS MODIFIED="2011-07-23 22:58:04 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 22:58:04 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-2010" MODIFIED="2012-05-07 11:56:17 +0200" MODIFIED_BY="[Empty name]" NAME="Belcaro 2010" YEAR="2009">
<REFERENCE MODIFIED="2012-05-07 11:56:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Cesarone MR, Errichi B, Di Renzo A, Grossi MR, Ricci A, et al</AU>
<TI>Pycnogenol Treatment of Acute Hemorrhoidal Episodes</TI>
<SO>Phytotherapy Research</SO>
<YR>2010</YR>
<VL>24</VL>
<PG>438-44</PG>
<IDENTIFIERS MODIFIED="2011-07-23 22:58:22 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 22:58:22 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chauvenet-1994" MODIFIED="2012-05-07 11:56:33 +0200" MODIFIED_BY="[Empty name]" NAME="Chauvenet 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-05-07 11:56:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chauvenet M, Libeskind M</AU>
<TI>Interest of hemisynthesis diosmin in the hemorrhoidal crisis: double blind randomized multicentric trial versus placebo</TI>
<TO>Interet de la Diosmine D'hemisynthese dans la poussee hemorroidaire aigue</TO>
<SO>Revue Francaise de Gastro-enterologie</SO>
<YR>1994</YR>
<VL>30</VL>
<PG>642-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colak-2003" MODIFIED="2012-05-07 11:56:47 +0200" MODIFIED_BY="[Empty name]" NAME="Colak 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-05-07 11:56:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colak T, Akca T, Dirlik M, Kanik A, Dag A, Aydin S</AU>
<TI>Micronized Flavonoids in Pain Control After Hemorrhoidectomy; A Prospective Randomized Controlled Study</TI>
<SO>Surgery Today</SO>
<YR>2003</YR>
<VL>33</VL>
<PG>828-32</PG>
<IDENTIFIERS MODIFIED="2011-07-23 22:58:41 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 22:58:41 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cospite-1992" MODIFIED="2012-05-07 11:57:00 +0200" MODIFIED_BY="[Empty name]" NAME="Cospite 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-05-07 11:57:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cospite M, Cospite V</AU>
<TI>Treatment of Haemorrhoids with Daflon 500mg</TI>
<SO>Phlebology Suppl.</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>53-6</PG>
<IDENTIFIERS MODIFIED="2011-07-23 22:59:09 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 22:59:09 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cospite-1994" MODIFIED="2012-07-05 13:04:49 +0200" MODIFIED_BY="[Empty name]" NAME="Cospite 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-07-05 13:04:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cospite M</AU>
<TI>Double-Blind, Placebo-Controlled Evaluation of Clinical Activity and Safety of Daflon 500 mg in the Treatment of Acute Hemorrhoids</TI>
<SO>Angiology</SO>
<YR>June 1994</YR>
<VL>6</VL>
<NO>2</NO>
<PG>566-73</PG>
<IDENTIFIERS MODIFIED="2011-07-23 22:59:45 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 22:59:45 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-07-23 22:59:27 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Debien-1996" MODIFIED="2012-07-05 13:06:33 +0200" MODIFIED_BY="[Empty name]" NAME="Debien 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-07-05 13:06:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Debien P, Denis J</AU>
<TI>Treatment of functional signs of acute hemorrhoidal crisis: A multicenter, randomized, diomine semisynthetic combination versus Ginkgo biloba extract-heptaminol-troxerutin</TI>
<TO>Traitement des signes fonctionnels de la crise hemorroidaire aigue: Essai multicentrique, randomise, diomine d'hemisynthese versus association extrait de Ginkgo biloba-heptaminol-troxerutine</TO>
<SO>Actualites Therapeutiques</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>259-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dimitroulopoulos-2005" MODIFIED="2012-05-07 11:57:57 +0200" MODIFIED_BY="[Empty name]" NAME="Dimitroulopoulos 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-05-07 11:57:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dimitroulopoulos D, Tsamakidis K, Xinopoulos D, Karaitianos I, Fotopoulou A, Paraskevas E</AU>
<TI>Prospective, Randomized, Controlled, Observer-Blinded Trial of Combined Infrared Photocoagulation and Micronized Purified Flavonoid Fraction Versus Each Alone for the Treatment of Hemorrhoidal Disease</TI>
<SO>Clinical Therapeutics</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>746-54</PG>
<IDENTIFIERS MODIFIED="2011-07-23 22:58:52 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 22:58:52 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godeberge-1994" MODIFIED="2012-07-05 13:06:58 +0200" MODIFIED_BY="[Empty name]" NAME="Godeberge 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-07-05 13:06:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godeberge P</AU>
<TI>Daflon 500 mg in the Treatment of Hemorrhoidal Disease: A demonstrated efficacy in comparison with placebo</TI>
<SO>Angiology</SO>
<YR>1994</YR>
<VL>45</VL>
<NO>6, Part 2</NO>
<PG>574-8</PG>
<IDENTIFIERS MODIFIED="2011-07-23 22:59:59 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 22:59:59 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ho-1995" MODIFIED="2011-07-23 23:00:43 +0200" MODIFIED_BY="[Empty name]" NAME="Ho 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-07-23 23:00:43 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ho YH, Foo CL, Seow-Choen F, Goh HS</AU>
<TI>Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy</TI>
<SO>British Journal of Surgery</SO>
<YR>1995</YR>
<VL>82</VL>
<PG>1034-1035</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:00:43 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:00:43 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ho-2000" MODIFIED="2012-05-07 11:58:47 +0200" MODIFIED_BY="[Empty name]" NAME="Ho 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-05-07 11:58:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ho YH, Tan M, Seow-Cheon F</AU>
<TI>Micronized Purified Flavonidic Fraction Compared Favorably with Rubber Band Ligation and Fiber Alone in the Management of Bleeding Hemorrhoids</TI>
<SO>Diseases of the Colon &amp; the rectum</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>1</NO>
<PG>66-9</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:01:59 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:01:59 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2006" MODIFIED="2012-05-07 11:59:03 +0200" MODIFIED_BY="[Empty name]" NAME="Jiang 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-07 11:59:03 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang ZM, Cao JD</AU>
<TI>The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>6</NO>
<PG>1141-7</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:02:34 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:02:34 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Torre-2004" MODIFIED="2012-07-05 13:07:14 +0200" MODIFIED_BY="[Empty name]" NAME="La Torre 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-07-05 13:07:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Torre F, Nicolai AP</AU>
<TI>Clinical Use of Micronized Purified Flavonoid Fraction for the Treatment of Symptoms After Hemorrhoidectomy: Results of a Randomized, Controlled, Clinical Trial</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2004</YR>
<VL>47</VL>
<PG>704-10</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:02:51 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:02:51 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mentes-2001" MODIFIED="2012-05-07 11:59:42 +0200" MODIFIED_BY="[Empty name]" NAME="Mentes 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-07 11:59:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mentes BB, Gorgul A, Tatlicioglu E, Ayoglu F, Unal S</AU>
<TI>Efficacy of Calcium Dobesilate in Treating Acute Attacks of Hemorrhoidal Disease</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>10</NO>
<PG>1489-95</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:03:47 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:03:47 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Misra-2000" MODIFIED="2012-05-07 12:00:00 +0200" MODIFIED_BY="[Empty name]" NAME="Misra 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-05-07 12:00:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Misra MC, Parshad R</AU>
<TI>Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids</TI>
<SO>British Journal of Surgery</SO>
<YR>2000</YR>
<VL>87</VL>
<PG>868-72</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:04:03 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:04:03 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mlakar-2005" MODIFIED="2012-05-07 12:00:12 +0200" MODIFIED_BY="[Empty name]" NAME="Mlakar 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-05-07 12:00:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mlakar B, Kosorok P</AU>
<TI>Flavonoids to reduce bleeding and pain after stapled hemorrhoidopexy: a randomized controlled trial</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>2005</YR>
<VL>117</VL>
<PG>558-60</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:04:21 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:04:21 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panpimanmas-2010" MODIFIED="2012-05-07 12:00:24 +0200" MODIFIED_BY="[Empty name]" NAME="Panpimanmas 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-05-07 12:00:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panpimanmas S, Sithipongsri S, Sukdanon C, Manmee C</AU>
<TI>Experimental Comparative Study of the Efficay and Side Effects of Cissus quadrangularis L.(Vitaceae) to Daflon (servier) and Placebo in the Treatment of Acute Hemorrhoids</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2010</YR>
<VL>93</VL>
<NO>12</NO>
<PG>1360-7</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:04:59 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:04:59 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarabia-2001" MODIFIED="2012-05-07 12:00:40 +0200" MODIFIED_BY="[Empty name]" NAME="Sarabia 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-07 12:00:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarabia M, Leon S, Vivas J, Lizarzabal M, Rangel R, Fernandez J, et al</AU>
<TI>Calcium Dobseilate Versus Purified Flavonoid Fraction of Diosmin in the Treatment of Hemorrhoidal Crisis: A Randomized, Controlled Study with an Initial Double-Blind, Double-Dummy Period</TI>
<SO>Current Therapeutic Research</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>7</NO>
<PG>524-9</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:05:20 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:05:20 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Squadrito-2000" MODIFIED="2012-05-07 12:01:18 +0200" MODIFIED_BY="[Empty name]" NAME="Squadrito 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-05-07 12:01:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Squadrito F, Altavilla D, Bosso SO</AU>
<TI>Double-blind, randomized clinical trial of troxerutin-carbazochrome in patients with hemorrhoids</TI>
<SO>European Review for Medical and Pharmacological Sciences</SO>
<YR>2000</YR>
<VL>4</VL>
<PG>21-4</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:05:44 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:05:44 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thanapongsathorn-1992" MODIFIED="2012-05-07 12:01:35 +0200" MODIFIED_BY="[Empty name]" NAME="Thanapongsathorn 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-05-07 12:01:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thanapongsathorn W, Vajrabukka T</AU>
<TI>Clinical Trial of Oral Diosmin (Daflon <SUP>R</SUP>) in the Treatment of Hemorrhoids</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>1085-8</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:06:02 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:06:02 +0200" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wijayanegara-1992" MODIFIED="2011-09-09 14:12:19 +0200" MODIFIED_BY="[Empty name]" NAME="Wijayanegara 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-09-09 14:12:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wijayanegara H, Mose JC, Achmad L, Sobarna R, Permadi W</AU>
<TI>A Clinical Trial of Hydroxyethylrutosides in the Treatment of Haemorrhoids of Pregnancy</TI>
<SO>The Journal of International Medical Research</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>54-60</PG>
<IDENTIFIERS MODIFIED="2011-09-09 14:12:19 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-09-09 14:12:19 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-09-09 14:09:38 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-07-05 15:50:44 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Garner-2002" MODIFIED="2011-06-27 13:32:41 +0200" MODIFIED_BY="[Empty name]" NAME="Garner 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-06-27 13:30:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garner 2002</AU>
<TI>Comparison of the absorption of micronized (Daflon 500mg) and non-micronized 14 C diosmin tablets after oral administration to healthy volunteers by accelerator mass spectroscopy and liquid scintillation</TI>
<SO>Journal of Pharmaceutical Sciences</SO>
<YR>2002</YR>
<VL>91</VL>
<NO>1</NO>
<PG>32-40</PG>
<IDENTIFIERS MODIFIED="2011-06-27 13:30:46 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-27 13:30:46 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-06-27 13:32:41 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kubchandani-2001" MODIFIED="2012-05-07 12:02:39 +0200" MODIFIED_BY="[Empty name]" NAME="Kubchandani 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-07 12:02:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khubchandani 2001</AU>
<TI>Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids</TI>
<SO>Techniques in Coloproctology</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>1</NO>
<PG>57-8</PG>
<IDENTIFIERS MODIFIED="2011-06-27 13:40:11 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-06-27 13:40:03 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marsicano-1995" MODIFIED="2012-07-05 15:46:57 +0200" MODIFIED_BY="[Empty name]" NAME="Marsicano 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-07-05 15:46:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marsicano LJ, Perez M</AU>
<TI>Effectiveness and safety of calcium dobesilate association with dexamethasone acetate and lidocaine with Prednisolone capronate with dibucaine hydrochloride, in the treatment of hemorrhoids</TI>
<TO>Efectividad e inocuidad de la Asociacion de Dobesilato de Calcio con Acetato de Dexametasona y Lidocaina con Capronato de Prednisolona con Clorhidrato de Dibucaina, en el Tratamiento de las Hemorroides</TO>
<SO>Gen Revista de la Sociedad Venezolana de Gastroenterologia</SO>
<YR>1995</YR>
<VL>49</VL>
<NO>4</NO>
<PG>296-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mlakar-2008" MODIFIED="2012-05-07 12:03:30 +0200" MODIFIED_BY="[Empty name]" NAME="Mlakar 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-07 12:03:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mlakar B</AU>
<TI>Flavonoids reduce bleeding after closed haemorhoidectomy-prospective randomized controlled trial</TI>
<SO>European Surgery</SO>
<YR>2008</YR>
<VL>40</VL>
<NO>1</NO>
<PG>34-6</PG>
<IDENTIFIERS MODIFIED="2011-07-23 23:03:19 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-07-23 23:03:19 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quijano-2005" MODIFIED="2012-07-05 15:50:44 +0200" MODIFIED_BY="[Empty name]" NAME="Quijano 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-05 15:50:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quijano CE, Abalos E</AU>
<TI>Conservative management of symptomatic and/or complicated haemorrhoids in pregnancy and the puerperium</TI>
<SO>Cochrane database of systematic reviews (Online)</SO>
<YR>2005</YR>
<VL>93</VL>
<NO>12</NO>
<PG>1360-7</PG>
<IDENTIFIERS MODIFIED="2012-07-05 15:50:44 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandhu-2004" MODIFIED="2012-05-07 12:05:27 +0200" MODIFIED_BY="[Empty name]" NAME="Sandhu 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-05-07 12:05:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandhu PS, Singh K</AU>
<TI>A randomized comparative study of micronized flavonoids and rubber band ligation in the treatment of acute internal haemorrhoids</TI>
<SO>Indian Journal of Surgery</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>5</NO>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1998" MODIFIED="2011-09-25 23:05:57 +0200" MODIFIED_BY="[Empty name]" NAME="Smith 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-09-25 23:05:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RB, Moodle J</AU>
<TI>Comparative efficacy and tolerability of two ointment an suppository preparations ('Uniroid' and Proctosedyl') in the treatment of second degree haemorrhoids in general practice</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>1</NO>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2006" MODIFIED="2012-05-07 12:06:05 +0200" MODIFIED_BY="[Empty name]" NAME="Tan 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-07 12:06:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan KY, SNG KK, Tay KH, Lai JH, Eu KW</AU>
<TI>Randomnized clinical trial of 0.2 per cent glyceryl trinitrate for wound healing and pain reduction after open diathermy haemorrhoidectomy</TI>
<SO>British Journal of Surgery</SO>
<YR>2006</YR>
<VL>93</VL>
<PG>1464-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-07-05 16:48:22 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-07-05 16:48:22 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abramowitz-2001" NAME="Abramowitz 2001" TYPE="JOURNAL_ARTICLE">
<AU>Abramowitz L, Godeberge P, Staumont G, Soudan D</AU>
<TI>[Clinical practice guidelines for the treatment of hemorrhoid disease]</TI>
<SO>Gastroenterol Clin Biol</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>6-7</NO>
<PG>674-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alonso_x002d_Coello-2006" MODIFIED="2012-05-07 12:06:39 +0200" MODIFIED_BY="[Empty name]" NAME="Alonso-Coello 2006" TYPE="JOURNAL_ARTICLE">
<AU>Alonso-Coello P, Zhou Q, Martinez-Zapata MJ, Mills E, Heels-Ansdell D, Johanson JF, et al</AU>
<TI>Meta-analysis of flavonoids for the treatment of haemorrhoids</TI>
<SO>British Journal of Surgery</SO>
<YR>2006</YR>
<VL>93</VL>
<PG>909-20</PG>
<IDENTIFIERS MODIFIED="2011-09-27 18:07:12 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-09-27 18:07:12 +0200" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Banov-1985" MODIFIED="2010-12-11 18:25:46 +0100" MODIFIED_BY="Nirmal Perera" NAME="Banov 1985" TYPE="JOURNAL_ARTICLE">
<AU>Banov L, Knoepp LF, Erdman LH, Alia RT</AU>
<TI>Management of hemorrhoidal disease</TI>
<SO>J S C Med Assoc</SO>
<YR>1985</YR>
<VL>7</VL>
<PG>398-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1998" MODIFIED="2012-05-07 12:06:54 +0200" MODIFIED_BY="[Empty name]" NAME="Beck 1998" TYPE="BOOK_SECTION">
<AU>Beck DE</AU>
<TI>Hemorrhoidal disease</TI>
<SO>Fundamentals of anorectal surgery</SO>
<YR>1998</YR>
<PG>237-53</PG>
<EN>2nd ed. London: WB Saunders</EN>
<ED>Beck DE, Wexner SD</ED>
<PB>WB Saunders</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-2011" MODIFIED="2012-07-05 15:35:37 +0200" MODIFIED_BY="[Empty name]" NAME="Beck 2011" TYPE="JOURNAL_ARTICLE">
<AU>Beck DE, Roberts PL, Saclarides TJ, Senagore AJ, Stamos MJ, Wexner SD</AU>
<TI>Chapter 11. Haemorrhoids</TI>
<SO>The ASCRS Textbook of Colon and Rectal Surgery</SO>
<YR>2011</YR>
<VL>2nd edition</VL>
<PG>182</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Billingham-2004" MODIFIED="2010-12-11 18:24:50 +0100" MODIFIED_BY="Nirmal Perera" NAME="Billingham 2004" TYPE="JOURNAL_ARTICLE">
<AU>Billingham RP, Isler JT, Kimmins MH</AU>
<TI>The diagnosis and management of common anorectal disorders</TI>
<SO>Curr Probl Surg</SO>
<YR>2004</YR>
<VL>41</VL>
<NO>7</NO>
<PG>586-645</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bleday-1992" MODIFIED="2012-05-07 12:07:14 +0200" MODIFIED_BY="[Empty name]" NAME="Bleday 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bleday R, Pena JP, Rothenberger DA, Goldberg SM, Buls JG</AU>
<TI>Symptomatic hemorrhoids: current incidence and complications of operative therapy</TI>
<SO>Dis Colon Rectum</SO>
<YR>1992</YR>
<VL>35</VL>
<NO>5</NO>
<PG>477-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2012-05-07 12:07:42 +0200" MODIFIED_BY="Nirmal Perera" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-Working-Group-2004" MODIFIED="2012-05-07 12:08:17 +0200" MODIFIED_BY="Nirmal Perera" NAME="GRADE Working Group 2004" TYPE="JOURNAL_ARTICLE">
<AU>GRADE Working Group</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>British Medical Journal</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>1490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenland-1985" MODIFIED="2010-12-11 17:03:50 +0100" MODIFIED_BY="Nirmal Perera" NAME="Greenland 1985" TYPE="JOURNAL_ARTICLE">
<AU>Greenland S, Robins JM</AU>
<TI>Estimation of a common effect parameter from sparse follow-up data</TI>
<SO>Biometrics</SO>
<YR>1985</YR>
<VL>41</VL>
<PG>55-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hain-2011" MODIFIED="2012-07-05 15:35:06 +0200" MODIFIED_BY="[Empty name]" NAME="Hain 2011" TYPE="JOURNAL_ARTICLE">
<AU>Hain J</AU>
<TI>Medical treatment of haemorrhoids using flavonoids</TI>
<SO>Practical Gastroenterology</SO>
<YR>2011</YR>
<VL>35</VL>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-05-07 11:52:14 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deek JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-12-14 11:02:00 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews and Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2009</YR>
<PB>Chichester (UK): John Wiley &amp; Sons</PB>
<IDENTIFIERS MODIFIED="2010-12-11 17:30:14 +0100" MODIFIED_BY="Nirmal Perera"/>
</REFERENCE>
<REFERENCE ID="REF-Ibanez-2000" MODIFIED="2012-05-07 12:08:46 +0200" MODIFIED_BY="Nirmal Perera" NAME="Ibanez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ibañez L, Ballarín E, Vidal X, Laporte JR</AU>
<TI>Agranulocytosis associated with calcium dobesilate. Clinical course and risk estimation with the case-control and the case-population approaches</TI>
<SO>European Journal Clinical Pharmacology</SO>
<YR>2000</YR>
<VL>56</VL>
<PG>763-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-1990" MODIFIED="2012-05-07 12:08:51 +0200" MODIFIED_BY="Nirmal Perera" NAME="Johanson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF, Sonnenberg A</AU>
<TI>The prevalence of hemorrhoids and chronic constipation. An epidemiologic study</TI>
<SO>Gastroenterology</SO>
<YR>1990</YR>
<VL>98</VL>
<NO>2</NO>
<PG>380-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-1992" MODIFIED="2012-05-07 12:08:57 +0200" MODIFIED_BY="Nirmal Perera" NAME="Johanson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF, Rimm A.</AU>
<TI>Optimal nonsurgical treatment of hemorrhoids: a comparative analysis of infrared coagulation, rubber band ligation, and injection sclerotherapy</TI>
<SO>Am J Gastroenterol</SO>
<YR>1992</YR>
<VL>87</VL>
<PG>1600-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" MODIFIED="2012-05-07 12:09:03 +0200" MODIFIED_BY="Nirmal Perera" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2005" MODIFIED="2012-07-05 15:55:39 +0200" MODIFIED_BY="[Empty name]" NAME="Kumar 2005" TYPE="BOOK">
<AU>Kumar V, Abbas A, Fausto N</AU>
<TI>Chapter 17, The Gastrointestinal Tract</TI>
<SO>Pathologic Basis of Disease</SO>
<YR>2005</YR>
<PG>854-855</PG>
<EN>7th Edition</EN>
<ED>Robbins and Cotran</ED>
<PB>Elsevier Saunders</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantel-1959" MODIFIED="2012-05-07 12:09:08 +0200" MODIFIED_BY="Nirmal Perera" NAME="Mantel 1959" TYPE="JOURNAL_ARTICLE">
<AU>Mantel N, Haenszel W</AU>
<TI>Statistical aspects of the analysis of data from retrospective studies of disease</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1959</YR>
<VL>22</VL>
<PG>719-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martinez-2005" MODIFIED="2012-07-05 16:46:57 +0200" MODIFIED_BY="[Empty name]" NAME="Martinez 2005" TYPE="COCHRANE_REVIEW">
<AU>Martinez MJ, Cosp BX, Moreno RM, Vargas E, Capellà D</AU>
<TI>Phlebotonics for venous insufficiency</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-07-05 16:46:57 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-05 16:46:57 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1002/14651858. CD003229.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moesgaard-1982" NAME="Moesgaard 1982" TYPE="JOURNAL_ARTICLE">
<AU>Moesgaard F, Nielsen ML, Hansen JB, Knudsen JT</AU>
<TI>High-fiber diet reduces bleeding and pain in patients with hemorrhoids: a double-blind trial of Vi-Siblin</TI>
<SO>Dis Colon Rectum</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>454-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quijano-2005" MODIFIED="2012-07-05 16:48:22 +0200" MODIFIED_BY="[Empty name]" NAME="Quijano 2005" TYPE="COCHRANE_REVIEW">
<AU>Quijano CE, Abalos E</AU>
<TI>Conservative management of symptomatic and/or complicated haemorrhoids in pregnancy and the puerperium</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-07-05 16:48:22 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-05 16:48:22 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858. CD"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schunemann-2008" MODIFIED="2012-07-05 15:43:03 +0200" MODIFIED_BY="Nirmal Perera" NAME="Schunemann 2008" TYPE="BOOK_SECTION">
<AU>Schunemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and "Summary of findings" tables</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>336-57</PG>
<ED>Higgins JPT, Green S</ED>
<PB>Chichester (UK): John Wiley &amp; Sons</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomson-1975" MODIFIED="2012-05-07 11:53:32 +0200" MODIFIED_BY="Nirmal Perera" NAME="Thomson 1975" TYPE="JOURNAL_ARTICLE">
<AU>Thomson WH</AU>
<TI>The nature of haemorrhoids</TI>
<SO>British Journal of Surgery</SO>
<YR>1975</YR>
<VL>62</VL>
<NO>7</NO>
<PG>542-52</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-07-09 12:17:47 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-07-09 12:17:47 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-03-21 11:30:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011">
<CHAR_METHODS MODIFIED="2012-03-21 11:30:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized observer-blinded randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-05 21:49:35 +0100" MODIFIED_BY="[Empty name]">
<P>Mean age of controls 53.2 years and mean age of Diosmin was 51.3 years.</P>
<P>Male and female participants.</P>
<P>China, university hospital surgical department.</P>
<P>Eighty-six consecutive patients aged 12-75 years with grade III and grade IV acute mixed haemorrhoids and indication for haemorrhoidectomy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-16 00:16:47 +0200" MODIFIED_BY="[Empty name]">
<P>Milligan-Morgan haemorrhoidectomy performed on all patients with the exception of three who were subject to a haemorrhoidopexy. The patients were then subject to two groups;</P>
<P>Group 1; Diosmin 500mg, three tablets twice daily, after meals for three days followed by two tablets twice daily from day four to day seven.</P>
<P>Group 2; Identical placebo regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 21:38:35 +0200" MODIFIED_BY="[Empty name]">
<P>Assessment of pain via patient self-questionnaires; verbal response scales and visual analogue scales.</P>
<P>Number of patients experiencing post-operative symptoms of bleeding, heaviness, pruritis and mucosal discharge at pre-specified time intervals of two and eight weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 22:06:09 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were patients complicated with fistula or anal fissure, inflammatory bowel disease, dermatitis, proctitis, pregnancy, severe cardiovascular state or pulmonary complications.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:30:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Annoni-1986">
<CHAR_METHODS MODIFIED="2012-03-21 11:30:51 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blinded randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:30:56 +0100" MODIFIED_BY="[Empty name]">
<P>Mean age of participants was 42.1 +/- 12.48 years</P>
<P>Male and female</P>
<P>Italy, University hospital setting</P>
<P>Fifty patients (33 male and 17 female) with 2nd, 3rd and 4th degree haemorrhoids were enrolled</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:30:56 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to receive two treatments;</P>
<P>Group 1; 20 patients (12 male and 8 female) were treated with O-rutosidea (HR), 4 g per day in total (2 sachets in 1/2 glass water twice a day)</P>
<P>Group 2; Comparable placebo with similar therapeutic regime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-23 00:42:19 +0100" MODIFIED_BY="[Empty name]">
<P>Haemorrhoidal symptoms based on a visual analogue scale</P>
<P>(VAS score) assessing the symptoms of pain, discharge, bleeding and inflammation. Assessment was performed by doctors by rectal examination and symptoms graded on a 4 point severity scale (0= absent, 1=mild, 2=moderate, 3=severe)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-23 00:43:43 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were treatment with NSAIDS or steroids in the previous 30 days or surgical treatment in the past 6 months.</P>
<P>Also excluded were those treated with analgesics, anti-inflammatories, local anaesthetics or ice.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-07 11:37:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Basile-2001">
<CHAR_METHODS MODIFIED="2011-09-25 22:06:26 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized double-blinded placebo controlled phase IV study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:06:44 +0200" MODIFIED_BY="[Empty name]">
<P>Average age of participants were 47 years in the Troxerutin group and 41 years in the placebo group.</P>
<P>Male and female participants.</P>
<P>Italy, university hospital setting.</P>
<P>Thirty patients were enrolled within the age group of 18-60 years with confirmed haemorrhoidal disease which had an indication for either surgery or rubber band ligation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-07 11:37:42 +0200" MODIFIED_BY="[Empty name]">
<P>Following haemorrhoidectomy patients were randomised to either two groups;</P>
<P>Group 1; Troxerutin 150 mg and carbazochrome 1.5 mg in combination. 3ml ampoules twice a day for five consecutive days after surgical procedure.</P>
<P>Group 2; Placebo, IM 3 ml ampoules twice a day for five consecutive days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-21 11:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Haemorrhoidal symptoms based on a visual analogue score (VAS), pain, discharge, bleeding and pruritus.</P>
<P>Pain medication intake.</P>
<P>Time taken to restore physiological defecation.</P>
<P>Oedema evaluation based on four-point evaluation scale (0=none, 1=mild, 2=moderate, 3=severe).</P>
<P>Camera pictures taken at T1 and T4.</P>
<P>Blood coagulation tests.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 22:07:29 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were unwillingness to co-operate, poor motivation, emotional or intellectual problems, participation in other studies involving marketed products, history of allergies or hypersensitivities, pregnancy or lactation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:31:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Basile-2002">
<CHAR_METHODS MODIFIED="2012-03-21 11:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blinded randomised controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Mean age of participants was 45.6 +/- 7.4 years.</P>
<P>Male and female participants.</P>
<P>Italy, university hospital setting.</P>
<P>Sixty patients (33 male and 27 female) aged 18-65 years were enrolled for haemorrhoidectomy or rubber band ligation and then randomised into two treatment groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>Following a haemorrhoidectomy or rubber band ligation patients were randomised to receive one of two treatments;</P>
<P>Group 1; troxerutin 150mg plus carbazochrome 1.5 mg in 3 ml ampoules twice a day for five consecutive days after surgery starting on the day of surgery.</P>
<P>Group 2; Comparable placebo with similar therapeutic regime.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:07:59 +0200" MODIFIED_BY="[Empty name]">
<P>Haemorrhoidal symptoms based on a visual analogue scale (VAS score) assessing the symptoms of pain, discharge, bleeding and inflammation.</P>
<P>Oedema based on a four-point scale; (0=absent, 1=mild, 2=moderate, 3=severe).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:31:38 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were chronic or severe disease (diabetes mellitus, coagulation disorders/oncological diseases) altered hepatic function, renal function, portal hypertension or pelvic tumours.</P>
<P>Unwillingness to co-operate, poor motivation, emotional problems, participation in other studies involving investigational or marketed products within one month preceding study entry, a history of allergy to the phlebotonics used, pregnancy and lactation were also exclusion criteria.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:31:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcaro-2010">
<CHAR_METHODS MODIFIED="2011-08-17 23:22:51 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled clinical trial evaluating Pycnogenol<SUP>R</SUP> treatment for acute external haemorrhoidal episodes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:08:30 +0200" MODIFIED_BY="[Empty name]">
<P>Average age for the oral Pycnogenol<SUP>R</SUP> group and the placebo were 49.3 years and 48.9 years respectively.</P>
<P>Male and female adult participants.</P>
<P>Germany, university hospital setting.</P>
<P>Eighty-four participants suffering from an acute episode of external haemorrhoids (lasting 24-48 hours prior to exclusion were chosen).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:31:46 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to the following treatment groups;</P>
<P>Group A; High dose Pycnogenol<SUP>R.</SUP>
</P>
<P>Group B; Comparable placebo.</P>
<P>Group C; topical 0.5% Pycnogenol <SUP>R</SUP> cream in combination with high dose Pycnogenol<SUP> R</SUP> oral treatment as in group A.</P>
<P>Group D; Oral Pycnogenol <SUP>R</SUP> in combination with topical sham cream.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-21 11:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Frequently observed signs and symptoms which included acute intravascular thrombosis, acute severe perianal pain, purple/black edematous and tense subcutaneous perianal mass, tenderness, ischaemia/necrosis of the overlying skin and bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 22:09:22 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were;</P>
<P>i) Patients requiring any other cardiovascular treatment.</P>
<P>ii) Recently received surgery.</P>
<P>iii) Diagnosed with infections/tumours.</P>
<P>iv) Severely handicapped.</P>
<P>v) The need for surgery (bleeding, thrombosis, prolapse, pain not responding to medical treatment or other complications).</P>
<P>vi) Portal hypertension.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:32:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chauvenet-1994">
<CHAR_METHODS MODIFIED="2012-03-21 11:32:04 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blinded controlled multicentric randomised controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-04 22:33:51 +0100" MODIFIED_BY="[Empty name]">
<P>94 participants male and female in a French hospital setting.</P>
<P>Patients were suffering from either external haemorrhoidal thrombosis requiring medical treatment or internal congestive haemorrhoidal crisis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-02 22:44:57 +0100" MODIFIED_BY="[Empty name]">
<P>Diosmin; 1800 mg Diosmin for four days divided into 3 doses, (morning, noon and evening). Then 1200 mg Diosmin divided into three doses (morning, noon and evening) for four days</P>
<P>Placebo; Similar placebo regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-12 00:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>Pain and oedema/congestive status on D0 and D7 (main criteria)</P>
<P>Global score of other signs D0 and D7, overall assessment of investigator on D7 and pain relief</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:32:16 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were anal fissure, haemorrhoidal prolapse, thrombosed haemorrhoidal prolapse, cryptitis, phlebitis, anti-inflammatory drugs such as NSAIDs or steroids and intolerance to Diosmin</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:32:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colak-2003">
<CHAR_METHODS MODIFIED="2012-03-21 11:32:27 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised controlled observer-blinded clinical study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:09:39 +0200" MODIFIED_BY="[Empty name]">
<P>Median age for MFF group was 41 (22-86) years and median age of control group was 45 (32-63) years.</P>
<P>Male and female participants.</P>
<P>Turkey, university hospital setting.</P>
<P>112 patients who had symptomatic 3<SUP>rd </SUP>or 4<SUP>th</SUP> degree haemorrhoids requiring haemorrhoidectomy were enrolled.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-25 22:09:48 +0200" MODIFIED_BY="[Empty name]">
<P>Post-haemorrhoidectomy the patients were randomly assigned into the following groups;</P>
<P>Group 1; MFF for 1 week after haemorrhoidectomy.</P>
<P>Group 2; Control group for 1 week after haemorrhoidectomy (not receiving MFF).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:10:01 +0200" MODIFIED_BY="[Empty name]">
<P>Pain scores after haemorrhoidectomy based on a linear analogue scale (0-10).</P>
<P>Number of patients who required intramuscular analgesic injections.</P>
<P>Comparison of urinary retention, hospital stay, and patient satisfaction levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:32:33 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with concomitant anal disease such as fistulae, fissures, Crohn's, ulcerative colitis, rectal cancer or those taking oral anticoagulants were excluded.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:32:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cospite-1992">
<CHAR_METHODS MODIFIED="2011-09-25 22:10:18 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized double-blinded controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-04 21:18:20 +0100" MODIFIED_BY="[Empty name]">
<P>59 adult patients with haemorrhoids.</P>
<P>University hospital setting, Italy.</P>
<P>Patients had at least one acute episode in the 2 months prior to entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-25 22:10:29 +0200" MODIFIED_BY="[Empty name]">
<P>Group 1; Daflon 500mg.</P>
<P>Group 2; Diosmin 900 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:10:53 +0200" MODIFIED_BY="[Empty name]">
<P>Grading of anal symptoms on a four-point scale (0-3).</P>
<P>Frequency and duration of acute episodes.</P>
<P>Patient satisfaction scales.</P>
<P>Investigator satisfaction scales.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:32:54 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were associated recto-sigmoidal conditions, progressive local parasitic infestations, anal fissure, complete and effective prior haemorrhoidectomy, entropic treatment in the previous two months and treatment with any other experimental drug, concomitant therapy with anti-inflammatory drugs, anticoagulants or platelet anti-aggregates.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 12:16:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cospite-1994">
<CHAR_METHODS MODIFIED="2011-09-25 22:11:03 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blinded placebo controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>Mean age of participants was 44.6 years in Daflon group and 42.6 years in placebo group.</P>
<P>Male and female regardless of age or sex.</P>
<P>100 participants were recruited with a history of haemorrhoidal disease confirmed by endoscopic examination suffering from an uncomplicated and acute attack of haemorrhoids lasting no more than three days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-25 22:11:28 +0200" MODIFIED_BY="[Empty name]">
<P>Group 1; Daflon 500 mg for seven days at the dosage of six tablets daily (3 bd) during the first four days and four tablets daily (2 bd) during the following three days.</P>
<P>Group 2; Placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:11:30 +0200" MODIFIED_BY="[Empty name]">
<P>Number of patients with symptoms; proctorrhagia, anal discomfort, pain, anal discharge, proctitis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-09 12:16:48 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were; need of a surgical procedure, associated anal fissure, permanent prolapse, patients treated with phlebotonics, anticoagulant, anti-inflammatory drugs, those taking analgesic or topical medications not authorized from the study protocol.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:33:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Debien-1996">
<CHAR_METHODS MODIFIED="2012-03-21 11:33:15 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentric randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-24 00:52:04 +0100" MODIFIED_BY="[Empty name]">
<P>Patients who were aged eighteen who were suffering from a haemorrhoid crisis defined by pain lasting for at least 48 hours and of intensity superior or equal to 6/10 on an analogue scale.</P>
<P>Clinical exam had to reveal one of the following; congestion, external haemorrhoid oedema, thrombosis with no surgical indication and swelling of internal haemorrhoids.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1; Diosmin. One tablet morning, noon and evening for seven days.</P>
<P>Group 2; Gingko biloba-heptaminol-troxerutin. Two tablets in the morning, one tablet at midday and one tablet the evening.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-12 14:32:31 +0100" MODIFIED_BY="[Empty name]">
<P>Intensity of pain was recorded on a Visual analogue scale daily two hours after taking the medication.</P>
<P>Three days after the medication was complete patients were evaluated for any functional or physical signs of a haemorrhoid crisis.</P>
<P>Compliance and adverse effects were also recorded.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-17 22:06:20 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria included any other associated pathologies including rectal, sigmoid, colon, intestinal or proctological other than haemorrhoid crisis.</P>
<P>If there were any of the following treatment; venotonics, anticoagulation, antithrombotics, anti-inflammatories (NSAIDS or steroids) or any previous topical treatment to haemorrhoids.</P>
<P>Also patients with intolerance to the treatment, pregnant women, lactating women and sexually active women who did not take contraception were also excluded.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:33:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dimitroulopoulos-2005">
<CHAR_METHODS MODIFIED="2012-03-21 11:33:28 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised controlled single-blinded study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:33:35 +0100" MODIFIED_BY="[Empty name]">
<P>Mean age was 49.2 years (range, 29-71 years).</P>
<P>Male and female participants.</P>
<P>Presenting with rectal bleeding due to grades I, II and III acute internal haemorrhoids with no previous treatment for haemorrhoids within the last 6 months and without colonic disease.</P>
<P>Greece, university hospital setting.</P>
<P>A total of 351 patients presenting with rectal bleeding due to grades I, II and III acute internal haemorrhoids were enrolled into the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:33:35 +0100" MODIFIED_BY="[Empty name]">
<P>Patients (117 each) were randomly assigned into the following groups;</P>
<P>Group 1; MPFF and IRP group; Patients received 6 tablets (3000mg) of oral MPFF daily in 2 equally divided doses, after breakfast and before dinner for five days.</P>
<P>Group 2; MPFF group; Patients assigned to give MPFF dose as above.</P>
<P>Group 3; IRP group; Patients underwent an IRP procedure.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:12:22 +0200" MODIFIED_BY="[Empty name]">
<P>Primary end-point; rate of bleeding cessation (expressed in percentage of patients with no bleeding) within five days after intervention.</P>
<P>Secondary end-point; prevention of relapse within 90 days after intervention.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:33:47 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were pregnancy, history of acute haemorrhoidal attack occuring at least 6 months before enrolment, grade IV haemorrhoids, concomitant large-bowel and anal canal diseases, history of pelvic radiation, use of anti-coagulation, anti-platelet agents and non-steroidal anti-inflammatory drugs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:33:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godeberge-1994">
<CHAR_METHODS MODIFIED="2012-03-21 11:33:47 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blinded, placebo controlled, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:33:51 +0100" MODIFIED_BY="[Empty name]">
<P>Mean age of patients in Daflon group was 46 years and men age of patients in Placebo group was 48 years.</P>
<P>Male and female participants aged over 18 years.</P>
<P>Hospital setting France.</P>
<P>One hundred and twenty outpatients (54 men,66 women) suffering from an acute episode of symptomatic haemorrhoidal disease during the previous two months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-25 22:12:51 +0200" MODIFIED_BY="[Empty name]">
<P>Group 1; Daflon 500mg, two tablets daily.</P>
<P>Group 2; placebo compound.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:13:04 +0200" MODIFIED_BY="[Empty name]">
<P>Changes in number, mean duration, mean severity of attacks.</P>
<P>Change in mean score per feature.</P>
<P>Change in overall symptom and sign score.</P>
<P>Percentage of patients improved in each group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:33:52 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were indication for non-medical treatment (permanent irreducible prolapse, external thrombosed pile, anal fissure; documented concomitant disease, previous haemorrhoidectomy; treatment with any of the following at inclusion or in the previous two months (venotropic agent, anticoagulant, platelet antiaggregant, anti-inflammatory agent).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:34:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ho-1995">
<CHAR_METHODS MODIFIED="2011-09-25 22:13:35 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled observer-blinded clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:13:47 +0200" MODIFIED_BY="[Empty name]">
<P>Mean age of patients was 39.5 years.</P>
<P>Male and female.</P>
<P>Singapore, general hospital setting.</P>
<P>228 consecutive patients with symptomatic prolapsed irreducible haemorrhoids were recruited for a standardized diathermy excision of three piles without ligation of pedicles.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:34:07 +0100" MODIFIED_BY="[Empty name]">
<P>Post elective haemorrhoidectomy patients were randomised into two groups (114 each);</P>
<P>Group 1; Daflon 500 mg (two tablets three times daily for three days, followed by one tablet three times daily for the four days).</P>
<P>Group 2; Control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:14:14 +0200" MODIFIED_BY="[Empty name]">
<P>Reactionary haemorrhage.</P>
<P>Secondary haemorrhage (occuring 7-14 days post-op).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 22:14:21 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were not stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:34:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ho-2000">
<CHAR_METHODS MODIFIED="2011-09-25 22:14:31 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled observer-blinded clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:34:15 +0100" MODIFIED_BY="[Empty name]">
<P>Mean age of participants were 44.7 years in the FIBER group, 44.4 years in the BAND group and 41.4 years in the MPFF group.</P>
<P>Male and female adult participants.</P>
<P>Singapore, general hospital setting.</P>
<P>162 patients with bleeding non-prolapsed haemorrhoids were recruited and randomly assigned to the three groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:34:22 +0100" MODIFIED_BY="[Empty name]">
<P>162 patients were randomly assigned to the following treatment groups;</P>
<P>Group 1; FIBER group. 3.5g sachet of ispaghula husk twice daily for three months.</P>
<P>Group 2; BAND group. Rubber band ligation of internal piles.</P>
<P>Group 3; MPFF group. Micronized Purified Flavonoidic Fraction (Daflon<SUP>R</SUP>) in addition to a similar dose and duration of ispaghula husk.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:15:01 +0200" MODIFIED_BY="[Empty name]">
<P>Time taken for relief of haemorrhoidal bleeding.</P>
<P>Recurrence of haemorrhoidal bleeding at 6 month follow-up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were previous treatment for the episode of bleeding, no history of bleeding disorders and total colonoscopy was performed to exclude other sources of per rectum bleeding.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:34:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2006">
<CHAR_METHODS MODIFIED="2011-09-25 22:15:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized double-blinded controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:15:45 +0200" MODIFIED_BY="[Empty name]">
<P>Mean age of participants were 43.2 years (range 18-76 years).</P>
<P>Male and female.</P>
<P>Chinese nationality, university hospital setting.</P>
<P>Ninety patients aged over eighteen experiencing an acute haemorrhoidal disease episode for less than 48 hours were enrolled.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:34:25 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised into the following therapeutic regimen;</P>
<P>Group 1; Micronized Purified Flavonoid Fraction (MPFF); six tablets per day for four days followed by four tablets per day for three days.</P>
<P>Group 2; Active placebo with identical therapeutic regime.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:16:34 +0200" MODIFIED_BY="[Empty name]">
<P>Symptoms and signs that were recorded by investigators using a four-point grading scale.</P>
<P>Functional improvement in symptoms as recorded by the patient.</P>
<P>Global efficacy of treatment as recorded by patients and investigators.</P>
<P>Safety of treatment recorded on day four and day seven.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:34:28 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were the presence of severe haemorrhoidal manifestations, anal fissure, permanent prolapsed haemorrhoids, parasitic infection, systemic pathology requiring treatment.</P>
<P>Phlebotonic medication, anti-coagulant and anti-platelet agents, analgesic or anti-inflammatory drugs as well.</P>
<P>Also excluded were patients less than 18 years old, those taken part in another clinical trial, patients with a past history of GI resection, alcohol or drug abuse, allergies to diosmin or any other phlebotonic medication, abnormal hepatic enzymes or abnormal renal function.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-25 22:20:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-La-Torre-2004">
<CHAR_METHODS MODIFIED="2011-09-25 22:18:05 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled clinical trial evaluating the combination of micronized purified flavonoid fraction with short-term routine antibiotics and anti-inflammatory therapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:18:50 +0200" MODIFIED_BY="[Empty name]">
<P>Fifty-patients with an average age of 56 years were (35-74) years were recruited.</P>
<P>Male and female participants aged over 18 years.</P>
<P>Italy, university hospital setting.</P>
<P>Fifty patients with an average age of fifty-six with irreducible prolapsed haemorrhoids and an indication for haemorrhoidectomy, past history of haemorrhoids longer than six months, symptomatic irreducible prolapsed haemorrhoids and informed consent were selected.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-25 22:19:59 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to the following treatment groups immediately after surgery;</P>
<P>Group 1; Posthaemorrhoidectomy antibiotic and anti-inflammatory therapy (control group).</P>
<P>Group 2; Posthaemorrhoidectomy antibiotic and anti-inflammatory and MPFF.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-20 01:23:06 +0200" MODIFIED_BY="[Empty name]">
<P>Self-assessment of specific symptoms such as pain,bleeding, tenesmus and pruritus. These were scored with an observation period of 60 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 22:20:09 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were fistula, chronic anal fissure, inflammatory bowel disease, diabetes, other metabolic or endocrine disorders, coagulation disorders and previous anorectal surgery.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:34:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mentes-2001">
<CHAR_METHODS MODIFIED="2011-09-25 22:20:55 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized double-blinded controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:21:17 +0200" MODIFIED_BY="[Empty name]">
<P>Median age of Doxium and controlled diet group were 43 (range 19-59) years and 42 (18-60) years respectively.</P>
<P>Turkish nationality, university hospital setting.</P>
<P>45 adult patients with 1<SUP>o </SUP>or 2<SUP>o </SUP>degree internal haemorrhoids. Internal symptoms had existed for longer than six months and rectal bleeding was currently present indicating an acute attack.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:34:28 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised into the following groups;</P>
<P>Group 1; (controlled group) n=16. Dietary and lifestyle advise measures only.</P>
<P>Group 2; (Doxium <SUP>R</SUP>) n=30. Loading dose of Doxium <SUP>R</SUP> three tablets per day in three divided doses for one week followed by two tablets daily for one week and dietary and lifestyle advise.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:22:16 +0200" MODIFIED_BY="[Empty name]">
<P>Relief of symptoms (2=no relief of symptoms/worsening), 1=partial relief of symptoms, 0=significant relief or lack of symptoms).</P>
<P>Anitis score.</P>
<P>Cessation of bleeding plus lack of severe anitis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 22:22:47 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were concurrent fistulae, chronic anal fissure, inflammatory bowel disease, diabetes or other metabolic or endocrine abnormalities, alcoholism, drug abuse, coagulation disorders, abnormal sexual habits, previous anorectal surgery or previous treatment of haemorrhoidal disease with any method other than diet or topical agents.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-09-25 22:25:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Misra-2000">
<CHAR_METHODS MODIFIED="2011-09-25 22:23:18 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized double-blinded controlled clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:23:52 +0200" MODIFIED_BY="[Empty name]">
<P>Mean age of the MPFF and placebo group were 34.8 years and 33.3 years respectively.</P>
<P>Male and female aged over 18 years of age.</P>
<P>India, university hospital setting.</P>
<P>100 consecutive patients were chosen who had a past history of haemorrhoids of less than 18 months presenting with acute rectal bleeding of less than three days in association with visible grade I or II internal haemorrhoids upon proctoscopic examination.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-25 22:24:17 +0200" MODIFIED_BY="[Empty name]">
<P>Group1; Micronized Purified flavonoid fraction; Two sequential phases. First phase involved taking six tablets per day for four days and four tablets per day for three days. In the second phase (prevention of relapse) patients whose bleeding had stopped by the end of the first phase took two tablets per day for 83 days.</P>
<P>Group 2; Placebo; identical regimen.The placebo tablet had an identical appearance.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:24:43 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure was the number of patients with no bleeding on the third completed day of treatment.</P>
<P>Secondary outcomes measures were the number of patients in whom relapse of bleeding was prevented and the mean time between cessation of bleeding and relapse.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 22:25:07 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were presence of anal fissure, inflammatory bowel disease, colorectal cancer, pregnancy, previous laser treatment, use of a flavonoid drug 1 month before inclusion. Also treatment with analgesics, topical anti-haemorrhoidal ointments, NSAIDS, steroids, anticoagulants or anti-platelet agents.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-07 11:38:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mlakar-2005">
<CHAR_METHODS MODIFIED="2012-03-21 11:34:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled observer-blinded clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:35:07 +0100" MODIFIED_BY="[Empty name]">
<P>Average age of participants were 49 years.</P>
<P>Male and female.</P>
<P>Slovenia, medical centre.</P>
<P>63 patients (44 females and 17 males) with 3<SUP>rd</SUP> degree haemorrhoids had ambulatory stapled haemorrhoidopexy under spinal anaesthesia during the period of one year and were randomised to either the control or Detralex group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>Following haemorrhoidopexy the patients were randomised to the following groups;</P>
<P>i) Detralex; two tablets three times daily for five days after the operation.</P>
<P>ii) Control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-07 11:38:39 +0200" MODIFIED_BY="[Empty name]">
<P>Self-assessment of the presence of blood on defecation, degree of pain and consumption of analgesics for the first week after the operation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 22:27:11 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were not specified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:35:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Panpimanmas-2010">
<CHAR_METHODS MODIFIED="2012-03-21 11:35:19 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised double-blinded controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:35:27 +0100" MODIFIED_BY="[Empty name]">
<P>Majority of patients were in the 25-40 year age category.</P>
<P>Thailand, university hospital setting and general hospital setting. Trials were carried out in three different hospital settings.</P>
<P>Five-hundred and seventy patients (299 females, 271 males) aged under fifty years were recruited who had suffered an acute symptomatic haemorrhoidal episode within the last five days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:35:27 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised into three groups;</P>
<P>Group 1; C.quadrangularis, three tablets twice a day for four days then two tablets twice a day for three days.</P>
<P>Group 2; MPFF group, similar regime as in group.</P>
<P>Group 3; Placebo group; identical therapeutic regime.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-08-21 23:10:34 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were evaluated based on bleeding, discharge, pain, pruritis, erythema and direct patient interviews. Each symptom was scored on a graded severity scale from 0 to 3 on the first and seventh day of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were previous haemorrhoidectomy, treatment with anticoagulation or ASA, taking other anti haemorrhoidal drugs at the time, permanent prolapsed internal haemorrhoids requiring surgery, patients suffering from moderate to severe hypertension, cardiovascular diseases, renal failure, cirrhosis, pregnancy and lactation.</P>
<P>Discontinuation criteria were severe side effects and life-threatening situations.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:35:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sarabia-2001">
<CHAR_METHODS MODIFIED="2011-09-25 22:30:12 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled study with an initial double-blind period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>Age range was 18-75 years.</P>
<P>Male and female participants.</P>
<P>Venezuala, university hospital setting.</P>
<P>A total of fifty-one patients with a diagnosis of acute haemorrhoidal crisis were randomised to receive either calcium dobesilate or a micronized flavonoid fraction of diosmin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-21 11:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to either of the following groups;</P>
<P>i) Calcium dobesilate 1 capsule (500 mg) TID for &gt; 4 weeks,</P>
<P>ii) Micronized flavonoid fraction of diosmin two tablets 500-mg tablets TID for &gt; 4 weeks.</P>
<P>For the first ten days, patients in both groups were given dummy capsules or tablets to maintain the double-blinded provision.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-21 11:35:38 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment of haemorrhoidal symptoms on a four-point scale (pain, discharge, bleeding, oedema, inflammation, pruritis and anal pressure).</P>
<P>Use of pain medication, new acute episodes, patient perspective of efficacy, incidence of adverse events and compliance were assessed with direct patient interviews.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:35:46 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were previous rectal surgery, indication for surgery, chronic or serious disease, altered hepatic or renal function, pelvic tumour or portal hypertension.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-07 11:38:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Squadrito-2000">
<CHAR_METHODS MODIFIED="2012-03-21 11:35:46 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blinded, randomised parallel group controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 22:34:32 +0200" MODIFIED_BY="[Empty name]">
<P>Average age for the control group and study group were 40.3 years and 40.6 years respectively.</P>
<P>Male and female participants.</P>
<P>Italy, university hospital setting.</P>
<P>One hundred patients with acute uncomplicated haemorrhoids who were at least thirty years of age were enrolled provided their diagnosis was endoscopically confirmed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-25 22:44:16 +0200" MODIFIED_BY="[Empty name]">
<P>Patients were allocated into the following groups;</P>
<P>Group 1; Troxerutin 150 mg and carbazochrome 1.5 mg twice daily by intramuscular route.</P>
<P>Group 2; Saline containing carbazochrome 1.5mg to give the solution the same appearance as the combination product (control drug).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-07 11:38:52 +0200" MODIFIED_BY="[Empty name]">
<P>Subjective efficacy variable; (anal discomfort, spontaneous local bleeding, and pain at defecation).</P>
<P>Objective efficacy variables (proctorrhagia, proctitis, anal prolapse).</P>
<P>All evaluated by a four-point scale 0=absent, 4=severe.</P>
<P>Safety assessment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:36:15 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were advanced haemorrhoids requiring surgery, type 1 diabetes, congestive heart failure treated with anti-platelet drugs, presence of clinically significant renal, hepatic or other severe disease.</P>
<P>Use of various medications such as fibrinolytic drugs, venous acting medications, investigational drugs within 30 days of screening, analgesic (other than 5% lidocaine ointment), NSAIDS within 7 days of screening or concomitant use of medications were not allowed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-21 11:36:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thanapongsathorn-1992">
<CHAR_METHODS MODIFIED="2012-03-21 11:36:15 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blinded randomised controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:36:18 +0100" MODIFIED_BY="[Empty name]">
<P>Average age of participants in placebo and Diosmin group were 32 years.</P>
<P>Male and female.</P>
<P>Thailand, university hospital setting.</P>
<P>One-hundred new and consecutive patients with acute symptoms due to first and second degree internal haemorrhoids were enrolled.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-25 22:37:45 +0200" MODIFIED_BY="[Empty name]">
<P>Group 1; Oral Diosmin. Twelve tablets in three divided doses during the first four days and then two tablets twice daily for another ten days.</P>
<P>Group 2; Placebo; identical therapeutic regimen.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-12 00:07:55 +0200" MODIFIED_BY="[Empty name]">
<P>Assessment of symptoms assessed in relation to subjective symptoms, which were;</P>
<P>i) bleeding ii) pain iii) prolapse iv) burning v) pruritis vi) tenesmus vii) heaviness.</P>
<P>Assessment of symptoms in relation to objective assessment which were i) swelling ii) congestion iii) bleeding iv) exudation v) prolapse.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-18 21:18:36 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria were surgical anorectal diseases, previous internal haemorrhoid treatment, pregnancy, portal hypertension and haematological diseases.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 12:17:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wijayanegara-1992">
<CHAR_METHODS MODIFIED="2012-03-21 11:36:22 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blinded randomised placebo controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-21 11:36:27 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women between 12 and 34 weeks gestation.</P>
<P>Female participants, pregnant.</P>
<P>Indonesia, antenatal clinic centres.</P>
<P>A total of 100 patients were recruited to the trials based on certain inclusion criteria; i) severity of haemorrhoids (1st, 2nd and 3rd degree haemorrhoids) ii) Between weeks 12 and 34 gestation iii) a pregnancy with no medical or obstetric complications iv) No other treatment was given except for vitamins.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-09 12:17:47 +0200" MODIFIED_BY="[Empty name]">
<P>Random allocation of patients into the following treatment groups;</P>
<P>i) One tablet orally of hydroxyethyl-rutoside taken orally twice daily for four weeks.</P>
<P>ii) Corresponding placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 22:40:31 +0200" MODIFIED_BY="[Empty name]">
<P>Global opinion of the patients involved.</P>
<P>Overall evaluation of the efficacy of the clinicians.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-09 14:31:08 +0200" MODIFIED_BY="[Empty name]">
<P>Exclusion criteria included i) fourth degree haemorrhoids ii) All participants were informed not to use any other systemic or local treatment (except vitamins) including non-prescription drugs during the trial period.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-07-01 21:24:10 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-03-21 11:36:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garner-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-21 11:36:27 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial evaluating the effect of phlebotonics in treating haemorrhoids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-21 11:36:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kubchandani-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-21 11:36:27 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceedings describing randomised controlled trials.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-01 21:24:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marsicano-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-01 21:24:10 +0200" MODIFIED_BY="[Empty name]">
<P>Poor methodology existed with inadequate description of sequence generation, blinding and allocation concealment.</P>
<P>Baseline imbalance existed with crucial differences in characteristics between participants from both groups such as gender.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-21 11:36:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mlakar-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-21 11:36:32 +0100" MODIFIED_BY="[Empty name]">
<P>Describes a quasi-random method of randomizations in which patients are allocated based on the order of presentation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-25 22:43:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quijano-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-25 22:43:02 +0200" MODIFIED_BY="[Empty name]">
<P>Review evaluating various methods of conservative management of haemorrhoids in pregnancy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-21 11:36:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sandhu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-21 11:36:33 +0100" MODIFIED_BY="[Empty name]">
<P>Describes a quasi-random method of randomizations in which subjects were randomly allocated to their treatment of their choice after discussing the advantages and disadvantages of either method.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-19 17:10:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-19 17:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>Suppository preparations were not true phlebotonics upon closer evaluation of formulary but were predominantly antibiotic corticosteroid combinations.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-25 22:43:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-25 22:43:45 +0200" MODIFIED_BY="[Empty name]">
<P>Substance evaluated was not true phlebotonic on closer evaluation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-05-22 16:37:28 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-07-17 22:14:02 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-05-22 16:37:28 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-29 02:12:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011">
<DESCRIPTION>
<P>Sealed envelopes were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-23 00:43:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Annoni-1986">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 00:46:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basile-2001">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-03 13:32:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basile-2002">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-20 16:44:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2010">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 00:03:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chauvenet-1994">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 00:37:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colak-2003">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 00:52:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cospite-1992">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 01:05:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cospite-1994">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 22:28:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debien-1996">
<DESCRIPTION>
<P>Not present </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 00:53:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dimitroulopoulos-2005">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 00:22:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Godeberge-1994">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-09 18:18:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ho-1995">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-19 15:05:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ho-2000">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-24 23:38:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2006">
<DESCRIPTION>
<P>Yes explicitly stated allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-21 23:19:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Torre-2004">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-19 14:20:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mentes-2001">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 22:15:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Misra-2000">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-19 17:48:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mlakar-2005">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 23:56:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panpimanmas-2010">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 00:27:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sarabia-2001">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 00:06:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Squadrito-2000">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 23:59:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thanapongsathorn-1992">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 22:40:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wijayanegara-1992">
<DESCRIPTION>
<P>Inadequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-05-22 16:37:28 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-29 02:21:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011">
<DESCRIPTION>
<P>Observer blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-23 00:44:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Annoni-1986">
<DESCRIPTION>
<P>Double-blinded and unlikely that blinding was broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-27 16:22:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basile-2001">
<DESCRIPTION>
<P>Double-blinded study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-25 21:44:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basile-2002">
<DESCRIPTION>
<P>Yes, double-blinded controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-02 21:48:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2010">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-12 00:03:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chauvenet-1994">
<DESCRIPTION>
<P>Double-blinded and blinding unlikely to be broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-07-17 21:53:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colak-2003">
<DESCRIPTION>
<P>Blinding took place of key outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-25 21:57:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cospite-1992">
<DESCRIPTION>
<P>Double-blinded conditions and unlikely to be broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-07-26 19:57:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cospite-1994">
<DESCRIPTION>
<P>Double-blinded provision maintained and unlikely to be broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-17 22:15:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debien-1996">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-09 17:23:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dimitroulopoulos-2005">
<DESCRIPTION>
<P>Blinding of observers took place</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-16 16:55:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Godeberge-1994">
<DESCRIPTION>
<P>Double-blinded provisions maintained and unlikely to be broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-08-19 23:44:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ho-1995">
<DESCRIPTION>
<P>Observer-blinded only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-07 23:28:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ho-2000">
<DESCRIPTION>
<P>Key study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-08-20 23:08:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2006">
<DESCRIPTION>
<P>Double-blinded condition were applied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-27 19:51:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Torre-2004">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-07 01:10:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mentes-2001">
<DESCRIPTION>
<P>Blinding of key study personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-17 22:16:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Misra-2000">
<DESCRIPTION>
<P>Double-blinded study and unlikely that provisions were broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-24 00:59:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mlakar-2005">
<DESCRIPTION>
<P>Yes, blinding took place of key study personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-16 16:32:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panpimanmas-2010">
<DESCRIPTION>
<P>Double-blinded provisions maintained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-07-17 21:12:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarabia-2001">
<DESCRIPTION>
<P>Double-blinded </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-15 01:01:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Squadrito-2000">
<DESCRIPTION>
<P>Double blinded provisions maintained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-13 23:40:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thanapongsathorn-1992">
<DESCRIPTION>
<P>Double-blinded provisions maintained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-11 16:04:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wijayanegara-1992">
<DESCRIPTION>
<P>Double-blinded and unlikely to be broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-05-22 16:37:28 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-29 02:22:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011">
<DESCRIPTION>
<P>No loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-23 00:45:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Annoni-1986">
<DESCRIPTION>
<P>No incomplete data outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-10 20:05:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basile-2001">
<DESCRIPTION>
<P>No missing outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-09 17:04:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basile-2002">
<DESCRIPTION>
<P>No incomplete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-02 21:49:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belcaro-2010">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-12 00:03:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chauvenet-1994">
<DESCRIPTION>
<P>No incomplete data outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-06 02:04:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colak-2003">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-07-18 20:46:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cospite-1992">
<DESCRIPTION>
<P>No incomplete data outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-10 01:02:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cospite-1994">
<DESCRIPTION>
<P>No incomplete data outcome sufficient to introduce a plausible effect size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-17 22:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Debien-1996">
<DESCRIPTION>
<P>No loss to follow up </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-09 17:23:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dimitroulopoulos-2005">
<DESCRIPTION>
<P>No incomplete outcome data </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-21 11:34:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Godeberge-1994">
<DESCRIPTION>
<P>Plausible effect size among missing outcomes not enough to have a clinically relevant impact on intervention effect estimate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-09 18:18:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ho-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-07 23:33:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ho-2000">
<DESCRIPTION>
<P>No missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-21 23:21:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2006">
<DESCRIPTION>
<P>No incomplete outcome data were present</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-27 19:51:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Torre-2004">
<DESCRIPTION>
<P>No incomplete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-07-18 20:49:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mentes-2001">
<DESCRIPTION>
<P>Incomplete data outcome addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-09-25 22:25:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Misra-2000">
<DESCRIPTION>
<P>Plausible effect size among missing outcomes not enough to have a clinically relevant impact on observed effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-09 16:29:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mlakar-2005">
<DESCRIPTION>
<P>No incomplete outcome data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-16 16:35:07 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Panpimanmas-2010">
<DESCRIPTION>
<P>Plausible effect size among missing outcomes enough to induce clinically relevant bias in intervention effects estimates</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-13 01:07:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarabia-2001">
<DESCRIPTION>
<P>No incomplete data outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-15 01:01:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Squadrito-2000">
<DESCRIPTION>
<P>All outcome data reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-21 11:36:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thanapongsathorn-1992">
<DESCRIPTION>
<P>Attrition occurred in placebo group however missing outcomes not enough to have statistically significant impact on the observed effect size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-09-25 22:41:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wijayanegara-1992">
<DESCRIPTION>
<P>Incomplete outcome data adequately addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-05-22 16:37:28 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 21:39:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011">
<DESCRIPTION>
<P>Outcome measures were stated and these were addressed in the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-21 11:31:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Annoni-1986">
<DESCRIPTION>
<P>Outcomes assessed were stated and these outcomes were addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-10 20:06:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basile-2001">
<DESCRIPTION>
<P>Primary and secondary outcome measures as assessed by the study protocol were addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 17:05:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basile-2002">
<DESCRIPTION>
<P>The outcomes to be addressed were stated and all outcomes were addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-25 11:58:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belcaro-2010">
<DESCRIPTION>
<P>Primary and secondary outcomes of interest have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 00:03:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chauvenet-1994">
<DESCRIPTION>
<P>No selective reporting </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-06 02:05:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colak-2003">
<DESCRIPTION>
<P>Study protocol was available and primary and secondary outcome were assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:44:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cospite-1992">
<DESCRIPTION>
<P>No selective reporting </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-09 18:16:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cospite-1994">
<DESCRIPTION>
<P>Outcome measures were pre-specified and these were stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 22:28:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Debien-1996">
<DESCRIPTION>
<P>No reporting bias present </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 22:02:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dimitroulopoulos-2005">
<DESCRIPTION>
<P>No selective outcome reporting took place</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-18 19:52:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Godeberge-1994">
<DESCRIPTION>
<P>Insufficient information to permit judgement of 'yes' or 'no' answer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-09 18:18:34 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ho-1995">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-28 00:34:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ho-2000">
<DESCRIPTION>
<P>Primary and secondary outcome measurements were detailed and these were addressed in the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 22:17:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2006">
<DESCRIPTION>
<P>All assessments were reported and primary and secondary end-points were stated as appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 22:20:41 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-La-Torre-2004">
<DESCRIPTION>
<P>Only analysed data on patient's self assessment of symptoms. Did not include data from PRs and anoscopy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-07 01:11:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mentes-2001">
<DESCRIPTION>
<P>Study protocol was available and primary and secondary outcomes were addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 22:17:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Misra-2000">
<DESCRIPTION>
<P>Primary and secondary outcome measures were stated and these were included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-27 14:37:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mlakar-2005">
<DESCRIPTION>
<P>Primary and secondary outcomes of interest were stated and these were addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-16 16:35:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panpimanmas-2010">
<DESCRIPTION>
<P>All of the study's pre-specified outcomes that are of interest have been reported in a pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-13 01:08:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarabia-2001">
<DESCRIPTION>
<P>No selective outcome reporting </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-15 01:02:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Squadrito-2000">
<DESCRIPTION>
<P>Outcome measures were addressed in the study design and these were addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-03 22:00:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thanapongsathorn-1992">
<DESCRIPTION>
<P>Primary and secondary outcome measures were stated and these were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-11 16:07:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wijayanegara-1992">
<DESCRIPTION>
<P>All outcome measures of interest were reported in the study protocol and these were addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-05-22 16:37:28 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-29 02:22:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011">
<DESCRIPTION>
<P>No baseline imbalance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-23 00:46:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Annoni-1986">
<DESCRIPTION>
<P>No baseline imbalance however Arcapia Lda is a pharmaceutical company which supported the research</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:44:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basile-2001">
<DESCRIPTION>
<P>No other bias to be reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 21:44:29 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Basile-2002">
<DESCRIPTION>
<P>No baseline imbalance. Arcapia Lda is a pharmaceutical company which supported the research</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 01:08:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belcaro-2010">
<DESCRIPTION>
<P>Free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-21 11:32:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chauvenet-1994">
<DESCRIPTION>
<P>No baseline imbalance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:44:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colak-2003">
<DESCRIPTION>
<P>No other source of bias to be specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:47:51 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cospite-1992">
<DESCRIPTION>
<P>Other bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:48:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cospite-1994">
<DESCRIPTION>
<P>Other bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-17 22:21:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debien-1996">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:47:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dimitroulopoulos-2005">
<DESCRIPTION>
<P>No other obvious source of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:48:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Godeberge-1994">
<DESCRIPTION>
<P>Other bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-09 18:18:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ho-1995">
<DESCRIPTION>
<P>No exclusion criteria were stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-07 23:33:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ho-2000">
<DESCRIPTION>
<P>No other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:48:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2006">
<DESCRIPTION>
<P>Other bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:49:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-La-Torre-2004">
<DESCRIPTION>
<P>Othe sources of bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-21 11:34:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mentes-2001">
<DESCRIPTION>
<P>Poor compliance with dietary measures meant that randomizations was stopped early when the number of control patients reached 16 (instead of 30)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:49:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Misra-2000">
<DESCRIPTION>
<P>Other source of bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 16:30:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mlakar-2005">
<DESCRIPTION>
<P>Clear of other source of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:50:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panpimanmas-2010">
<DESCRIPTION>
<P>Other source of bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:50:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sarabia-2001">
<DESCRIPTION>
<P>Other source of bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:50:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Squadrito-2000">
<DESCRIPTION>
<P>Other source of bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:50:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thanapongsathorn-1992">
<DESCRIPTION>
<P>Other source of bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-11 16:09:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wijayanegara-1992">
<DESCRIPTION>
<P>Other sources of bias not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2011-07-17 22:02:20 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2011-07-17 22:02:20 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2012-05-22 16:37:28 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Adequate sequence generation</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-21 11:30:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011">
<DESCRIPTION>
<P>Computer-based randomizations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-02 22:42:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Annoni-1986">
<DESCRIPTION>
<P>Randomly allocated central number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-20 18:20:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Basile-2001">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-20 14:20:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Basile-2002">
<DESCRIPTION>
<P>Randomly allocated using a cental number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-27 14:49:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belcaro-2010">
<DESCRIPTION>
<P>Sequence generation not fully specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-12 00:04:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chauvenet-1994">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-17 23:28:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colak-2003">
<DESCRIPTION>
<P>Computer-generated table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-10 23:39:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cospite-1992">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-24 02:04:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cospite-1994">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-21 11:33:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Debien-1996">
<DESCRIPTION>
<P>Computer based randomizations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-05 23:30:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dimitroulopoulos-2005">
<DESCRIPTION>
<P>Random assignment using sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-22 22:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Godeberge-1994">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-09 18:17:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ho-1995">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-19 15:05:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ho-2000">
<DESCRIPTION>
<P>Random allocation with sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-11 00:11:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2006">
<DESCRIPTION>
<P>Computer generated sequential method </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-18 20:48:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Torre-2004">
<DESCRIPTION>
<P>Computer generated random allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-21 11:34:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mentes-2001">
<DESCRIPTION>
<P>Simple randomizations was used using a random table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-17 22:15:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Misra-2000">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-19 17:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mlakar-2005">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-27 18:15:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panpimanmas-2010">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-06 14:57:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sarabia-2001">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-21 11:36:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Squadrito-2000">
<DESCRIPTION>
<P>Computer generated randomizations procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-21 11:36:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thanapongsathorn-1992">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-11 15:56:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wijayanegara-1992">
<DESCRIPTION>
<P>Not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2011-07-17 22:02:20 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2011-07-17 22:02:20 +0200" MODIFIED_BY="[Empty name]" NO="11">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2011-07-17 22:02:20 +0200" MODIFIED_BY="[Empty name]" NO="12">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" MODIFIED="2011-07-17 22:02:20 +0200" MODIFIED_BY="[Empty name]" NO="13">
<NAME>New Item</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="GROUP" NO="14">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="GROUP" NO="15">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-06-22 17:10:11 +0200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-06-22 17:10:11 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-08-24 23:56:53 +0200" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Phlebotonic compared with control for haemorrhoidal disease</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Patients with haemorrhoids</P>
<P>
<B>Settings: </B>University or general hospital setting</P>
<P>
<B>Intervention: </B>Phlebotonics</P>
<P>
<B>Comparison: </B>Placebo or control intervention</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Control</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Phlebotonic</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
<P>Pain</P>
<P/>
</TD>
<TD>
<P>527 per 1000</P>
</TD>
<TD>
<P>111 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>OR 0.11</P>
<P>(0.01 to 1.11)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>190</P>
<P>(2 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
<P>+++O <SUP>1,2</SUP>
<BR/>moderate</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Bleeding</P>
</TD>
<TD>
<P>253 per 1000</P>
</TD>
<TD>
<P>40 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>OR 0.12</P>
<P>(0.04 to 0.37)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>190</P>
<P>(2 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
<P>+++O <SUP>4</SUP>
<BR/>moderate</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>Bleeding post-haemorrhoidectomy</P>
</TD>
<TD ALIGN="CENTER">
<P>115 per 1000</P>
</TD>
<TD>
<P>25 per 1000</P>
</TD>
<TD>
<P>OR 0.18</P>
<P>(0.06 to 0.58)</P>
</TD>
<TD ALIGN="CENTER">
<P>314</P>
<P>(2 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>++++<SUP>5</SUP>
</P>
<P>high</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Pruritus</P>
</TD>
<TD>
<P>143 per 1000</P>
</TD>
<TD>
<P>33 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>OR 0.23</P>
<P>(0.07 to 0.79)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>176<BR/>(2 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>++++ <SUP>5</SUP>
<BR/>high</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Discharge or leakage</P>
</TD>
<TD>
<P>266 per 1000</P>
</TD>
<TD>
<P>67 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>OR 0.12</P>
<P>(0.04 to 0.42)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>139<BR/>(2 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
<P>+++O <SUP>6</SUP>
<BR/>moderate</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>Analgesic consumption (day 2)</P>
<P>post-operative</P>
</TD>
<TD>
<P>564 per 1000</P>
</TD>
<TD>
<P>436 per 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>OR 0.54</P>
<P>(0.30 to 0.99)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>202<BR/>(3 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+++O <SUP>7</SUP>
<BR/>moderate</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Overall symptom improvement (positive outcome)</P>
</TD>
<TD>
<P>566 per 1000</P>
</TD>
<TD>
<P>938 per 1000</P>
</TD>
<TD>
<P>OR 15.97 (5.97 to 42.84)</P>
</TD>
<TD>
<P>368</P>
<P>(5 studies)</P>
</TD>
<TD>
<P/>
<P>++00 <SUP>1,8</SUP>
</P>
<P>low</P>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; OR: Odds Ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
<P>
<SUP>1.</SUP>     Serious inconsistency ; high statistical heterogeneity (I<SUP>2</SUP>&gt;75%) . Heterogeneity may most likely be due to differences in formulations, doses and regimes of phlebotonics.</P>
<P>
<SUP>2.</SUP>    No serious study limitations. Adequate blinding, however <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK> did not describe sequence generation or allocation concealment in adequate detail.</P>
<P>
<SUP>3.</SUP>    No serious study limitations. Adequate methods of blinding, however methods of allocation concealment or sequence generation unclear for <LINK REF="STD-Mlakar-2005" TYPE="STUDY">Mlakar 2005</LINK> and <LINK REF="STD-Ho-2000" TYPE="STUDY">Ho 2000</LINK>.</P>
<P>
<SUP>4.</SUP>     No serious study limitations. Adequate blinding, however methods of sequence generation or  allocation concealment unclear for <LINK REF="STD-Misra-2000" TYPE="STUDY">Misra 2000</LINK> or <LINK REF="STD-Ho-1995" TYPE="STUDY">Ho 1995</LINK> .</P>
<P>
<SUP>5.</SUP>    No serious study limitations. No statistical heterogeneity. Adequate methods of blinding, sequence generation and allocation concealment which were described in adequate detail.</P>
<P>
<SUP>6.</SUP>    No serious inconsistency. Adequate methods of blinding, however methods of sequence generation and allocation concealment are unclear for  <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>.</P>
<P>
<SUP>7.</SUP>    No serious limitations. Adequate methods of blinding, however allocation concealment unclear for <LINK REF="STD-Basile-2001" TYPE="STUDY">Basile 2001</LINK>, <LINK REF="STD-Basile-2002" TYPE="STUDY">Basile 2002</LINK> and <LINK REF="STD-Colak-2003" TYPE="STUDY">Colak 2003</LINK>.</P>
<P>
<SUP>8.</SUP>    No serious limitations. Adequate methods of blinding, however allocation concealment or sequence generation unclear for <LINK REF="STD-Cospite-1994" TYPE="STUDY">Cospite 1994</LINK>, <LINK REF="STD-Mentes-2001" TYPE="STUDY">Mentes 2001</LINK>, <LINK REF="STD-Thanapongsathorn-1992" TYPE="STUDY">Thanapongsathorn 1992</LINK> and <LINK REF="STD-Wijayanegara-1992" TYPE="STUDY">Wijayanegara 1992</LINK>.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-06-23 17:05:16 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-06-23 17:05:16 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Phlebotonic versus placebo or control intervention</NAME>
<DICH_OUTCOME CHI2="6.527355272974429" CI_END="1.1140587509171946" CI_START="0.011129035114447478" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.1113480981360479" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="48" I2="84.67985948090868" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.04690809436226015" LOG_CI_START="-1.9535424872947749" LOG_EFFECT_SIZE="-0.9533171964662573" METHOD="MH" MODIFIED="2012-01-28 17:15:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.010622809067406092" P_Q="1.0" P_Z="0.061755587338614554" Q="0.0" RANDOM="YES" SCALE="881.2768514421987" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.343404091145628" TOTALS="YES" TOTAL_1="99" TOTAL_2="91" WEIGHT="100.00000000000003" Z="1.8680465171689975">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.10569389568533871" CI_START="0.012454115264951902" EFFECT_SIZE="0.036281179138321996" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="42" LOG_CI_END="-0.9759500944969971" LOG_CI_START="-1.9046871191268304" LOG_EFFECT_SIZE="-1.4403186068119138" MODIFIED="2012-01-28 17:15:53 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.5455447255899809" STUDY_ID="STD-Cospite-1994" TOTAL_1="50" TOTAL_2="50" VAR="0.2976190476190476" WEIGHT="52.28277762221354"/>
<DICH_DATA CI_END="1.6282698269259592" CI_START="0.0888861424717089" EFFECT_SIZE="0.3804347826086957" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.21172637514466883" LOG_CI_START="-1.0511659411352279" LOG_EFFECT_SIZE="-0.4197197829952796" MODIFIED="2011-09-15 13:58:00 +0200" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.7418291980005985" STUDY_ID="STD-Jiang-2006" TOTAL_1="49" TOTAL_2="41" VAR="0.5503105590062112" WEIGHT="47.717222377786484"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.160235858256144" CI_END="1.1241870635084055" CI_START="-3.211642468699604" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.0437277025955993" ESTIMABLE="YES" I2="96.0254744604397" I2_Q="96.0254744604397" ID="CMP-001.02" MODIFIED="2012-02-04 15:04:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.275969983120632E-7" P_Q="5.275969983120632E-7" P_Z="0.34536836574631824" Q="25.160235858256144" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="2.350101539733243" TOTALS="YES" TOTAL_1="55" TOTAL_2="58" UNITS="" WEIGHT="100.0" Z="0.9436112243611922">
<NAME>Pain scores (post-haemorrhoidectomy)</NAME>
<GROUP_LABEL_1>Phlebotonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.541780465379617" CI_START="-0.4472173587996501" DF="0" EFFECT_SIZE="0.04728155328998346" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2012-01-28 18:06:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8513453651935062" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="33" WEIGHT="50.68678079253092" Z="0.18740211417225802">
<NAME>Up to seven days</NAME>
<CONT_DATA CI_END="0.541780465379617" CI_START="-0.4472173587996501" EFFECT_SIZE="0.04728155328998346" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="3.4" MODIFIED="2012-01-28 18:06:42 +0100" MODIFIED_BY="[Empty name]" ORDER="40" SD_1="1.65" SD_2="1.69" SE="0.25229999938273245" STUDY_ID="STD-Mlakar-2005" TOTAL_1="30" TOTAL_2="33" WEIGHT="50.68678079253092"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.4560421847574254" CI_START="-2.874209285441794" DF="0" EFFECT_SIZE="-2.16512573509961" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2012-01-28 17:59:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="2.169466291044654E-9" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="49.31321920746908" Z="5.984581733348931">
<NAME>Up to ten days</NAME>
<CONT_DATA CI_END="-1.4560421847574254" CI_START="-2.874209285441794" EFFECT_SIZE="-2.16512573509961" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="1.36" MODIFIED="2012-01-28 17:59:18 +0100" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="0.44" SD_2="0.57" SE="0.36178396946849284" STUDY_ID="STD-La-Torre-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="49.31321920746908"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.566093940381438" CI_END="0.36835422149532204" CI_START="0.03922454207798557" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.12020202020202021" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.43373434858195414" LOG_CI_START="-1.4064421178280841" LOG_EFFECT_SIZE="-0.9200882332050191" METHOD="MH" MODIFIED="2012-02-09 20:28:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4518153832104389" P_Q="1.0" P_Z="2.0900511348104453E-4" Q="0.0" RANDOM="NO" SCALE="513.71" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="91" WEIGHT="100.00000000000001" Z="3.707875801338682">
<NAME>Bleeding</NAME>
<GROUP_LABEL_1>Phlebotonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.566093940381438" CI_END="0.36835422149532204" CI_START="0.03922454207798557" DF="1" EFFECT_SIZE="0.12020202020202021" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="23" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.43373434858195414" LOG_CI_START="-1.4064421178280841" LOG_EFFECT_SIZE="-0.9200882332050191" MODIFIED="2012-01-28 18:22:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4518153832104389" P_Z="2.0900511348104453E-4" STUDIES="2" TAU2="0.0" TOTAL_1="99" TOTAL_2="91" WEIGHT="100.00000000000001" Z="3.707875801338682">
<NAME>Bleeding at day 7</NAME>
<DICH_DATA CI_END="2.6395584607542335" CI_START="0.026382194868725894" EFFECT_SIZE="0.2638888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4215312851669869" LOG_CI_START="-1.5786890761238659" LOG_EFFECT_SIZE="-0.5785788954784394" MODIFIED="2011-06-15 21:56:43 +0200" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="1.1749393414727207" STUDY_ID="STD-Jiang-2006" TOTAL_1="49" TOTAL_2="41" VAR="1.3804824561403508" WEIGHT="14.545454545454547"/>
<DICH_DATA CI_END="0.35028109577489275" CI_START="0.026170535669339235" EFFECT_SIZE="0.09574468085106383" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="20" LOG_CI_END="-0.45558330037053596" LOG_CI_START="-1.582187387950212" LOG_EFFECT_SIZE="-1.0188853441603738" MODIFIED="2011-06-15 21:53:50 +0200" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.6617728178244763" STUDY_ID="STD-Misra-2000" TOTAL_1="50" TOTAL_2="50" VAR="0.43794326241134746" WEIGHT="85.45454545454547"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.14132377511436303" CI_END="0.576908001205376" CI_START="0.059119299336740004" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.18467917265631495" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" I2="0.0" I2_Q="99.99999999999999" ID="CMP-001.04" LOG_CI_END="-0.2388934377184975" LOG_CI_START="-1.228270721703736" LOG_EFFECT_SIZE="-0.7335820797111168" METHOD="MH" MODIFIED="2012-02-09 20:40:48 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7069686507533129" P_Q="0.0" P_Z="0.003655396034827555" Q="1.4597597254329993E-31" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="157" WEIGHT="99.99999999999999" Z="2.9064634476876305">
<NAME>Bleeding post-haemorrhoidectomy (dichotomous variable)</NAME>
<GROUP_LABEL_1>Phlebotonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8488886056720857" CI_START="0.05607721138798332" EFFECT_SIZE="0.21818181818181817" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.07114929575835197" LOG_CI_START="-1.251213591134886" LOG_EFFECT_SIZE="-0.661181443446619" MODIFIED="2012-02-09 20:40:48 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.6931756085166473" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TOTAL_1="43" TOTAL_2="43" VAR="0.4804924242424242" WEIGHT="59.59155548691385"/>
<DICH_DATA CI_END="1.1178800945819827" CI_START="0.0163688950939339" EFFECT_SIZE="0.13527180783817952" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.04839522300114218" LOG_CI_START="-1.7859806346260756" LOG_EFFECT_SIZE="-0.8687927058124669" MODIFIED="2012-01-28 18:39:57 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="1.0775214590771685" STUDY_ID="STD-Ho-1995" TOTAL_1="114" TOTAL_2="114" VAR="1.16105249477179" WEIGHT="40.40844451308614"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06585512663691978" CI_END="0.7931283806883285" CI_START="0.06541713086568567" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.22778099805027138" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.10065650938876046" LOG_CI_START="-1.1843085075440458" LOG_EFFECT_SIZE="-0.6424825084664032" METHOD="MH" MODIFIED="2012-06-23 17:03:38 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7974701792419949" P_Q="0.7978366978623497" P_Z="0.02012164098784843" Q="0.06561170857705607" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="84" WEIGHT="100.0" Z="2.3240718965769918">
<NAME>Pruritus</NAME>
<GROUP_LABEL_1>Phlebotonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9740620279225186" CI_START="0.06288742220107629" DF="0" EFFECT_SIZE="0.2475" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.011413386523086533" LOG_CI_START="-1.2014362069377384" LOG_EFFECT_SIZE="-0.6064247967304125" MODIFIED="2012-01-28 21:18:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04576442572564212" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="77.56758180955894" Z="1.9975596106795428">
<NAME>Post-haemorrhoidectomy</NAME>
<DICH_DATA CI_END="0.9740620279225186" CI_START="0.06288742220107629" EFFECT_SIZE="0.2475" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="-0.011413386523086533" LOG_CI_START="-1.2014362069377384" LOG_EFFECT_SIZE="-0.6064247967304125" MODIFIED="2012-01-28 21:18:14 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.6990252954195317" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TOTAL_1="43" TOTAL_2="43" VAR="0.48863636363636365" WEIGHT="77.56758180955894"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4209280410318286" CI_START="0.007445602483843125" DF="0" EFFECT_SIZE="0.1595959595959596" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.5341439389288558" LOG_CI_START="-2.1281001542151103" LOG_EFFECT_SIZE="-0.7969781076431273" MODIFIED="2012-01-28 21:25:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2406024030889431" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="41" WEIGHT="22.43241819044106" Z="1.173482470273957">
<NAME>Acute haemorrhoidal episodes</NAME>
<DICH_DATA CI_END="3.4209280410318286" CI_START="0.007445602483843125" EFFECT_SIZE="0.1595959595959596" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5341439389288558" LOG_CI_START="-2.1281001542151103" LOG_EFFECT_SIZE="-0.7969781076431273" MODIFIED="2012-01-28 21:25:26 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="1.5638153586335641" STUDY_ID="STD-Jiang-2006" TOTAL_1="49" TOTAL_2="41" VAR="2.445518475898223" WEIGHT="22.43241819044106"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2937213765523815" CI_END="0.4164107476394123" CI_START="0.03569471833423222" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.12191662867851898" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.3804780697948987" LOG_CI_START="-1.447396040694358" LOG_EFFECT_SIZE="-0.9139370552446283" METHOD="MH" MODIFIED="2012-02-09 20:56:44 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5878456750081422" P_Q="1.0" P_Z="7.85467218062601E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="64" WEIGHT="99.99999999999999" Z="3.35786585524646">
<NAME>Discharge and Leakage</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phlebotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.38959847451237284" CI_START="0.027850967481393075" EFFECT_SIZE="0.10416666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.40938275228663495" LOG_CI_START="-1.555159713792502" LOG_EFFECT_SIZE="-0.9822712330395684" MODIFIED="2012-02-09 20:56:44 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.6730350588759775" STUDY_ID="STD-Cospite-1994" TOTAL_1="26" TOTAL_2="23" VAR="0.4529761904761905" WEIGHT="89.46968545813705"/>
<DICH_DATA CI_END="6.8768004915594485" CI_START="0.010816100507866997" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8373864248550831" LOG_CI_START="-1.9659292857322084" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2012-01-28 21:53:18 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="1.646681525035542" STUDY_ID="STD-Jiang-2006" TOTAL_1="49" TOTAL_2="41" VAR="2.7115600448933783" WEIGHT="10.53031454186294"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.507159145757363" CI_END="42.84287181959577" CI_START="5.966142329894604" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="15.987703746853045" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="99" I2="38.52924278626286" I2_Q="81.47731691519077" ID="CMP-001.07" LOG_CI_END="1.6318785745221245" LOG_CI_START="0.7756936097954901" LOG_EFFECT_SIZE="1.203786092158807" METHOD="MH" MODIFIED="2012-02-04 23:13:34 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.1643399256171596" P_Q="0.020150839425492006" P_Z="3.5604511326296354E-8" Q="5.398785885507686" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.48045082518852555" TOTALS="YES" TOTAL_1="193" TOTAL_2="175" WEIGHT="100.0" Z="5.511373086246118">
<NAME>Overall symptom improvement</NAME>
<GROUP_LABEL_1>Phlebotonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours phlebotonic</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="217.24962719202614" CI_START="17.485267187225833" DF="0" EFFECT_SIZE="61.633333333333354" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="6" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="2.3369590398567928" LOG_CI_START="1.2426722730222288" LOG_EFFECT_SIZE="1.7898156564395107" MODIFIED="2012-01-28 22:11:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.441562426686634E-10" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="49" WEIGHT="28.304343477270955" Z="6.411434976473034">
<NAME>Pregnant women</NAME>
<DICH_DATA CI_END="217.24962719202614" CI_START="17.485267187225833" EFFECT_SIZE="61.63333333333333" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="6" LOG_CI_END="2.3369590398567928" LOG_CI_START="1.2426722730222288" LOG_EFFECT_SIZE="1.7898156564395107" MODIFIED="2012-01-28 22:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.6427894636454796" STUDY_ID="STD-Wijayanegara-1992" TOTAL_1="48" TOTAL_2="49" VAR="0.41317829457364336" WEIGHT="28.304343477270955"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0998692335725404" CI_END="24.409409127870493" CI_START="3.7958223114950775" DF="3" EFFECT_SIZE="9.625683340832609" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="93" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="1.3875572666924363" LOG_CI_START="0.5793058742127465" LOG_EFFECT_SIZE="0.9834315704525913" MODIFIED="2012-02-04 22:12:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.777105683083125" P_Z="1.8465436646856958E-6" STUDIES="4" TAU2="0.0" TOTAL_1="145" TOTAL_2="126" WEIGHT="71.69565652272904" Z="4.769532047283616">
<NAME>Non-pregnant women</NAME>
<DICH_DATA CI_END="62.491276146724516" CI_START="1.836991104131323" EFFECT_SIZE="10.714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="1.795819393571578" LOG_CI_START="0.2641070531833082" LOG_EFFECT_SIZE="1.0299632233774432" MODIFIED="2012-02-04 22:12:34 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.8997354108424372" STUDY_ID="STD-Annoni-1986" TOTAL_1="17" TOTAL_2="17" VAR="0.8095238095238094" WEIGHT="19.607816205378494"/>
<DICH_DATA CI_END="126.02291204994026" CI_START="1.913641145367422" EFFECT_SIZE="15.529411764705882" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="34" LOG_CI_END="2.100449510770365" LOG_CI_START="0.2818605002127494" LOG_EFFECT_SIZE="1.1911550054915572" MODIFIED="2012-01-28 22:13:32 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="1.0682481869623306" STUDY_ID="STD-Cospite-1994" TOTAL_1="49" TOTAL_2="45" VAR="1.1411541889483063" WEIGHT="15.597870829539406"/>
<DICH_DATA CI_END="52.521989678883315" CI_START="2.364024403211875" EFFECT_SIZE="11.142857142857142" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="7" LOG_CI_END="1.720341170010591" LOG_CI_START="0.37365195534185597" LOG_EFFECT_SIZE="1.0469965626762237" MODIFIED="2012-01-28 22:13:56 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.791051910915539" STUDY_ID="STD-Mentes-2001" TOTAL_1="29" TOTAL_2="16" VAR="0.6257631257631258" WEIGHT="22.86500321685531"/>
<DICH_DATA CI_END="32.551936387107794" CI_START="0.3278180131654906" EFFECT_SIZE="3.2666666666666666" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="45" LOG_CI_END="1.5125768281491407" LOG_CI_START="-0.48436718620347585" LOG_EFFECT_SIZE="0.5141048209728324" MODIFIED="2012-01-28 22:14:08 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="1.1730147990630218" STUDY_ID="STD-Thanapongsathorn-1992" TOTAL_1="50" TOTAL_2="48" VAR="1.3759637188208615" WEIGHT="13.624966270955822"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1663736730141374" CI_END="0.9931281281018031" CI_START="0.29614237742756266" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5423166279455692" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.0029947175288851592" LOG_CI_START="-0.5284994414250357" LOG_EFFECT_SIZE="-0.2657470794769604" METHOD="MH" MODIFIED="2012-02-05 01:19:36 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.558117100087334" P_Q="1.0" P_Z="0.047445377033268" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="101" WEIGHT="100.0" Z="1.9823026552829863">
<NAME>Analgesic consumption</NAME>
<GROUP_LABEL_1>Phlebotonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.74366318107169" CI_START="0.17881456082586789" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5732967681691281" LOG_CI_START="-0.7475971196069284" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2011-10-11 18:40:43 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.7758996082098522" STUDY_ID="STD-Basile-2001" TOTAL_1="16" TOTAL_2="14" VAR="0.602020202020202" WEIGHT="12.77796216395619"/>
<DICH_DATA CI_END="2.458863102549841" CI_START="0.2460235671427243" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.39073435002289436" LOG_CI_START="-0.6090232888730305" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2011-10-11 18:41:03 +0200" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.5872625859675933" STUDY_ID="STD-Basile-2002" TOTAL_1="29" TOTAL_2="31" VAR="0.3448773448773449" WEIGHT="23.000331895121143"/>
<DICH_DATA CI_END="0.9110746093242493" CI_START="0.1783500860400022" EFFECT_SIZE="0.40310077519379844" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="43" LOG_CI_END="-0.040446056516528134" LOG_CI_START="-0.7487266768123715" LOG_EFFECT_SIZE="-0.3945863666644498" MODIFIED="2011-10-11 18:41:19 +0200" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.4160475424073936" STUDY_ID="STD-Colak-2003" TOTAL_1="56" TOTAL_2="56" VAR="0.17309555754323197" WEIGHT="64.22170594092266"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7807275378572349" CI_END="0.03542959393139943" CI_START="-0.036467274045853156" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RD" EFFECT_SIZE="-5.188400572268618E-4" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-1.4506338252102355" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2012-06-23 17:05:16 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9925804866750555" P_Q="1.0" P_Z="0.9774324841017918" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="246" TOTAL_2="265" WEIGHT="100.00000000000001" Z="0.028287958975433777">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Phlebotonics</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours phlebotonics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12204765807621579" CI_START="-0.07553603016923904" EFFECT_SIZE="0.023255813953488372" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:32:25 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.05040492830581831" STUDY_ID="STD-A-ba_x002d_bai_x002d_ke_x002d_re-2011" TOTAL_1="43" TOTAL_2="43" VAR="0.002540656797514684" WEIGHT="17.003931172791678"/>
<DICH_DATA CI_END="0.1212545709944118" CI_START="-0.1212545709944118" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:32:44 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.06186571383497471" STUDY_ID="STD-Basile-2001" TOTAL_1="16" TOTAL_2="14" VAR="0.0038273665483109813" WEIGHT="5.9052412134966445"/>
<DICH_DATA CI_END="0.11124875090666525" CI_START="-0.16686610352068082" EFFECT_SIZE="-0.027808676307007785" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:33:04 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.07094897064973656" STUDY_ID="STD-Basile-2002" TOTAL_1="29" TOTAL_2="31" VAR="0.005033756436257179" WEIGHT="11.850026452976525"/>
<DICH_DATA CI_END="0.09016625069010467" CI_START="-0.09016625069010467" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:33:14 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.04600403446253327" STUDY_ID="STD-Belcaro-2010" TOTAL_1="20" TOTAL_2="21" VAR="0.002116371186829949" WEIGHT="8.101702884370397"/>
<DICH_DATA CI_END="0.12074396985071356" CI_START="-0.09081199706159793" EFFECT_SIZE="0.014965986394557818" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:33:33 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.05396935060568407" STUDY_ID="STD-Cospite-1994" TOTAL_1="49" TOTAL_2="45" VAR="0.0029126908047992514" WEIGHT="18.552037721922638"/>
<DICH_DATA CI_END="0.041001098181696755" CI_START="-0.041001098181696755" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:33:45 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.020919312040990644" STUDY_ID="STD-Ho-2000" TOTAL_1="39" TOTAL_2="61" VAR="4.3761761626833607E-4" WEIGHT="18.815047562823906"/>
<DICH_DATA CI_END="0.04675396791206636" CI_START="-0.08675396791206637" EFFECT_SIZE="-0.02" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:34:00 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.0340587727318528" STUDY_ID="STD-Misra-2000" TOTAL_1="50" TOTAL_2="50" VAR="0.00116" WEIGHT="19.77201299161823"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0758595557983757" CI_END="0.04708465403141967" CI_START="-0.04084275627463275" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0031209488783934614" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="34.97752534800385" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-1.3271206163411726" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.5057133450845743" METHOD="MH" MODIFIED="2012-03-06 16:25:40 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.214825466584197" P_Q="1.0" P_Z="0.8893424416378961" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="152" WEIGHT="100.0" Z="0.13913630295604887">
<NAME>Non-Compliance</NAME>
<GROUP_LABEL_1>Phlebotonic</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Phlebotonic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.13467023114392093" CI_START="-0.060293813910360865" EFFECT_SIZE="0.03718820861678004" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:53:37 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.049736639701579544" STUDY_ID="STD-Cospite-1994" TOTAL_1="49" TOTAL_2="45" VAR="0.0024737333288047387" WEIGHT="33.47042975737968"/>
<DICH_DATA CI_END="0.01798133764481051" CI_START="-0.10889042855390142" EFFECT_SIZE="-0.045454545454545456" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.032365841209190636" STUDY_ID="STD-Ho-2000" TOTAL_1="39" TOTAL_2="66" VAR="0.0010475476771785426" WEIGHT="34.97838808930594"/>
<DICH_DATA CI_END="0.07916284128124079" CI_START="-0.037496174614574135" EFFECT_SIZE="0.020833333333333332" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-28 22:54:00 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.02976049989081594" STUDY_ID="STD-Jiang-2006" TOTAL_1="48" TOTAL_2="41" VAR="8.856873537512557E-4" WEIGHT="31.551182153314382"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-07-05 16:14:23 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-01-28 18:22:53 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.1 Pain (dichotomous variable)</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-02-04 15:04:44 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.2 Pain scores (post-haemorrhoidectomy).</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-02-09 20:29:14 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.3 Bleeding.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2012-02-09 20:42:33 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.4 Bleeding post-haemorrhoidectomy taken at 2 weeks (dichotomous variable).</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2012-06-23 17:03:40 +0200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.5 Pruritus.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2012-03-06 16:08:53 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.06" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.6 Discharge or Leakage.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2012-02-04 23:13:35 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.07" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.7 Overall symptom improvement.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxMAAAGACAMAAADh6c+mAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAABClklEQVR42u19C3RcV3nuP5JmzpwZeaQ9loidxo5li6SXQlpsx3rZpRmb5qYpDbcNdK1mNU27VgNdPHLXIjelwK0JlNsamtvktgGS0JUmaYHQhAvcGihgQdCDWDhKVwKsEvRyEltOJJ2j92h0JM/d573Pc84ZzWhmpP+zR+ecffb+9/P/97/P2f/5IwQQCASDOmwCBAJ5AoFAnkAgth5PZDKZKJccokft0rzBRutLOhOGyabvptjxxiFbYEtiIyTLgJZkjEu0WgpjKRNtLC6WaGHLX/Eye7R3MhZLSL41icVuajVqwm9CTWponuiV4h03FIp0ssORrDdEHpMnfnjp+SO/YQu9rrO6WqJ14fKlRZhr9WusXKpziS1/qGbYNEyeWL+0BI2SX01WUzmzJl2bUJOa0p3GYU2RFfG0fCWkuNjdAj1pjvNUsue5WAo4KkYAUjEuJcuTrByTihUhH48lJ4PksKsnkRZ6lykJLtYkk0gnuEdjMtFMppHKqLs5mXKl8XpPMh2dOZoFKRmXnxsK/E1EmQ6iXMIYXtOwDq1UCsf7tPLr7VJN2NXzXVqTnmaQEpxchSE+3qzNHvyQWROJ1jTG8WZNytoPNbaeyNPf1Hx3Vj5vO/zdxuE2enL5O10ZSB0/nTzclKNiBJoPJ/nDcpNd0di9LMfcd5xf6tgfhH4cfq4cmw6fTh6Se2d9tOe9qzJRmu8FaBpOnD7cVPFWeA+8BEA5Aho6ErJQeKLr2cv0sNj5Wqpzh6GVQAMsTq+e7z6hld9sl+pBHH5FrskaNHQm1mVVqevf5Jq8vePS+a63GQoTRKHpW6uLXU/oNSlvP9QSTwj7gQoKEKMgNx/kID4CK/RkIg4dcD0cHFWu5DYeHaPXAN+bArmF6flotDcbJIseUKYgSjs1CnKK8d0KHypk05T+aIreqzQek0uZpgXjYOTH9PoeGB2XZQP80tpTK7oefvLsHGT3pP7EKL/ZLtUk44yajE7Q6w44OKHU5MpvP5XVa3Ld0Bws16VStN4aytsPkVp5Z0cnzAFYWYtmqKSgP/o/eowG968qAX1S7Cg9qFdcj3GqxsxAUBU0dvQphSmix2jagZxJAhQaSiZ9UnB65QHXQ0sp3GovX3qpBwYSotJYvdmm+gtp8tah+HXGfa1dqqlXlfZ21iTbdBQGea0m6aU6pSa/uM24r/UDzhO9uVwkylzXw1O9vXIPCwKtRp18iOgzimCp2CAIQfsIrtVoM9RM3CEHn6h4S6zATwHaqUbRL5dHFhbKQZh8/kzPshaHT3Ttg0V4+SXLTCtUWYfn5JrwVMvTqjCoHvhL/3GmW6+JwHcRWIKXuc3qhxp+PxGD4daM/Oh130/oKKFXB6h6StuW/j2wHzhLzANShg+k3w58TEhnEjo1Df06Tz0JB4Zpv1UalwbeLkjZdpEOqfZ98qwGB+RD4tZ6Af5IjzQ7uDJZD9cOm+V3tAtUQU2eFGbS/QlaLKUKWVBWiLQma6ZImh3kWuvUmrSrNSlvP9TzNcIBbTBuHOmP/p98z1dWJmfr2+C1R18dfGTynrGRqTlIjd0vTY70d56bZ2Pek41dmqsPkMvy4uCnpUvfp9QeX319Tifxhc/eLyn5U0JffH3eKEulcF96/dNc3egKrE2vPPgCjPd/cjW2G8aXheX7LvTX643V2PHh+OjKzkmj/Fq7VBPuIz/+9H31Cyuw+CsvcbQKP/7k+UtyTd45wF1sXNZrsqNjgh9befpKGB8feUBSO1Tuh+2+nkAgNgm4twOBQJ5AIJAnEAjkCQQCeQKBQJ5AIMrME0IjFzueHFL2qDPw2a4+lD8e45JSgJgbRUaB662+RLBETDz7Dn0v0i2JwlSTHlSHQIhlYgIMZeKO+9qZ09YjaFtI0JdhrQ0M0oq5AS+5pvIkKOVjx/O0vGrFmuUNwY1prQV4LpaXNtaztVZe9p3dlYuzCz+74RNrnXssb6R8XlB98di/fHrxhv/6XOGYG0Ub9I6Pu1M/f5VXruPjcjKXeJaC+pDudCMdkOpnVj5+Avb+UfSp3e//tp7QFtO75AXaAu79+td2g0pEoWVkTYu2vph5fc0tlWdmdcdnH7jwN7mHd599SS7jxN+uD/3jgjb6ohduOj8jbahna6287DxxD6wB37sS1feo05+6P5/PtIKkijt137pqS0CLAG+iKR7WYwM03UR5figRb87IJBIJ0w5B+WUyjzIb/EOjLyPL7UQmK9sBCJp9hLKl3rrf3g6lDEo81Z7AbUZQNokkM62qTQZjN9FKJU/SzXrHtNdQ9/bbbguwG/rpT4B7Bb28NCbXrDSUbAOi2noUg8EPgOS9s4GHy7QPYtFEVquHbl9h2JWkea6p+c64JltpJaYPwipNJe86hvXdeTihScrmo/H0sd6ljUq0GitvHXt6UO5ZCcxdn+r+/BgNe0LZKGPsW5+6oEwy8FbrWMg/2/VZuL7z31S+n3nFtEPQcFeys6Hosh57U6cEk52Duw4nk4f3gWofoWypt+63t0EtgxJPtSdwiTP9ow4JpI4f5Q6fVm0yDLuJ/9a12NSx6MJopr2Gurff0dOr8Bn6+wDUt+nlpe2ZvFe5K9uA5KDY7bWn1mHtlLfooP3ytpnV5U6i1UO3rzDsJ9bmew5dftDYZBeRNxHdTiXiEpcUoK61TlodVe+swUulmOVrrLwMT8wPQtfJpEXaqvvzL9Gufb/ClMa+9azCs8/YU0yMwjcgDilRucruNO0Q9AgjxW5Ck3XHQ7AT7oMHaClGoAdM+wjLfnsHmDJY7QlY0hwlvRO4VUipNhmG3cQopKS/cSHN2Gss/x67t1/FQLe01t/Vvyb9rH/KKC9tmpEu5bZuA1IcUl2t3Sm2+JbKnHz2Gcieuzul5KDUQ7OvMO1KospPL0EDtPNy+Qf6Ex17gJ+Lt3L7Yw/Jd3Rzkg2ixsrL8ET04vAgdFik7VFIH6Eib2Btcm1wChQTkCNK0dSsj1x8zpoinaZcfxmOqFu6aaR1OGIpJY0QKa6gvRS3DK4Ifz/4LoBbb4Uzcv5yCWXM9Xc/caXXzi2mDOS6yz/WkthIjw3kpNzA2Dp8+Fa97Gq84cGug8eybtItndbYhrzl8pg65pnGhIajsSPRow2KLNHKq7afhXxRuAeW6Y8pPluZF/qgHb538nONcEzPqEcuq9E/SrvJv2NaklfOLqYHAJZyR0appJ1dHVsZf/fSBxXODrzJfiuVl30Wm569+LzGjAOKDqXvz48efeNRRXez71tPz10cpjzQD1pZFKODehCMNYNmh9CnRxjaUJnTsaNX9cRoc2mGE6aiwu63t+OEaQthtydgSMd7mnviacUmw2LAJV78w6GeJreGM6ha9/brsoyjvwY6M8j7VPXyRtT23Cim+tcGphwSV1cDGzv3wc3wys+ZSUvP1t1+Ir20ms0zKu2BWHokmldrcQ1sv/IyWcYz6fQ35IkJ5M6ebFHUDmV//jcplypFtu1bj2ey6f9HU9wBLfvUhwUHqIDMwrBRYM0OoR5a1Qgn2je0gX+iv7N9QrYDmDTNIWTZYN1vb8OAaVmh2RO4YXqgIzZt2mQokO0O+Fv/x8vgss2csdeoc6EapeJuCqapyIsy5V2B9ictXV9kO8R6onaJaw438UdZKpNyB9jCKMYJTvsJNVHiTolQmcdzk2rv5H4OA9Idyp3+FSGbSW54lNVWeRmeWDi7FPv40A/gqf49IA78iVyLtWcXH5AL1w+Du5XHieeWbj43Z6T44dBvR08MzULXwGJMnRaWB3tpHe8j8tShDOJzNy+dmwVxcOGbanaLZ2eKX09QaQ4PpWH84NLVVAfVkOz/JZh781zjszu8GImW4blZJV5iYO7bHqSjK9AXhYkzN8+dndVvPNR/FTxzdv6Ks41uVP966bk5SvEq4AfnftchGgeAi0J0EAZeYsq79uxSnd40oKQtDvIMZEe/OQKPNc8O7GPWK70/Wpb7mZbjENN7RqJ/fyWZHRahsX7f4rkJ+ZMAu4FPHlJqcWZtd/OZ2Q3zRG2VN4j9hABXdr8wHVwoJMZGPnzW7YFYpe2YKw4uPr7jxh9ly0G6ZakIsq0LK5VqiioubxCe4PJ1iRCzfN9vrkM0MeXGLbC6vXkivbIG9c8cKQfp5HQRFpNJ127aFFRxedHODoFAIGoFv1eRXBtwnkBULyoyOnGvOAKBPIFA+OpO1nV9h/KwVH2d0msP66tr+H7gZyYty8vYuohanyekhOa8obe39144aw0L6P/BQLX5bEAgiuCJG81T4e39CXuY6v9BsZ0Q7o5xeUHe565aSpAkl7XugY9psw2XApJJw92caXuR5rkU4eJpEFg7COwKRBXyxNArxun+7viUPUyG4v/hArQNN373+D7Y2/Wsuiv8cqLnLsse+D/TPQU0rMIqnIQHG0zbi/X5nsPri93L0MbaQWBXIKqQJxZ3GtPESvv37GGG/wfFD8PIm+lY74BR1XpofAoes+yBv2xykSAN3COsy/sJNduL8SjARJRGcdpBIBCVh/U9tr4hqe+k+a1dLYz1/wAxefO/5vPBcArwvf91NvEW40pLljp87vDwwXOHz80r3g9U3w2GPwQwHEhs951QCDdkKjIq3J/FDrvsY2T9P0RkiwDJZg5g3QOvoR5yA2P9OWW3tdNngN0OAoGoLt1J4006I3wYRsDvcyKKRUACPq3uczfA7oHXfB5chJ6GdLRHMUm1+wyw2kEgENXKEzLWC9i1jp9b2nd2DrqezTLmAMl2dg+8bHtAsVe2EPnfAL9rt70AsNlBIBDVuJ4ICY4f23Hj2SVsRcRWWk9siCeyJJ+PVm4LPgJ5ohxo2EhifgVgFacJxHZYTyAQyBMIBAJ5AoFAnkAgkCcQiIKwfeaxAVsEsS2hbeiTv+283DzrwRMiMf/Qg7hh+3CVgqhamlsPpYQYnK5YTBEKxveh6qi1EUDApYX1eMYd18YzqJlUlC37xKU8ohpuKZ0lFyalSdeemQhb+lMWkSULUzTYu1ftDlKCoSsa7atxmHkoKUswuZQuqnXE+8b3oeqotRmgt7RbVqJ7emcbGnGN0e0oD3GUzpoLsfeUlYB6IOKWnjLykeWmOX/dSe80XUhoraN2ARGtIosY8bTpxRQ2Lg1ZLnFTZjFGSpWOBElibTlTPBEXGmZcV741ecdRBkdKUqHGLSu8PUF9zYwwkIdl5pU5wxNOwcWKF0O6EKvIEh33wJhqNgNicBkmFinu/DWHoqkSr6xI4LyZuMw0IAZS/IhXQWwVqm29qTdIhGgkPt/rNU/Q5mE5g+i8Iod7CA3CtLqHxiVaD+Vp4sBdR0KvJwKurUTPoc9mqY56eX51KbIjKz1Ai2o9BKmlqQ+RQvzoCBfD1L6m1xPx+eDPnUTPLve8Ep2do/SPeijDNGHwY6GuE0mw9UE41UFXPPzqx2aplpO4jzZPXYvoiwP2EKCWBAI3j0eFtsN3Iq0s4c8T7HrPsvZzKLWWWUB061YC5ZkmxOAkxbJMUhrVQJK3BCpXQU0sQC1FjznDeFAokq3PDKaDPbCyhOWdnao2WZcVIhMiuj5XKjBT2O6XelASQoB46S2uUWEzC+DQ1TfwBM+lqQvW0jWJv+YUokW3KBoKKKWGNLMqB5q66lSMHDqEGVNtabEsEijEIiHseiJYfPdYWnX1yhMzmnpO/IiY0V0P/izomkSfB1wIKE9L2PDCmW3d5UUhxbSgcBfxy+SVQtimL76rKtTJVWZTFIgltssibKswxQbWTNsIdQGethA/5RVZonII2/hkszKqAbQ0J6J18UQTGXLcqsdvySCqFm3jZSHbupTMvzIbm84uLsyKf39tls/1P1wfZD2BQFQaZVhP9N2cW5/yn0MZ3Ulo5GLHk8ZUon3xrCVhkjOdcWs30zwMNcZid0sgZRQv082xhwAe6NPi3xQ73jgkx62Oz4ZLx2mph5KxWKNUSqocpSokuVjKhWpLgot9kLZOMsYlldstNHtesraT3iscx7fIJwltk07zTTG+D1pp2kQrSIlYLNmqp1e6QInWmFEdfOsfqBuSi6PlN6SGm2lkGZnQ65+0pDTCLfVRy5Tx/vpdbelLjcfr3nz+UqEPzTC605WLsws/u+ETa/q8BcrE1XmVMX+dN0/Vm8LZC7kvHRGiMJtbvebMxPg43D5wZn3yHQ8rcSYPvnrhI4f+SqJxk+/+7qnKN0l6Ny31P3e++IaDMyVkinQHpfpgx4stB2dzjpuXL6eElLCa6pj95i+m5Jatk5peGnptnW0nDdlfF/iVtTWQGrvUlicHn+v9xy9JdVJK+I2R9dT6+U+9be+Ill7pAipEJz8v5z4+Pv74D86qdXqykwZo+T2965bP0U4x0yglOv+oXP/WiJZy4QolpR5uqU/21198Ay3TuDYWalh3klqXuWkh+pzqlHun5pubOfKu88Q9sAZ874oyByiCoTnOD6l+JPJUagAnn8oSiNfl24HcaVgFYZT+2aVOPo9F8/DLnHp3Vw+fFnqVj+jXj+yvPEsMKUN2HfjpUrrplhSqEvAjblRXclMLILsbmD6mfjp9cXVqBOot7aRh54AwlaN9dGNEp9wvHFldoimmn4UGWMrtvgJ+oKfXcZv2PXbDX4ikFELLbx0+zuSpl2j3z2lx4S0ajwgLAwk23FKfnQO8UqbaRms6yS2OzlKRNCN/JX+nx9GNJ+rgIG+ZzS9/pyuj+JFoOn46ebgpp5x+a3Wx6wktQg7eBHfI34XNU3bKxpIztDHvEHJj6t04GJ9UHgGp8k2TUfr+M9DXUkqe+KxCNa+2ghsO0IbloCUL2ven4ycH5yztpGH9j5J3yvrVkL6T/w8iCS4pKCl+9LJ8+LX2C0Z6DbdcUI+Gv5CG78h/tfw+Ae/iEoI9DeyXe/2Wi5oo7uGm2HBLfZQyzdQyP0jfa4zOjL56iZ7OFPi58cT8IHSdTDKPpibioDruOgwHR2FFOV2uS6XgMb0bKY/FgW+XR0NksbHjauCTh/ZzbVyzfLeH/ehs5XmidV35qHPX4MnrImulU1G/rVCNwdd5dx8aLUt0Wn558LqbB15WAy7+fveHLO2koWeE6+qgAYtRXZD0PJjs2COneL7ravkwPLJXT6/jLrWJDX8hre/9dfmg5ffRgQcTnXvsafqWZUVBT3l4YIINt9ZHKdPVtcwTV96ah7BMzfBE9OLwIHS8jdGUj8AP1daCtD68yV9eHlP8qKjSBOC+oVRuIAJLZ6LyZDu7+q6V6VxK4R/ty+IKJYhUvHWyamlu6D79Qr50D9tWPqIcxKH3tPa7vetpWTj6ERFI9wv39uzR2uJd8HlLOxkYucU2gd0yAjL3pkcVXzbpMUWyKOlt+Gn3l1Xnm0tPq72k5reYi46qFJg0rcePDpvv4Pg8l2bD7fVxlKnGMDW7JDW2Nb9BUZF8f648AenZi89T2T+gS3VB0G7XmX4mluBlUw2O0FEfXZSW8nX6NUB7Q7R7al2VNdcaj7SqoHWO3JxRFkTyeiJXOqonFarRxdXFSL3LGmYBTp+Qm4Lq92tMu7HtpKHf3h0DutiRF2QWqg4BY/gL6bxOKQ6bX96aRpivO80YH7fqKbVwa336XXOrNURnI1LjAX6XpibtdD+68kQ8k05/gzZRBCaVR4Kw7ydUYZKlfQyGD1AlaQBkJrl22EjRQBuc51rTR3lI3NnSLq/CISvC4KRClY99TEirSvwOXZmuIHp7e+UFUT1kW0pYGo0qz02me1zm6OsjE/IDjSj0ZWnOmQzwd7YesLWTLrHhQDusMA+7ORjmZdU01voTev5+jjZw3ExvgeEvRCuOlh/PtfCUrpZGfaD6JOxgX9Ou6ym1cGt9aJl4WNkKj2GjwlIuf2DPnzMMYD+6PYvNzuTqx4e+/8jC1AuXroDxNnjt0VcHH/nCZ++XJu8ZG5mag9TY/VJqbOXpK0F7OPfwC3dEm9ey0ke/DM3D2Y4zl05B3xfXIfm38seVYfnF6PukS99/hMZdvea1amhZudSD/yuauzRbX2KqzdL9a9Muq5R4z1fb2trGl4VH+cm5ehqTDC93yn7RmHbSH1jMZKVLr53SCNJfbuZx7hdL9eTy8hOvz8M/PJ5dfef3QU9vPCtXDnV732uEyH+1/AYfz8bf+fSpZjVNW5+84DnTc4VcIkdKa7hWn5ywzMtlqv1nsTJOZVefy+/ZwXP2J2n/paG1lXEyuqH32MKVsflAEZuzk+jst9SP0cK6AJzcn920vEpVx/Jka7zL3jkDO7lY7OfWwbmxvR3plWA+fOOf+2McxKXWBury4Va/jd86VmRWMYjkthJPKAup3HouH+WiLzmFNe53QlTxXFhFfk8RiO0L5AkEAnkCgUCeQCCQJxAI5AkEojRg/U+oB+cH+0J9Vm7zIZbJrwXTLvjAepvyBKnNbzUV5VQiJMvhN6y2u+4kiqL2tTjlzBYM5g0axzXm5oPUNHlEtc4TVsFI7F6FPJ1RkPL4HwosxsvOjCLyBK6xfcSj7DaBuEeo8KqibCy55V1XIQrOE+BYdjsvXLxMQIWmCYMjy8UUOEkgT9i0KNex4eY8pEK6E66AEZuoO4GLMwnDPYUIPvPG5i2ut723BMQmzBO6HqTo0aYqbXFcZ1WVVI27ktK6jPkTfD+xzYD2E4jqBdpPIBC1sJ5AIJAnEAjkCQQCgTyBQCBPIBDhecLiBB6KeBEmujuMD0RRdN4ViywGAlE184Sb0/QNJUcgqoUn7BYUrImEKKpGFIwFBRvNjK8Mc9FB0Z5WJ6HZZjDkwLhTafMMxHaC6x5ApwWFeSr/B5sFhWk+QXRzBuJF0ZFWP+jxnLmirRuiYjwhBlNrWHMC50CV2YKwV57EiCsJ4oiAQFSMJ4ihwRRmEzHgusGNKQrqQeKG1iUIRMl1JyCF172k+OWxWGhztzMCzhiICq+x/acK0X+qsM0MroabIpNCdKMuOu7gVIGo4DxhsaAw1H71VLOpsFoVMFcaQ4i2mwZFMEgoR/OgxyWOCGjDgNhMFGU/UeARUMAnRE7uQSAsqIz9RENofiio3eMgR2zBNbYPSAliWOIhByFqZI2NQCBPIBAI5AkEAnkCgQi+xhZd17z6E9NQa2HR/qVK0fIWgqGrZ2vPlQkxtwHq16Lr2px5R6K9DHE74H5CRHCe8BsrGxxEos/XXIkLecs3zFmG1e75p3HuuWX32ip5IlMgQulOImPEoBlL2EwpwMMbhdPQQSdis8BQTS18OY4E5kkxHHciEEHnCZvAZU0ebKYU4OONwjrsLJYYrL2FHETchrYxOxBWUyKegzrkrg9jowryBiI4T3jJapcwm61E4OFJ3GQ3CahsAfsyHcc2YjN4QhPYwSWw6K3HBNja6jasC/iXdN19iECUjSdI4TW31xB1WD6E8GTk+gCqoH8JfIqE2IQ1Nrh+WcZ9RDq9UfjbyImOINPTkAJ7BoQUnAeQJRBlnidMQwnLM09PiwmwGllYbIgsiRgLDHXxrL42cHnboMV01aq8ZgUzjbUCtuoALkMQ/qg9/xMlGc7IEzUB9D8RDKVwQoosgdhKPFGK5QOyBGJL8QQCgTyBQCBPIBDIEwgE8gQCgTyBQCBPIBDIEwgE8gQCgTyBQCBPIBDIEwgE8gQCgUCeQCCQJxAI5AkEAnkCgUCeQCDKxBPJjHLIKJDPWhJc7IOSGpaW/2w8x74EtjqiVnhCSnSoJ729vffCWflscT219BPNenm5NDme7MRWR9QKT9xongpv71fE+UpuagFW1bBulTfyXCwlzxgkyWW1WSUdS0r0kEiAkOJidwsgJblmOqdkMo/ycUKvYhzfR6+yfDwdownkVFwemjLNkOKA/mJNCsVErLmZu7MPBDkPgc0DgagITwy9Ypzu745PaacH9DgDWYH+TR0/nTxMhzBc5nvu0qJ8Ktkhfztt5hXYd/h043AbNHQk71Xu/PfG7iw0fWt1sesJenVFY/cyZTDloz11CViT/9VB0+HTyUPNNGh99OjByxMjJ2Df8cTc4TY5j4SRBwJRAZ5Y3GlMEyvt39NOW5aAV8/47n+lf6+Hg6OwQk/Gp+ExLc6hUaDiHrI76ZSSGqF34zDSpdwZn4LLsPx7qZQS93vylYY/XRckblWQ/hRykBoFeTqY2E35ajfkaR6jWRqsJH8M+wixubB+BzCjynDoO3luXmOJhZ6PnFBvPXVlvgd6Y0d7IdO/KsfUYiunAznlKnpMnlBySiTo1SKRtw794jbjSkuVOnzm+HOHzhw/E4keM9Jrv9hRGsGSB2Jbopq+Azisf0d2aAFOn9AC0/EeJYEgQMQotPIkShD063p4qrc3R++bQQBL8DLnyKIB+P7xfh52wgkLRbVQlMoqDgkEVAdPyKP8wzCinl0fmeCNO2Pt9E8Mhg9Q3UhDb6/MyaQdtEFP77ZmklR7an+SzePaYfNqABR2+Rp0R9OxbiWApahS2S9l8JEtolp4QsY6pNWTePdtGeOlRFpeI0yc++ul5+as0R9ePDujnk2cuXnu7CysPbtUB/36bX5w7nfNyMn+X1Ioy1MFnY2+TSnevPTcLEtv4tyh5NAcdg6iCtYTxSl9TpWfi4/vuPFH+BgVUYvriRLwBJd3qP7plTWof+YIdipie/IEArGleAL3ACIQyBMIBPIEAoE8gUAgTyAQyBMIRDlg9Y9d0B+o4SJeOeoetC2HzYZRlMK5aw65IVRBC8b3pWppKLatSODWNhIbeVh6gbnN0rR0ip7S6iPc2W0WgkzuYg15xVQ2r6ZKxhMiKdRNhBknSqPRn/Ww6SxhLVnhqIRJFASF4vtStTSUpckKt7UjsZ6HyN5nmp0wRbB2ipbS0kUu3WYhyOZeCv/LtTpP6JyhShyRlTSEEUOiVxtVgCWIGGiCs5Q6LOv6xfel6tpQJFzVHCWxhhPfJMS/DsS7NBqpapofgjFmPYQQeiQgT1hlvyE2iNmsxKvMm9+CNlUhUP1LyRL+VIlPI4kkfH8paYg3z5BQdbD3l4VgFSpLwYo0v+HSN1jbTZnQiVsRiCfrEtHQckVSwfYSq1nnFS3yRp50xVLJEFcyxFgV+MwEjELnLZBraS1RBt0ppNao9qwxk5CqFyEVK53aUExBSyBDmFnbVWszZhWvTIg7Qaaw3uSrGKnS8gQJyRa1KUBKqjqFVLAKLDVC5SGGqIr/ishKcNvvCq2zK6sheqqKHkZU93ORspSOEFJYiIkh2MWVoLgNeaIhwLzvJTm0W9ZDxbSTKpZvRH92x6j56qIiVOLANTczst61kNIvtDcQxJ1gdTdseYD2E1sGJVGkSpekFED7CUS1KpDbS4NqwKG0VUBKHnEDKbbIGhuBQCBPIBDIEwiEHXcjTyAQFnw077PG9nsY7dyK4GZEUYHHdmJw4w0xlJ1H0CoZBhR+9hOmDUQA+wmXVIz5g71croYTHr3j03Hu5jA1Zz9RDGavnvfiCV8TCOIyZMC5DX/TH9uJBUteTFQ2ohiAqgef2a07gtlPOG1CiG9TuxhOePSOT8e5m8PUsP1EGOOi880Rd57QNnfYBRJjTyE3kimktvhT61Ci0X2Au1p3BDAHtKUybYYKJHEEEJdsfW4xF9U4MYQbcKEMKWaZCje4DQWbCNG1JmIRKyRY55RfcxLLEDVEMn0Eu7WIi3VHAPsJZypX4my5SCGGZrQfn1tbSUqFMKQQd/7dXZ7rCfdiBLORrOjLznDbcsTA8UiY/vId5SJhVmXB7CesVqXEsoIIXD3RZ1+66HFLtC1Xtjz4uyAgT7gONNEZSYln2lJs/gI72CLBwz7Ad1AWtnEorNe4qSlB7CeIh3z0b2p38wdSrPAN0VrVhuCGFI/fBf48IRJf2ec1S5uz/ObyRYgMi7QPKJBDkTUuSpGzaK1iYHvXUGsg2zSxHbZ12PyI1tnmBbahRI+pQfRWnLQ9+JuoNAXPMJDBgcvzJP8cglAVi+V2e0eQwuUKbv4QiCW2vf2ErizZNt8TZl3o0KeqwXoiVPaBo4aqkm/k4uwnHKk0UwefrETibv7gZoNhpebIpXBmWxYB7CdENLGobpTTcKKyYwDtJxDFr6lqPIPq1Z2KeTCBqDjKaDixLYcAzhMIBPIEAoE8gUAgTyAQpVhje3091G2F5e56ojLf2g9qFFGcn4xg/ic8qHrbKAT3P+HcIGuxA7H4n/AyhnAzHbEaZYCHlUbt2U+ophCp0vAEs+8eAvSW0/VEBR7ZhXB+UaSfjGD+J9yp+tgoBPY/4fY+27063sYQ7qYjxB7maUax7f1PgNVwgrWaMGSKn7XApsLLCsA/ahGM531P9M5gQ7YIhhmF6Nq+xLeKhdvFsXnRGlCtE0PhIVYfMB4JxBNEFl7Ml8IVOUECuyIilW2rsmUf0P9EyAIE9T/hHOdiuI/6Eo8kDm2vJrZxFC7h/EYHY0PY/Iv2bFJW9Sngh+vLaBHgVQDnmgCgVP4n3KojEhsz+H1r37qCdFhpbNO3tQ3BJijNaVv1SpIQxj/lsQggoTLfiP8JkQSqDms4EWhPOe5X8OUJHyMJMajrqU2dJsJEJeXLoPA0QUqw+BLNudFRHZH4JglUvxqfJjbslKXOJsaI31QhlmigVJQlxAqUjv3QzMZnJM1wwq06Hhm52VqIXkm2uebkMU8Q++eAHEYS1t31FdSpQmzzL6tFgDtVqy1Ccf4nPKW5S3UcGYXxP4H2ExrQ/8SWAfqfKBFwb8cWYooapFw7a2xEDQL9T+A8gUAgTyAQyBMIBPIEAlE9a2z9W1qlee5WcOeCmxOEoh6GiyHsJ6wGA4FJAym2AHbjilD2E5YkHo1lmnf42E/okez2Ew7bDj0ysRZd3Far7AbLw4VNfAzt5gRBLKYIIZxKkOBRLVKi+ALYjStC2U+AZ2LmQNhyesXVIlkK6dLmlgNb9Kqzn5D3vqY2gSfYnnR4nyhw5fBaIWpGRpbIRDTe3bpu9ykvR4pkM5OxtSQbqaWfTUTBHX7EuxpeMcRNdy/indHTXjfqobiXJqRYnhCJ0/tEgSvRLniIa2RToyKlG+lhPgBLiiAtFjI9FcN0QQD/EwEqQtgDKRFnW5SpTVSWvLPyfI89X04J2uBZRuJz5agNMdUMTwsv4jVILAdSemmzQeUwmFrmzzksJwT2P+FIbLUVKbBiE52ziH0fmy0GMb67bvuw7PZdY/sPsgBDTixsvOyShvFeUbxmE4RAkXvEg3m1KGiC6LTsDGw/Qdydf5FwqcDFHtsSw5VslfqfSFWGJ6wfHQjyCQJGdwo7b5KilfcinUqEIF2SWBvR+fw1oEA+Y/wtykspSbYA6oKrI6LPdCGC2/clAis8YtEsEcKphFgW0kEcYIgb5MwilvuFW9TLfkIsXdG3nO5knTUNo0nRdVu+pgBp96zOXfxUbZt/hKLN5INs8y/S2CNY/DL4n3AkLmy04uVMwnEbvO0nXE0uthUiJfrYBDqpqDjQfqL8a+xQ8zSyRA0xxUb0t22tOwVfcSE/VAXQfgIge8UKRKf5Mq6xEYgaQraxYeX8a69lV+oTaWEDdOp5bEtEtaJtPHDUH34lPz+/rLAGLC+ID77vpYX6jc8TQiMXO54cMtY3GeXQkjAi9CXBdjPNw1BjLHa3BFJGBjTHHgJ4oE+Lf1PseOOQHDeermzbJpXiSsfpYUgtaCmQyMhtEovJbdZ8U4zvc1kkGrk1ZtgASzv5QEhysZSk6i/x2E19en6CSsYkLx9a6D1eYnKx9o2U4GJJyehLtdwwxOmNIcTomXR3LEb7zMhXabNSNVi5MET4+re8OsUGTX9yfJFrljY6T1y5OLvwsxs+sabzKChM2nmVwavnzVP1pnD2Qu5LR4QozOZWrzkzMT4Otw+cWZ98x8NKnMmDr174yKG/kmjc5Lu/e6pyTSbt6FSKm95ND0/vuuVz4+OloNrYRcl9eW1p8uynJHLwObHhi84uGB8fX7jirASTn+9Qm5MGzO06K7Ht5IcHO15sOTibkwv/1unZV78kafk9vPvsS7QWlNrPrnlWUjqkF+qkppeGXltXc5HDv3TkxZa80TeNXY9+7dC0VkaNDsCTattQfE4+IxHha2N/ETHyVdpsvA3Gq3aeEN7+rw/lXldmCNiZBea4OLvjT0eLmC2YeeIeWAO+d0WZAxTB0Bznh2L0HCBPpQZw8qmUjHGGQDyQOw2rIIzSP7vUddhj0Tz8Mqfe3dXDp4VepbD1I/srKEZu1KSJPLRgHT5eIqoRZaJejXJARXG/EF1ddu2yhQE609522Qzo6J+1tJMv4wE/QluXItcnRleX9PwuQ0yjRvp+oEdeXJ0a0b6qrYavyqlzet9chmPToEs8jQ5Iq3rqyR757yqMHATeyFdtsyqeIZrikd+8ODOzU2YEAMfxC+OL0Xxf8TxRBwet0//l73RlaLv0QtPx08nDTTnl9Furi11PaBFy8Ca4A+hyJk/bOhtLztA2vkPIjal34/BzndIISJVsuFdUtUXRAj8B7+ISQimozmknw7QNViN8LOlKta2Ho5P6LReMgP05PmppJz/k1daluK0uoZVbzm8NlmLK1f7uxBEzevzkoFYqJVzpG1D7RoIoZPuAGeMyHWj4jn6561k1w3QabjfyvT5RxQzRmuLeODEJdNT5/V6fffMN+ZYieWJ+ELpOmusJgIk4dCgnh+HgKKwop8t1qRQ8pkVYp7wYB75dbr3IYmPH1cAnD+3n2rhm+W4PpFmBVzks7lRacF0ZIB8deDDRuacUVKOaZv5b0AVHez7b2OFGVTg8MEEPdxlNIawMUIWAbSc/xODrPChzzEjPTLJzr54fDPQn5VoI2UFWvbj4+90fUnNRwuPQbvTNh+DlwZtPDqyZq0OZTut7f11n8YSodpo82+v5tpZEepQL+TvzwSKO7vi/Ra4n6l//8Pieqz65JiuPbbIO+d5H2vouy1cX9r73VNsr6/Ip+c9XR7+6V1Mw6/eOQ7/QAOcj69J4/YWvjK+vrD9+arY+tSw3/YW9z53S1h5y6oo+v6DFrZuJyofV9fqLXzm/Xiqq0Hfi6PNfpqd/+UFXqh9/4+ufYJdn8Mj1v/g0ANtOflgSvp4ar1tX0r/wwa9MrGv5SeuPKLV45MhLn2bIn3r8K19VCqGG9wvLRt98df3K5Xv/z/WCriupdGBkWSvYFxPK2UXapW0vr2v5RtQ2g+pcTywPrs/+c5zLqusHr98V5IrJ1UeLnCcgPXvxeSr7B3SpLgja7Tr5VOskeNlUgyN0ho0uSkv5Ov0aoL0h2j21rsq4aw3hWAVS5cjNGWVtpGoIJVu/vx1eoAJ2wItqq/2t6Az8k3I028kP0cXVxYiyRNBy0PIzqa3YUkSYcKVv6vXwe+T1xKq13J3X6Y3SoZ7Rrh6if7R8O5g2q0rsnsvt3L97p6Im7dTUJfa4e1/j6tJ08euJeCad/gbtwghMqurXvp/Qlu2nAzoGwwfoRDwAMpNcO2ykaKCdxHOt6aM8JO5saZdX4ZAVYXBSocrHPiakVSV+B0Qr3ny9vb3ygojnWngo3UuZnbcvyk3OwfBPaQs5sU7XUpYn2Dz8jrrINdrJDzw3me6ZkRNysP+ndDWg5UfDeTm/D7Asx9/ZeoDGk3NRw5W+iet9UyevJ6LaY3SNjtYoNEw7i8KBG+GUnq8WWNWYEldylC1URgBgjruvblyZK2LgMbpTdiZXPz70/UcWpl64dIWsO7326KuDj3zhs/dLk/eMjUzNQWrsfik1tvL0lfrDuYdfuCPavJaVPvplaB7Odpy5dAr6vrgOyb/lZSm1/GL0fdKl7z9C465e89pKpXUn7TD4eDb+zqdPlYxqY3tbW9t4bubxx36x5PLYr27ve83I8q9+758pqovZTn5olu5fm16TE+ZmDn/ynT+s1/LL8n/HvT5xCv5j78sm+ebh5c5z88qpGq71TZPaN9mZ2GOTs/Vt/crspNJhCqaeLb67X7r0sUe0fPVKVvOzWHkQr6zNvPWHnOW53x8srOVzxb2129B3xYUrY/OBIjZnJ9OAKCMygcV568JKGamXuFahss3ulF5XJ+/4Nw5uYLxt7Fv76ZXlQPHin/tjHLZlRQzyAR/tJZJT4YlHcjXAExQtWelyPDayMQGM/icQVTz7of8JBKIKgDyBQCBPIBDIEwgE8gQCgTyBQJQGLv4n9EvrR0p9UKEPnbg5sChtBuUjjagNniC19ZUmNwcWJee5MpFG1JruJIqi9n045cwWDOYNGsc15ubNEpsgwZEdtvE8YZWPxC4i2QuLOwlSEWGKQxWxeTzhO+6IxecUqYJRKhbzEdhw+hkyIPKEfdntvBAdrFIxniDlUvqNj0gTXE8gT1i0KNd5gLhMKVtu4CAj4Bq74EyhPJYUSYE5ZJM1p3KTFnGQ4Dxh+OAiFhcUrHpkd4xGKqY7FelUosKkEdUMtJ9AVC/QfgKBqIX1BAKBPIFAIE8gEAjkCQQCeQKBCAb2/YRIzL/Ws4AQbbsgbBYZZqCNsPkGwNVkwXhfomXi5mfVXmr7SwX1lTzxyFYj6nwPYUTRb4u2rR6upTFqgdvMa50nNgzivBZdd4E4x7PJj47dS7a9TMSFAnMtuqVxZXEmjnwgvlE0TjX3DBeuj/IfWWKr6E52CwrWREIUVSMKxoKCjWbGt9MzbS8CjhNzeGuv00UvCgXmNtcyQRGzoCsbijjut8E84bSgME/l/2CzoDDlKdGUEBfFhZhjydxbSIJOO4RRzZwUiO9AV4tM9LQuug5xDnbixxIyrUD1QXapdZ4Qg2lFRPQTtsSpMLiZWRQxWEjxFIwi20Y/cVnnkAJ03Cvn1hDyfzS+qG2e0FenDvXcU7EpzE1BblcKBEQSTpUKZadBXB47IGp1jR1gpJAQurnouSoOPFxcBlZICoETFacFeShluNN8Cz138lm2iu5qOGGUba+ZQgy/wiVespmEZgWw7XAPwu1hFTvE1uQJiwWFoTAb5gTKmUWxZq6Yp5s2zRos5hjO7OR1q8VkQf80R2ADBjNTCwWPfE26nk9MrQWxBnhPHAZhtUbILTWGouwnRLKR26XKpoQUwuaE33zaHFTGfiL0Ozsx0OqhxhDy1Rqyw/ZcTxSvN5dswJDNo0DCk0W+2KrAPYAIBPIEAoE8gUAgTyAQJVhju1o7GO8bwr0iI459dfYH9eyeQPDecqd/nJKJU9DWwWaFYbPJwOeoiMA84TdWNjiI/Hb9EFfy7J49c1DrRfG3dXBs5GW37qr8hEyBCKU7iYxNhGYsYTOlAA9vFE4/FDoRmwWGamoRjOPc3oy78k9A7kQggs4TNoHLmpTZTCnAxxuFddhZLDFYewvWAsFFiWI2z9lYQvS0Ww0EY6MK8gYiOE84R5BnmMMbBQk1Mq2jPsQoFRnmwT5ElJ8nNIEdXAKL3npMgK+Pu20DJ0F5Cr9wjNgMniCF19xeQ9RhKRHCk5FFd7LrTH5LdJwrEOVeY2tjMhA3OL1RiFB4qhDd5gSiQD8NIf2RJRBlnidsfhdE4qaleHijsJsqWBIxFhjqMlp9wip6jmuR+HChR7EdVhiubiRwakF4ovb8T5RkOCNP1ATQ/0RATUlElkAgT5R6+YAsgdhSPIFAIE8gEMgTCATyBAKBPIFAIE8gEMgTCATyBAKBPIFAIE8gEMgTCATyBAKBPIFAIJAnEAjkCQSiABqwCRBbE+m1bP6+g7+SDp0wguY1iKpF0banQzeuruRn5LOWKP96FHUnxPaGkOI7x16dVlgCpifH4nc2SUXyREaBftWSYG6oc1EcpMYYlxdgSI3ZxDUD5LNafD4Wu1uS48arb+pJ0hrIZU8JICVisWRrSagmMkajCZa2MzMVGrlYXgIpH+MaBTlQujsWaxyC5thDAA/0FSy0SXeoUWlfWotYckjP1uwy+SAZV1o/AYnHbqKZPBqPxVt0kjokLiP3Mhf7oDJghpK0YJItXKPjqFoVQ8ofj5y/OMMGTZ+aWGxoDN7n9bxxOj7eBr3j+lXnVcZpG8inwsX/zJHrH32q+z2Rp3fd8rnxcYikltekZESJ0zofvfA/d8xING4i9/qp6mqmHZ20BnLZD70nklo//6m37R0pAdXGLkp1fHx8btdZ6eHdZ18aH2dvt0Y66O2/OTbNdc/m/pyfiR6+e5UGk4jwtbG/iNw+cGZ98h0P+5BX05t0v3REiMJsbkfH7Os3fHKNZrtwxVmJHn52zbOS0ke9sHrNmQk1stZP6bdOz776JSn9+guv3b8uae1gqNsy/cuXU0JKkAv2z50vvuHgjGQN1+iMt8F4RXquLVy2wm8/mZ9d+RnATk1Qm8fl+ZloKnnxVMh5QsfdHJeCGBU9IPFcjNfXKPtH6mEFjo3Cb8E6fFwOuTy1Djvj6t3s0Xia712ST093H6gu0XGjWkK17Eu53VfAD0pBNaJ1REf/LFyWG8yCt6zLf38LxkZgFf4BRkfhmBywCiMHgYfHonn4Zc6PvJrepLsKwij9swbTPMi3hIUBeSYXSJ9RmV3Gtxe0fsr1i9HVJVjp53fnlvV20Fk6p0TMTS2AzBKUJj8tn1nCNTq1MUEQvvXNK1OUAQBmdoLzGHtlLHJTSiiGJ5qGE6cPN9HW6YWUkFvqWtbzhBGIACV5Bj4B7+ISAtRN1gmrY/rdl3QCb4JcdbXW0CtqTZWyA8R/rf1CKajOabIix0fpUF2KJSzNfctF+e8ZSKchT//Rwx45QDm7nbbXHUJuzI+8mt6ke4dc/Dxt2r4++IwsQnu4KTn37sQRPckaZGNJRRHS+um2SIJ7QKDDPRH7kKS3g4bP6rrxAXUMfAb6WmSesIRH9DardrQ038mNXZwGWWfy+33x/DviBRcXTp7IwWhKG9XZPan3U1Glj/o0RKH96/T0owMPJjr3QHwfvz/2r7Fm+W4PGM+8IoocqyIsylJCLzvAxeGRvaWgqj7NEFYG5Al+oD/ZuYe9fZfSHkdVPuiRD/+kthPFY8AnD+3n2rhmb/JqepNuHPh2SknkTp7s76LZHh6YkHPPDjLqRWSxseNDTF1HemaSX98DPUfjjc9/SG8HbRB9W+PgliVQ1OeuwZPXRdZs4UabVT3WRmeCRfy3fH53aJ6gkuyINqqbr/vkV9VuVYY6wMu3LL1vgDZuLjpKpdJsbiw78cGldyt9B4aUlAVjFeLls0rZafnGQCod2fbuFTp6l3JH5BZxoF9tuQEjYEBt4tnVd61M51IrhaibdO8bSuUGIrA398LpozcA8HlOZpr2nqz5/H3pTHQEPg9mP1GpNqKkHtHCTax8RBv6C0c/onxE7obu0y/kiS3coFPtmF48k993JWiqkuev5c/3vTE3P13Es1hBgBPKyTL84c8ZXhEgfVduOR/VrwGGuXRP9DFVMl1jJIdINTZbeim3fDlWcrIzqvz3wHG5MSOyDiLQc1WDG1Iavb0h2j0VYkKNLkpL+Tqq3dD1BGXpVvVt6wzY2Uppe62fNAbsdyF35KT80AyGFuD0CU0NoOuJnC2c7e9qR3oum0/taVHWDoqqZD/+6lUHVh6emy5MyckTcTgwDIO0IQWqw15jLpfl4ZSIST88ygHPtfDKjPsODtpVmcu3rwjZTFI+3VGdL8flsh+Lwfu5lnaIl44sD78j/+UmeTeqAzB8gLYcbaZh+Kb8oDoKB24E+elHVoTByYJvhzS6NCHPtaaP8rRp6XqiXl4SK4/OPsC2deJOWjVOjqz1Ewf7f0rHOQ8HePMZgPpctbe3V14xXh+Z4NWwesi20NJZwzU6tYL07OL6T5rrDWnFHN/w+IH/WBKCsbezV8bPLd18bg4e6r8KugZ+1Vw3Ut0S/r0+8dfPC/BM/XzTQarHttRNwaGkoo5OfXV9V9O5WXWp9w/V2GBa2W+vn188OFc6snllUp6v39d0zuXB4cTQzUtnZmD6zOLNQ4qKMnNwaWmIrgf66qPA7eMLUTfpJuvmlv5QgLk3Hz9+9hmZJxSd6WFgujnxL/NvPTPB1HX+3KHjB9dg7rmlpqFeqz6nC8Du27SXD88MNc0PzdnCNTq1hGMR6Zp9u3Zawm69ulG6Swi8ySP43g5hdzzYUEqtXkwDYnORgaDbIFoXVspIvcS1KjZb6Q1ZiWpJO2dgZzw6HVL7C7Hfqe83s8GUlLiAY3SzEYN8wAcHieRUeOKRXG3xhIxH3y+t89FR3AOI2FKzH/qfQCCqAMgTCATyBAKBPIFAIE8gEMgTCERpwGwN0PyJ6g9nTd+ghbyEVsiLqJqt7va6DIXQHYSjT8htyxOktnzkigZjKL/y8Bz9iQR9B6PuJIqiPMhE7cwWDOYNGsc15ubNEhWeqhBbfJ6wykdiF5HshSGdiVvMTQHxuUIgSssTviONMgAz9knFxyUpq7YvWg4I5AnbYBC9bpR9aBZW+svEbkq11AMCecIYcK7zAHGZUracTk9QL8M1dqGZQnksaawpwGfe2ApAxQnnCbseJK+eGbWBVY9sqpISc8utJzTSBN9PbDOg/QSieoH2EwhELawnEAjkCQQCeQKBQCBPIIqGuGmJ4OnNy0pEnkAgvMC+nxBthgihX0xrmwHtvEccDEkcPGrN1Pb6Q39fokXwpaDftBVefSVPnAUGhqjzPYRotydRAhjafqUxDrjbvGZ5YsMgzmvRdReIc2Ra3o5bNzHZtjSRAhSI1wQqEs/5Ur7lwkgsXdZcg90G6V0a82DZN4moTZ5QpaHSndrINk5lsaftg1JvMCJRvhKN+A7BqQ+SoK+FmXmLiKzEdaVA2IEvEuuORaXAGxmYDEFin2Pspdnq438TFxSbmFUBnnBaUFjFHtgsKEx5SvSxQ7zEuGKAZMhW4j30nJsOddXMjYLI6E7Emb1oshXLP6LbDOJaMmLhL5lWoPoUq4VWNUhRMgU2K1WRWXnwhBisGbzGrX7XoSm4mVn4FdxjixHxpmCuZNx1d6PIxLdRSMEuty+Z3OsjMhqcumlMxD1Ttak76atIhjnEYBOUWJrZTCRuK4gwoosULU9IuIwKxJInEm0HJXFlJUSNrSdI4TEQZkC5fUTAQ3fyYgaXULGYiVy0rsPdMiuKrlsq4qoRImr2uZPPI1nR9YZobiT3HGgeFkq+D6qI16wRlHcs+ZICT8WKXiIT19luK4JsWqIKZdXgp89b7CJMcwLNIpOdTUT74xjLgChgxUlE2wC1BgQwYDATWCOrFApaj3o+KvUrmfeQtxteaHrUlnrwRKxnIgkQuagXXkWlEINoLp4f8IqUYWVfKgG5cToiKU9O2/ubT2btza9rkQBNJYZXdMNrsCRI91iiOWKH3tshUmwOS2ymOiBuMrNuPSYpQ6sVO0tsNFro99ikBDHKqhgWRYGEJ4t8EbL1SPn7n5QkGu4BRCCQJxAI5AkEAnkCgSgW3v4nrGv0cI/FHFsZRMcTenZPILhZILBbhsD6DrGQrYPdfsHyFBq/nb/hJbXH26ACkTe9gAGjEf/3E247KIrxeOIwLiKupgne+Treoovsix/R39bBsZGXfQotuhpKIBC+upPmS8J0Q8G6mBB16xo3bxROPxQ6EfamTlcMwRL+b2BCcSsCEVR3sglc1qTMZkoBPt4orMPOYonB2luwFgguSpRdDyKegzrklyuNjSrIG4jgPOEcQZ5hDm8URb00MS0f2Ah+9hDMcgPHNmITeEIMs1CxKS+in14jBlVnCu1VJ2GXUwjEhniCgLeELjBEHZYSITwZFWe3gE+RqgAZ+c/Gvnds/Vyy5ao46hoJk5JPDtaABs+laKCRRkTiWBX7zgPOx1gicXJMuO/pIEtUHL01TN2RSZ3bOFd2vmoHY4wTy4ZY9oo5J7ZNs5ZEJmGVrvoQStlpK7oWQbTnCj5bWB1pXA8hWA0RXthnMqpYz2jnxoUZosYzYsu3tAi2SMVSz2jkgckuY882wxIxaWWc8wSx6U6Wv9aVMBuJWE4Ju9om7OrbloYUWjAQZ34QIo3rAWeVMrJEr6mCsOfqpRmiXujXymmvcebpdSIodebKyI4JUM967QVgEtbe3o5S2DbjNFGOCUJTP3ozLqO616ag9LopLb2lod7rQa03gGrWCyX+DuAmMUVVkEC4DKuMb5xMsSuDjVLPbPy5EwJRvO7kO7Q34oyreOohM8V9sYiSsoUisnvdpHRmA6I7FPWMR8pMwBxwnkCUToPKKCoMq8swQaZ2Iwc6tB11qPuoQEGpa+SdapU1W3mdDY6I8jX6PUVsQQ1uQyiN/US45zj6dsCiv3oUzCGF9bNCott3ncFzA3s4I42ADimsRiMEXVNUJxie8OueUvcb2cgnVAM4pLDsN3FJ414p0XIrhJFGMIcUYP/2NLqmKIsGt1ECG7OfMD+4bFhGiLbYALoBhU4cNCqi6Gp7IZq0bGVh/KJobylEw4CDhOJhS002xPjElTopIFiQD2pknrBJteD2E8C4oRBZ5ch+H8CIAlabCuep3eQCbAYXBRxSsB/rdNuB5eaQwmvrR4DNiay093RIQVxVMGSPGuCJAlLQdR+35YOqQHwJuX8z1o1WobL4OKQopKeXzCGFMx9naZwb2g1zZnRNURs8EcR+omR2Cz62F0HL4stixcvh0o1Ux2KGuEx2iGrmiUD2E6V6YEICzUrE1ZGpO/84Q/0KGkAx8o/iRTyYOQi6pqgZ3amg8LLZS9i+TOMYGyLxmQ689nCb3yewfbm/sEMKkRTgXTHEbBCwIUKkwomhxnjC9tkbkbhpS1ZvFNqbBsbRg+t9cPqCcDq4MG8Qe1mKcUjhFlAKhxT6mfmCoqBDCpMhtq5riq2Akr/Hdh0ZVSMX0SEFoiD+P5SrNBVdGyhVAAAAAElFTkSuQmCC</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2012-06-19 17:15:23 +0200" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.08" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.8 Analgesic intake (post-operative day 2)</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2012-06-23 17:05:17 +0200" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.09" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.9 Adverse events (side-effects)</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2012-03-06 16:25:42 +0100" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-001.10" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Phlebotonic versus placebo or control intervention, outcome: 1.10 Non-Compliance.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2012-05-22 16:37:30 +0200" MODIFIED_BY="[Empty name]" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: Review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2012-05-22 16:37:30 +0200" MODIFIED_BY="[Empty name]" NO="12" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVUAAAPqCAIAAACsbVvwAAAw3ElEQVR42u3dvW4lx/X1YQIGDAcTTDBX4GuYyCAc2ZHvyRMyEGCFcxeGL8GwpFBW5MywPCNIEygY2ZlkC/2eefmHQJOnu6s/dnXtrmeBgXSGXGzu07/66jq1bm6IqGcNRNSf8E+EfyLCPxHhn4jwT0T4JyL8ExH+iQj/RIR/cifZUYp/6vUeKnmR8E9nu4FW/yvhn4jwT2cZCLij8E/9wm/kj3/Cv5sK/4R/wj91cieBH/9EhH8iwj91dCfZAox/6vA2evgf7ij8U7/8awLwT/gn/FN/TYA7Cv9EhH8iwj+deNgvVBL/RIR/IsI/9XgnGfzjn/pcBZh+hfBP+Cf806mbAHcU/qnHab8lAPwTEf6JCP9EhH8iwj8R4Z9OeCdZ/8c/dXgbKQL+Cf+Ef9IEEP6p28m/mwr/RIR/IsI/9TMFUBD8U0e30ewrhH/Cv5EF/gn/xXdnyYuEfzqyL93dedrETYt/0pcS/unUfalkUfxT03DG7f+TLI5/6rcvxT/+qXWW4p7/4R//1C7/Fc7/fujmXsU/Jej/Cf/U6PsNWsI/hQwudm9ZnCyAf0oDf9DM4qcHjaqNf2qrL7X+j39K00tH9KVxi//4xz/1y5L9v/gnfSnhn1rtSx+O/N1R+Ccjix08nSyOfzKzIPxTq30p/vFP7qQcJ4sR/inZzGLiFcI/HdmXVtj/h3/8U3Ms1fn8P/jxT5l66d2HKpYA8E/6UsI/NTlKt/8P/9T1sMLzf/wT/tN8srDzZQX8U4/8S0PDP+XoS3dfs5Asin9KNrIg/FNzfWlq/p0shH996c4NSoXNxX2uWeCfEvSl+/4in1nGP7XeBGT8lA7+8d/75L/zT+lJQ8M/hTQuKZxJTSnZhMXtin/qpS8N5d8ni/GvL+30miWL4h///X5Kx/o//vF/oxr4x7/5/25T6IyLC/b/Eu02uNirZRnkfxU0uPgnM4tO66z/p+P70lzn/+cdWeCfrCz0Pv7HP/UySndzzraJ+Cd9aRNjlqwVQIih4+5NTLdrFvgnLYvZUIIxC/77BbX9I7qGnGcWJWqz8N91L91nE5B3NQT/1CL/obN0a5b4pxZnj2T+T5R1zkL4p6hJdbezdPxT65QOMYt/cc7euMH+P9qR0iHsLK2h7c//TI8v9P+E/+OdKyeLpTgFyPo/tcj/EHaWTs1tBS0fBBrUGuK/0/m/9z0X/0GtofuAkrVZcef/tz/+N/+nrucs7lXjf2pl9ph9zUJriH/ql3+tIf5p/1tz9zPqIpxTn1mAf9rU4w2R+/8GJwsmaWfxbyzdqPO0w44RI/oD/OO/ReerN2fo+eK9jVnwj/8976SI29SepbgmQE07nf9730/w9nn+T7SyC/XhP/xTYNekJvindpcAUpz/UXMinev8/8H+P9pC6ZDh/I9qs2j7/wj/LfJfLf+rw3cQ//jvdGaBf/z32ATk+iBdnTYr3Tvo/H8yZtl/FaDP/gD/vVC0ezdY4Vl63CcLCf89jvynX6RE43/zfzps9njIyCX6/L+84zj803laluin9Bn3/+Cf+uql65//31UTgH/Sl2a6ZvN/ah2n0M//9zz/j2pQ3L566cZn6c7/xz81SmmFNsv5/4/eysHn/2hj/5/omit8sqjDauCfMt30oZv/ff6XupsIaFbwj3/j/94LkqU4Pv9HLfK/e7JQhScLSddE93/XsKEJaGpcmr2Xxj8lmPy3f/5X0l26Nd/BjR/fxj91yn9QGmr9NYvVF49/Cuma2nc+R2bxxsYL/51Sai6Nf/y74z3/H9IdiPp0NIR/OviO9yw98XgQG/iPGJcS/un8PZ6ztPBP7qTY9f8h4GQR7xr+qdM5i09D4b/rXtr5H3nfwcH5H9TOcDfRzuK4NKR0rSH+8Z+sZdnRs+RF/JMm4Ej+c7Us+Kce5//uooxtFv51/iHNStwpnW7X/d84hcC/a8Y/aQJccJqCGP/T+Ufp7s+JUlj/o4buy6BdujXP/8Q/0Sb+hwz538PeZ2kdMogz/qf1fV3G8z+j+1LnfxNtagJSfEoP//inlCOX0LF0rvG/+T8ddvfQUYMs/T9tnaWnWKUn/FMI/0OeVfo6yQK5PgKEfzo//3EnCybdDW3+T/s0AalX6fvkP6pBUQhqcywdnf/nXcM/9Tj/T3r+p/P/qJW7R0d64PRtl8rj392jCcA/uXtaHUvvniz40/DHaej4x3+ylQXn//v8HzVx91RgsubzP/k/RC02Afu2WdGfhsY/dT2syDWX7rnO+O+3l0663d3+vx3/BPx3PURvPOsuepSuCcA//hudpVdeVkgKAv6pRUrdVHXaLON/Ovks3Sp9eIOiEJSi/w89/wP/ZADZOks97//ZfU0U/1330m164r/wss3/qQn+a67Sp5uztDzPwr8mIGpQmm42lPHtwz9tAjXpLMCb6PkfnXlYkbeXzteaKAS12QRk3LOIf+prxltzZmH93/mf1Msdj/+rV+j8L+quxwvNLMm1/o9/anQunbRZSbEQgH9qdP6/731Jdd5B/BP+u29NFII65D/dnAX/tNsSQOefpc3bZj0sOP5pDfx66dRpKNb/qAv+QzPL8I//Lud7Mc/S0z1ZMGfBPzU9svBk4Sqxe5UC/9T6zCLj4f/7rtKFjwfdwbQjTlnuqOjPLLY/ZsE/7d9F77tBLW5mEf2ZRfwTNdemVBtW4J9ahyp0CB3t33id2/8T8N/pFD3oXp9+kXZswQfr/9ROX1phZ8Hg4Z/n/9TVcDr7J4saX1nEf9eT/87X0up8sqDl3ZD4p075T/rJAud/UNfDlp5blqjausmwZGQR1Li0nFnoPujxjt/r7pleWUgXp53oUve6bPzjf3/zXXrUvPv/ar6Dxv/URP9/9ZX2t75FVDhRm4V/8/9O+X9UkKTvoPE/tduy7HJr1elIM+6G8PyPzFla7P+zPLPEf0cUpd7/F7FmkS6zHP/Uxbx0DJ5cp3RGXLbz/6ndfqlCs7K9fakwGsrSZuG/08456HNp6pxrzwL+u+7/s5inG6XXbF/wT2e7L0NXFk6zs9D8nw5mKe+Y5Ry3vf6fFt8ric7ScnPin0L4H/Y7n7faWnocPFku2Pkf1BD/eecs1T4NmaC22OiwCeh8/J8xWQj/1HrnnGhnQcb8732rjX9qei49WAKMrDP+3T3G0oEddeN1xn+n8O9OacZOu875/y3XGf/473cuHU2p8/+p0R4v0fvu/P/w2gKDup2ztN9L45+S9dJZdunkHQ0N1v+ptbF0rjWLvKMh539Ri2NpaxZ1RkP4p+bG0nmnKln2LOKfGu3/pXRlHA3h3/w/E04ZrznB/QAM6nPOsu/+P+d/Uo981pxLd7hLZ5D/TV31SxXmLIl26cfNhvBPvc8s9j0NrfKTBf0/GVk0OrJofzUE/yjNd/HeSs//qK9RereI1rhU91m3PcmOt/uj/26Z/4cXmegDS7u/g/jvdwC5++2e5Tj9uGsec9j9QMSd225UdIV9hcdRLe8sTsp/xDuI/x5n0Yn4j65GFv6D3kH86//xv3MvHTT41/9Ti/P/oCeLoc8sH1mFBpa3/A7iv/eGQB16fgfxT9T9YFAhiPBPRPgnIvwTEf4pyRtJtOSJKf7Pwz9nzkud8Y9/zvgn/HPGP+GfM/4J/5zxT/jnjH/Kzv/7/7y/e3N3+8Xt80+f3/z55tknz15+/vLVl6++/eFbzt06478L/l9//frFZy8uN83Tr8vN9PFXH3Pu0xn/5+f/0kVcvW8efl2+h3OHzvg/Of+XfmP21rn/GutDOJ/V+Xj+9z0vrfynrn5ndB2ubsYc26G59Aqv/tNlxjg2aLw6jHz3/TvOnTgfz//ESWbR/FdegB1GzpmbOIjuaouwlP+7N3eFt87EGJLzKZ0T8F/eWy79qdlGpzAc4tGfUHgw2zT/V8sye+rj1X+6/eL2yl1yr2t3z8vPX3LuxLl1/qfjWTf+1DT/G3/j7FCi5Ed2Gf/fPygqv3ueffKMcyfOB/M/TcuivnrFT00POtZdRiH/hT+yC//X75uHenIDce7E+Xj+Jz6fPD0xHkubK/ypRzOFidH704uc/o2Fn7iuxr8ej/N5+v/VE/hdxv8r/orZdyKafzNezi3yP/u4a3omP3bN5T+14/x/y5wlmn8r3pyz8j+xkr/uqUF5/790/b/k8cTY7MDzf86HOB+//k+hTeq97HjjjP9++R/seOeM/575v+9Drq8k//9B40dvP+LcpzP+u+B/GP/0+NUZI+dOnPHfC/+cOeMf/5w54x//nDnjH/+c8Y9//HPGP+GfM/4pI/9E8n/1/5w56//xz5kz/vHPmTP+8c+ZM/7xz5kz/vHPmTP+e+H/xx/ff/fd3bt3t2/fPv/nP2/evHn2zTcv379/9eOPPWbpxlUjV53x3wX///7367dvX1xux6dfl9v0X//qK0s3rhrp6oz/8/N/6Xyu3pEPvy7fs8I544k3cdXIWGf8n5z/S480e1Pef431Tmc68S6uGhnr3Cn/Ff7e8lzj8lDgRScR/zQXfTgc/ctfbn7965tf/OLD1+9+d/PXvz4eoP73v2c+8TauGhnr3Cn/s0Gaob+6JP9je/bJT/ruu7uHd94vf/nhAv70p5s//vHDf/zqV0Wj09OceB9XjYx1xv/jV2ZfHMajhGfzhSdSfZfyX97/v3t3e3UI+ve/f7jan//88evffHPmxJu4amSsM/6vdMvTYUETASGFuG7kf+n4//4R1KOvv/3t5je/+eDzhz88/qc3b86ceBdXjYx17pH/jePt7d31GP+zoUDl4WUPdbVT+u1vP1j9/vfXV6cKnTMm3sZVI2OdO+V/LAv4EP6HuWyyjfP/q/3Sz3724Tf+4x9XbsoO+/9dqpGxzvr/JvgPXf8bm5eOffU5/99ejYx17o7/kjW5o8b/ddb/77/uVb475azr/ztWI2Od8b+Y/4n1/43j/zrP/6fvy96e/+9YjYx17nT9v5/W7V72/9Wphv1/1CL/g/3/taph/z+1yP/wf59Lez7+ubS+snTjqpGuzvjvgv9h/HPpV+eii5wzZunGVSNXnfHfC/+cOeMf/5w54x//nDnjH/+c8Y9//HPGP+GfM/4pI/9E8n/1/5w56//xz5kz/vHPmTP+8c+ZM/7xz5kz/vHPmTP+e+Ff/m9254h3EP9d8C//N7tz0DuI//Pz7/yf7M5x7yD+T86/8/+yO8e9g/3yX7g7soS38h/fftRvSXzAoxmj/N/UznHvYO/877X0Wviz24/6n93I/fRF+b/ZnePeQfwPE5gVxv6W/Gzh2KEw/3MR//J/szvHvYP43wHIYUlEz8b+fwX/8n+zO8e9g+b/N4WJOtN5W0v5X5QdtJF/+b/ZnePeQf3/zPi/MPbrUYZ3ySeuq/Ev//eU/f8u7yD+h0XsLRr/r2t3dudf/u9Z5//b30H8D7Od+b7z/+nneRH8y/892fr/ju+g+f/NxFL/UBz7W7j+P/Ybaz7/7zz/V2Yx/nsZ0fwk+/+yO9v/R+v5H+z/z+9s/z+t53+Q/5vfOegdxH8X/A/yf/M7R7yD+O+Ff86c8Y9/zpzxj3/OnPGPf874xz/+OeOf8M8Z/5SRfyL5v/p/zpz1//jnzBn/+OfMGf/458wZ//jnzBn/+OfMGf+98C//t47zf96/f3N398Xt7afPn//55uaTZ88+f/nyy1evfvi2xWvGfxf8y/+t4/z169efvXhx9eyPS3Pw1cfNXTP+z8+/83/qOF86+dnjvy7f09Q14//k/Dv/r47zpecvPP53bBRQ/5oH5/8myv8tTCt6NOeX/1vB+TLnHxv2X50IfP/u+Gvunf+9ll7r5P+uCBcY5P/Wcn5zd7fE+PosoPI1438Uzgbzf2ffTvm/Bzp/cXu7iP/PXx5/zfjfBOQh+b9LX5T/W8f5/lFf+dcnz46/ZvP/fPm/E87yfw90fkriixnj469Z/z8z/m8w/3cp//J/9f/43zr+L+z25f+a/5v/n4T/BvN/C9cUJtb/5f9a/8f/zFi9zfzf2cmF/N8DnT3/p7ZGND/J/r86zvb/UYv8D/b/13K2/59a5H+Q/1vL+TIKGHsWcHn97UfNXTP+u+B/kP9by3ns8/9X5/yHXzP+e+GfM2f8458zZ/zjnzNn/OOfM/7xj3/O+Cf8c8Y/ZeSfSP6v/p8zZ/0//jlzxj/+OXPGP/45c8Y//jlzxj/+OXPGfy/8x+X/Shau4xxRZ/x3wX9c/q9k4TrOQXXG//n5jzv/x8lCdZzj6oz/k/Mfd/6fkwXrOMfVuQv+F0X9hpZiUarv1Vfayf+VLFzHOa7OHfFfTnidNdiSo/5LkkJmrzwu/1eycB3nuDrjf+pU/zEIr37/0wiwwkuaaBR24T8u/1eycB3nuDr3zv/SVJ+x7989/7ek2Sp8j+PyfyUL13GOq3Pv8/9C/tcBvCX/c0f+4/J/JQvXcY6rs/7/Srswm/k99v1t8h+X/ytZ+MD+f5c6478o3nf1At6KxYjd+Y/L/5UsfOz8f3ud8b9y/r+6/y9sU3bkPy7/V7LwIev/O9a59/n/6vX/iWHCXvm/Q8zz/x3zfyUL13GOq3Mv/Hci+//O6mz/H63nf7D/P7+z/f+0nv8hMv9XsnAd56A6478L/ofI/F/JwnWcI+qM/17458wZ//jnzBn/+OfMGf/454x//OOfM/4J/5zxTxn5J5L/q//nzFn/j3/OnPGPf86c8Y9/zpzxj3/OnPGPf86c8d8L/1J6szvL/6WVd4+U3uzO8n9pJf9O6cnu7PwfWsm/U/qyOzv/b+SilwR7NkJj4am+0+cIl/9GKb3ZneX/Tv0x5ZF7LfBfmOo7HQqwiH8pvdmd5f/O958P/2PFIf/DZLbn1W+e/hUTw5PK/Evpze4s/3fZX1LCUgn/5Wm/s79i4vpXZIot4l9Kb3Zn+b8L/pLZ4fcsdUsbjr34H2tZNvIvpTe7s/zfrfwXhvY+5b/8B6e/s2T9bxiJHisPJpfS20//32/+7+z8f+OLhenAi75zRftV2Mqsnj1K6ZX/e+b1/8LQ3tl1wWrj/8L1v6Uti5Tek63/y/+dWWAfG/8Xvrj0wcHEd5ZHgFd7/i+lV/7vGfin8vfY/r/szvb/0aaVUfv/szvb/0/r+R+k9OZ3lv9L6/kfpPTmd5b/S+vvHs6c8Y9/zpzxj3/OnPGPf874xz/+OeOf8M8Z/5SRfyL5v/p/zpz1//jnzBn/+OfMGf/458wZ//jnzBn/+OfMGf+98C//VzXw3yn/8n9VA/+d8u/8H9XAf6f8O/9PNfA/D09hHaa/Z/ZfC4/6XXoo8CD/VzUWOuP/SnVmS7Ga/x0DBcrPBZf/qxr4X8bz7MH+5f86+0t3RF3+r2oscsb/ph67/F8P5F/+r2rgP4T/CZ7L5whL+V86/5f/qxr4j+L/auzvbD238L9L/99t/q9q4H/B/D9i/L89/3OX+X+f+b+qgf81HfI04WPJwivWGqPX/zvP/1UN/E9WoSCcdzpEuCRN+GpScJ3n/53n/6oG/rtbyLDjTTXw3/VCph3vqoH/fvkf5P+qBv575n+Q/6sa+O+Zf86c8Y9/zpzxj3/OnPGPf874xz/+OeOf8M8Z/5SRfyL5v/p/zpz1//jnzBn/+OfMGf/458wZ//jnzBn/+OfMGf+98C/xto5zXJ0jnPHfBf8Sb+s4x9U5yBn/5+ffiTd1nOPqHOeM/5Pz78S7Os5xdY5z7oX/8njfFbwtsi05YniQ/ytZON65F/4XxfuGLtteRXq6QZH/23mycJxzF/wvjfcdxs/8n3ixJP/rajSg/N9zOMfVOc65U/7X9b3T+T/lA43K/Eu8reMcV+c4Z/wvjveN43+siZkev8y+LvG2jnNcneOc8X9TOClYFAS4dJXuaYjY2Isr+Jd4e2D/v0ud45x7n/+XD7NX9P8b26OS+cKW2WOfibcZk4XjnHtf/083/59+myTetrP+v2Od45x74X9YEu+7dP3/aeswe9zS6muYnlxIvD3QOa7Occ4d8R+3iND+Rdr/V8fZ/j/8N3qR9v/Xcbb/nxptpCTe1nGOq3OQM/57GaRIvK3jHFfnCGf8m6Rw7tcZ//jnjH/CP2f8E/4545/wzxn/hH/O+Kf2+SeS/6v/58xZ/49/zpzxj3/OnPGPf86c8Y9/zpzxj3/OnPHfC//yf+s4y/+l5viX/1vHWf4vNce/83/qODv/h5rj3/l/dZyd/9c0GyfI/53+dfJ/D3SW/5ujY8yb/zvmMH0Z8n/rOMv/TTMqTp3/u5R/+b91nOX/5lsVS5r/sz3/T/6v/F/858v/XcG//N86zvJ/T8L/0Gr+7+xyo/zf1vp/+b9Nz/9z5f+uy/+T/3vs/F/+b7vr/+nm/yv6f/m/h6z/y/9trgnInv+7jn/5v3Wc5f+evPnIe5H2/9Vxtv8P/41epP3/dZzt/6dGGyn5v3Wc5f9So4MU+b91nOX/0qkmKZxP7Ix//HPGP+GfM/4J/5zxT/jnjH/CP2f8U/v8E8n/1f9z5qz/xz9nzvjHP2fO+Mc/Z874xz9nzvjHP2fO+O+F/1y5tPeS/xt9zfjvgv90ubSD/N8q14z/8/Of8Vwa5//UuWb8n5z/jOfSOf+vzjV3xH/hdsjpkm0v1Jbzf5cmiww5c2nl/9a55u74X0RyUFLw6vP/y9NKHipjLq383zrX3DX/Q1nm13QQWMmPPP3X7fyXN1gZc2nl/9a5ZvzvkPkz+yPlw5AS/peO/zPm0sr/rXPN+L9ZB+HqIfqwIf93tnE5TS6t/N8614z/qWjNWf4Lf6Rw/W8ozv9dxH/GXFr5v/r/w/r/wpF5+Y8seicmXlzHf8ZcWvm/5v9V1/93nP+vHv/XWf9PkUsr/9f6fwj/E8//d1z/Xzf+r/P8P0UurfzfOtfcF/8dTnDuZf9fHWf7/6hF/gf7/2s52/9PLfI/JMylHeT/Vrlm/HfB/5Atl/an2a/839Brxn8v/HPmjH/8c+aMf/xz5ox//HPGP/7xzxn/hH/O+KeM/BPJ/9X/c+as/8c/Z874xz9nzvjHP2fO+Mc/Z874xz9nzvjvhX8pvZzx3yn/Uno5479T/p3Swxn/nfLvlD7OsfxP7DQsdy4PujtqEWWXa9ty1O/0dk4pvZyPOf93NfNBjLXJ//aj/qd/u5Rezsec/18SrfP0OP2J8/YfRl89jdxaRFRhRO8u5sPcEf1b+G8t/zdjSg/nI/lfGq1TnsY3bIvorZn/ueVXr8j/kNLLuaH+fxFaS3vjXbrWvcyXTgSGmPwvKb2c8V+J/8Lx/7q/a/5GkdLLWf9/LP+zFV+d/7mOfym9nI9c/6/D/6JZ/dKWYuOSQWFDOWTL/7WWbv3/ynPpsbZgBczlj8Qj1v9XmE+P/8eqlDT/17N0z//z6cR/qf1/nOX/4v+K7P/njP+umzYpvZzx3/XQRkovZ/yb2nDmjH/8c+aMf/xzxj/+8c8Z/4R/zvgn/HPGP2Xin0j+r/6fM2f9P/45c8Y//jlzxj/+OXPGP/45c8Y//jlzxn8v/Mv/rVONXM7474J/+b91qpHOGf/n59/5P3WqkdEZ/yfn3/l/daqR0TkZ/4XpeouGVZX/9qtHgC89R7j8D5H/W6caGZ2T8V+ertcs/9P56CVH/S89/1v+b51qZHTOxP9sckbJ6f3DHonA0zkFs/12Zf7l/9apRkbn3PwXIlQSIrwxO2hR/u/2rCT5v6ud46qR0Tkr/4/62NCcv2FzHmEh/7ONyzr+5f/WqUZG55OM/xcB/PQT0Ru/c/anCtf/rrZxw1ws4rreo9v837hqZHTukf+l04eSBchZMldMZFY0LvJ/D6xGRueTrP/XnP8X/vgQmf+9Zf2/8/zfuGpkdE7G/8Tqes31/6X+heP/Os//O8//jatGRud8/Kd7NtHCZdj/V6ca9v/1xfy6zYiHNEP2/9ephv3/1OgwRP5vnWqkc8Z/L9MQ+b91qpHLGf+WITj364x//HPGP+GfM/4J/5zxT/jnjH/CP2f8U/v8E8n/1f9z5qz/xz9nzvjHP2fO+Mc/Z874xz9nzvjHP2fO+O+F/4z5v3HX/J/379/c3X1xe/vp8+d/vrn55Nmzz1++/PLVqx++lf9Lp+M/Y/5v3DV//fr1Zy9eXD1V5NIcfPWx/F86Ef8Zz/+Ju+ZLJz97sNjle5q6Zuf/0Er+M57/F3fNl56/8GDhsVGA8/9gtn7ZZsv5vyvO/8+Y/xt3zZc5/9iw/+pE4Pt38n9pP/435v+uCDLOmP8bd81v7u6WXPL1WYD8X/wPEwwH5f/Ovkenyf+Nu+Yvbm8X8f/5S/m/VMx/aP7PimTBIWf+b9w13z/qK//65Jn8XxqZrpcHhJbwvz1c/DT5v3HX/JTwFzOXLP+XIvv/oTj/dx7Is+T/xl1z5f5f/i/+l70Tu7+YMf837prrz//l/+J/t/n/Cv4z5v/GXXO19X/5v9b/F/z40uf/5cOHjPm/cddc7fm//F86vmG6l/1/D2X/H/774n+w//9/Zf8//vvif8iZ/xt3zZdRwNizgMvrbz+S/0vn4n/Imf8bd81jn/+/Oudv5Jrl/9L6u4czZ/zjnzNn/OOfM2f8458z/vGPf874J/xzxj9l5J9I/q/+nzNn/T/+OXPGP/45c8Y//jlzxj/+OXPGP/45c8Z/L/xnzP/lHO2M/y74z5j/y7mCM/7Pz3/G838413HG/8n5z3j+H+c6zvjfAbOl+Z+rj/rdfv5vivxfznWc8V+V/41H/e9y/n+K/F/OdZzxvz//sx+3qMx/xvxfznWc8b8z/yX5P5X5z5j/y7mOM/5X8r8l/3fi2yL4z5j/y7mOM/6P6f9r8p8x/5ez/v+0/FfO/8yY/8vZ/P+c/M+uHUav/6fI/+Vs/f+E6/9j5zHJ/+V8iDP+T94w3cv+P87475f/wf5/zvjvmf8hZ/4v5wrO+O+C/yFn/i/naGf898I/Z874xz9nzvjHP2fO+Mc/Z/zjH/+c8U/454x/ysg/kfxf/T9nzvp//HPmjH/8c+aMf/xz5ox//HPmjH/8c+aM/174l3jLGf+d8i/xljP+O+XfiTec8d8p/06844z/xRRF1KR+/q8Tbznjv7k12Gr5f06854z/rf3/1UP7f3r9aTWH4PzP8pZL4g1n/G/if4zGie+cLelq/peO/yXeccb/bvP/jUP06W9b0eLMvscSbznjf7fx/7H8r5j/6/E443/TytyOiA7V83/NeDnjfx/+y/v/iQjQfR8KWPHmbP1/nybg6gr/2Kp++XdenURUy//1xJsz/g8eUxz7G+1444z/qoOIQ+ppxzvnFc7472LEIfGWM/67nnFIvOWMfysOnDnjH/+cOeMf/5zxj3/8c8Y/4Z8z/gn/nPFPmfgnkv+r/+fMWf+Pf86c8Y9/zpzxj3/OnPGPf86c8Y9/zpzx3wv/P/74/rvv7t69u3379vk//3nz5s2zb755+f79qx9//LZZ57gs3f+8f//m7u6L29tPnz//883NJ8+eff7y5ZevXv3wbV/VwH8X/P/736/fvn1xuR2ffl1u03/96+MGneOydL9+/fqzFy+unqNxaQ6++rijauD//PxfOp+rd+TDr8v3NOUcd+LNpZOfPUrr8j2dVAP/J+f/0iPN3pT3X2O9U33nuBPvLj1/4VG6Y6OAM1XjtPwv/YsWbZncclXbj/pddP7vZS76cDj6l7/c/PrXN7/4xYev3/3u5q9/fTxA/e9/3x3uHHfi7WXOPzbsvzoR+P7dmauB/8PWYFcf9b/0/O/vvrt7eOf98pcffvxPf7r54x8//MevflU0Oq3sHHfi/Zu7uyXG12cBp6lGj/yXfBxi9kcenvD/NBegpJ7V+H/37vbqEPTvf//g8/OfP379m29eHu4cl3jzxe3tIv4/f3nmanTH/475XOWhQDvyP50sfvX1+0dQj77+9reb3/zmw2X/4Q+P/+nNm2eHO8cl3t0/6iv/+uTZmavR9fh/93y+ITj/cx3/Vzul3/72wzv++99fX5063Dku8fYpLy9mjM9cja7H/0H8F37iesuiwPb+/2c/+3B5//jHlZtyY/+/i/Np+v/Gq2H8H9j/F17YIv6nG5dF89Kxr+3z/+3OZ5r/t1yNfvmP6//LG6B1639L+/9H69L3X/cq351S2fkE6/8pqnFy/q92mBP5vEvX/yfW58fg35j/u4L/R8+lp+/LLc//d3Q+wfP/FNU4M/8dyv6/Emf7//DfF/+D/f//K/v/8d8X/8P/fS7t+fjn0j5q0DkuS/cyChh7FnB5/e1HHVUD/13wP4x/Lv3qXLQR57gs3bHP/1+d85+4GvjvhX/OnPGPf86c8Y9/zpzxj3/O+Mc//jnjn/DPGf+UkX8i+b/6f86c9f/458wZ//jnzBn/+OfMGf/458wZ//jnzBn/vfCfMaU3o3NcsrD8X1p592RM6c3oHJcsLP+XVvKf8VyajM5xJws5/4dW8p/xXLqMznEnCzr/LwSPFX/1xkJtz/9dlFw45Mylzegcd7Kw83934//pqds1+d+e/7s0uXTImUub0TkuWcD5/zX4nwj5Hcv2XXpu/9X3Y2mjsJT/jLm0GZ3jkoXk/+w5/h8L7b7K20T23orcno38rxv/Z8ylzegclywo/+8w/idenP2RpROBIP4z5tJmdI5LFpb/W4P/q0lh0/yXh3kdyH/GXFr9v/7/sP6/kMzyGf7069H8Z8ylNf83/w98/rdlMr9x/r89/3fj+n+KXFrr/9b/q/I/FIf8bln/3yX/d+Pz/xS5tJ7/17nmvvjvp4F7JPv/6jjb/0ct8j/Y/1/L2f5/apH/IWdKb0bnuGRh+b+0nv8hZ0pvRue4ZGH5v7T+7uHMGf/458wZ//jnzBn/+OeMf/zjnzP+Cf+c8U8Z+SeS/6v/58xZ/49/zpzxj3/OnPGPf86c8Y9/zpzxj3/OnPHfC//yf+s4x9U5whn/XfAv/7eOc1ydg5zxf37+nf9TxzmuznHO+D85/87/q+McV+c4Z/yPFmhpqk/hb9mS/zu9l1P+74HOcXWOc8b/4yqM/e/uTcyW6IGhOFxgkP9byzmuznHO+C/ivzAmuKSLrs+//N86znF1jnPG/3AV47F0sPKY4CEg/3cd//J/6zjH1TnOGf/r+Z+tbGFQTzT/8n/rOMfVOc4Z/8v4H+Ziwob//RB+C/zL/z2w/9+lznHO+F/MfzmWu+f/7jv/l/9bZ/6/vc5xzvif4nljTPDu+b+7rP/L/62z/r9jneOc8b+M//Lx/xjqG/N/tz//l/9b5/n/jnWOc8b/OZuwR7L/r46z/X/UIv+D/f+1nO3/pxb5H+T/1nKOq3OQM/674H+Q/1vLOa7OEc7474V/zpzxj3/OnPGPf86c8Y9/zvjHP/4545/wzxn/lJF/Ivm/+n/OnPX/+OfMGf/458wZ//jnzBn/+OfMGf/458wZ/73wL/83u7P8X1p598j/ze4s/5dW8u/8n+zOzv+hlfw7/y+7s/P/wlEpTPvdWKi98n/Lz/+W/5vdWf5vCP8laZ/78r/9qP8V1yb/N7uz/N/D+J8+7X8i83csAmAL/+WZwg8l/ze7s/zfqPH/urTfwm+LyP9dkf8h/ze7s/zfY/ifwHWWwPKBuvxfzke9g/gvTfudGOqPfdvu/M/fgvJ/u+n/5f+2Pv4vnKVH8y//96zzf/m/Ozz/K/yP1d82+zbI/+V81DuI/6K03/LVvtlFBPm/nNtJFu6X/3M3ao9k/192Z/v/aD3/g/3/+Z3t/6f1/A/yf/M7y/+l9fwP8n/zO8v/pfV3D2fO+Mc/Z874xz9nzvjHP2f84x//nPFP+OeMf8rIP5H8X/0/Z876f/xz5ox//HPmjH/8c+aMf/xz5ox//HPmjP9e+M+Y//uf9+/f3N19cXv76fPnf765+eTZs89fvvzy1asfvu0rpTfOGf9d8J8x//fr168/e/Hi6jkal+bgq487Sukd5P/Sav4znv9z6eRnj9K6fE9T1xxXZ+f/0Er+M57/d+n5C4/SHRsFnOmUvpOc/1e4IbGdVZO4Csy+OIwcFr7x/N8U+b+XOf/YsP/qROD7d2dO6T1P/u9E9EVv/XNJ1G9JUshsPTPm/765u1tifH0WcJqU3vPk/07f0GMRuoUvXv3Xks628BftckR/If9XUwbX8Z8x//eL29tF/H/+8swpvefJ/x27oWcjdMujeAq/c+kvWhH7tSX/t6S5LHyPM+b/3j/qK//65NmZU3rPk/9bMv9fF4w9O5be5Rctslo6EQjiP2P+71MSX8wYnzml9zz5v/MXMRKhtyP/W37RrFXh+L8m/xnzf0/T/+9S5/Pk/5YsXIfyvz1sc2Ma5yKqQ+f/Lef/nmn+v73O58n/LRnzr5urL4V2e/9fbjX7SC+U/4z5vydY/9+xzufJ/529iPKF8Y2D9l3m/0+tpsf/i/J/h5jn/ynyf0/w/H/HOsv/LfozyP6/Y6/Z/j/8N1oc+//rXLP9/9Ro45gx//cyChh7FnB5/e1HHaX0DvJ/aePgKGP+79jn/6/O+Ru55rg6y/+lAyZHnE/sjH/8c8Y/4Z8z/gn/nPFP+OeMf8I/Z/xT+/wTyf/V/3PmrP/HP2fO+Mc/Z874xz9nzvjHP2fO+Mc/Z87474X/jPm/GZ3l/1Jz/GfM/83oLP+XmuM/4/k/GZ2d/0PN8Z/x/L+Mzs7/axeMvUKHFx31P3El616cfSOvzhjT5f9mdJb/m6NX3PiXbvnxXdJHlvKfMf83o7P833z8T2QBz37DbChY4VUtbRSW8p8x/zejs/zfZLPi8nyhYXMA0S78rxv/Z8z/zegs/zfx/H82wLcc16WgRvOfMf83o7P833zDgeks4GFtWHDJJ66r8Z8x//c0/b/833bn/zvG/i4a/5ekeu7If8b83zPN/+X/ts7/0jl/yfx/IgJ09UOBdfxnzP89wfq//N8E8//pLOCJb5hd/x8m03tL8n+Dnv+nyP89wfN/+b/UypMO+//qONv/Ry3yP9j/X8vZ/n9qkf8hZ/5vRmf5v9Qi/0PO/N+MzvJ/qUX+OXPGP/45c8Y//jlzxj/+OeMf//jnjH/CP2f8U0b+ieT/6v85c9b/458zZ/zjnzNn/OOfM2f8458zZ/zjnzNn/PfCv/zfOs656oz/LviX/1vHOV2d8X9+/p3/U8c5Y53xf3L+nf9XxzljnU/C/44Jv+Xlm00NmrjOHV+cvkj5v3WcM9b5JPzvm/C7YmJW+Bs35v/OhovI/z3QOWOdz8//9An/hYfwDyMhvA+zACYig6evOZp/+b91nDPW+Zz8XyVnC28r8n+GgPzfdfzL/63jnLHOJ5//b6QoKP9v2JwyuIh/+b91nDPW+Zzr/6sTPldE/bbPv/zfA/v/xut88vl/xHrbgfm/+87/5f9myf81/9/K/9ikfcuL6/jfkv+7y/q//N90+b/W/1fO/4eRNN4tLxYGhI/xuTH/d/vzf/m/6fJ/Pf8PfEbQw99o/18dZ/v/8N/o32j/fx1n+/+p0TZO/m8d53R1xn8vYxz5v3Wcc9UZ/+Y4nPt1xj/+OeOf8M8Z/4R/zvgn/HPGP+GfM/6pff6J5P/q/zlz1v/jnzNn/OOfM2f8458zZ/zjnzNn/OOfM2f898K//N86znF1jnDGfxf8y/+t4xxX5yBn/J+ff+f/1HGOq3OcM/5Pzr/z/+o4x9U5zrmI/7HthOdrNVZE+m6nVP7vCZzj6hznvLj/r5C0e27+ryI9/dvl/3ae/xvnvA//Jd1U/e8ciuN9rx7dv+IyJn7q6Xeu4H/27ZT/e6BzXJ3jnHfgvzADp/537pv5W34ZsyOIyvzL/63jHFfnOOc9x/8rsnTLv3PHFwuH/duH5Uv5n40eW+p8L/m/dZzj6hznHMV/YZbusFPq7rAk3ndsXfMo/ocleWQr+Jf/e2D/v0ud45xD+G/wxRUDjZr8LxrVL/1x+b/Hzv+31znOOZb/RbG56ybeEb/9qPH/Fs/y1WP5v+nyf+OcY8f/5cPyp99ZvvBe4jk9/r/aFpTPI/Ya/5f8vdPHOcn/bef5/451jnNezH/NJ/BNWaWQ/X/HOp92/18i/ksOPOyN/8H+/1rO9v9To02n/N86znF1DnLGfxf8D/J/aznH1TnCGf+98M+ZM/7xz5kz/vHPmTP+8c8Z//jHP2f8E/45458y8k8k/1f/z5mz/h//nDnjH/+cOeMf/5w54x//nDnjH/+cOeO/F/7l/9Zxlv9LzfEv/7eOs/xfao5/5//UcXb+DzXHv/P/6jg7/2/rLTuWLxi9OnIspfJ/T+DcRf5vKAzTB2+fpouW/3tK5y7yf2vyP5vJUZLwsTpceCjOEbiaICD/V/7PCfN/Q5uAcv5LRg3bw4UnfmTRN5RPeeT/5nXuIv83jv9FA4GS5mPie/YdbC/N+ZP/e0rnLvJ/2+F/LLp3XbjwXoHFQ0EAifzffvr/s+X/NsL/RI+9savfcVlO/q/5/9nyf2s+Epuek18dHq+bn69LBy5fFNhx/i//V/7vkfm/jfA/FAT1DstjiMvX/yeGDxPj9unxv/zf1M7yfw9oJpZ+Q9Dvbbw+9v/Vcbb/7zzwZ8wRtv//cGf7/6nRJlL+bx1n+b/U6BBJ/m8dZ/m/1CL/nDnjH/+cOeMf/5w54x//nPGPf/xzxj/hnzP+KSP/RPJ/iWhht6EQRPgnIvwTEf6JCP9EhH8iwj8RnYd/IupT/w9LU9JdIoBVcAAAAABJRU5ErkJggg==</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2012-07-05 16:14:23 +0200" MODIFIED_BY="[Empty name]" NO="13" REF_ID="CMP-001.07" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Phlebotonic versus placebo or control intervention, for outcome: 1.7 Overall symptom improvement.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADAAMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdCQkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYAAJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkAmcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwzAP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8zzAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBmMzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNmzGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZM5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZzMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zMM//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP//2b//5n//8z///9BjlLGAAANfklEQVR42u2dbWxbVxnHTxJ7idvN6fGooApjKRpMUylipGqbVhOZN60aLZBKZXxZiwZS0dQP+4z4BGJIYYC0fan4wBCl40VU4yUqqNB5gbRNh1KKBqhCtE1SmhpW1SdLSerUXYtz7fjdqW9yb+45x7+f6vje65P63Hv//p/neXKub4sUAN7TyiEAhAUIC5qbUKMNVfYhc0/OglBSyao2uRZSFBtmtyniOIRVV1cy/0OWbqhE5rY7r8lcK4myGAqXgFIq95S3qJymFAcWx3KBrHCwgj/N/1vs97AshFVXG6IkdpJ1GlQGZQJBIawG3Ko0xmrkFzAqYqxGkkLXEGshrGWjSrSEU0Gonkrk4jFWPh6XuZZOTaHYUFZE7QgNYZXmerUyQlmxqXpz2RYUhbBcx0+yfByUta1JYVhNSYts0LEAPHMsVTG8gUl0TWorLEngbTDnolaUG0A3HhEIC/xwLP1iLKkIqyxwLA1jLFRlAYHqiqEQEBYgLAieLoQF9mWFCMverBBhAY4FOBbCam6oY4GFICxAWOAG6lhAVghkhQgLx0JYgGOBIVDHAgtBWICwwA3UsYCsEMgKERaOhbAAxwJDoI4FFoKwAGGBG6hjAVkhkBUiLBwLYQGOBYZAHQssBGEBwgI3UMcCskIgK0RYOBbCAhwLDIE6FlgIwgKEBW6gjgVkhUBWiLBwLIQFOBYYAnUssBCEBQgL3EAdC8gKgawQYeFYCAtwLDAE6lhgIQgLEBa4gToWkBUCWSHCwrEQFuBYYAjUscBCEBYgLHBDsHWsUMmyEkIWlhYWwdisMKqJsJTMPQSqsiMrDDR6rzkUKnRlg2NpGGMppTgxxjuWNjFWkfygqIi3DGZSP2HJkmeGRfBuKATwJXjnuFhAsHWsFlmmp2JwJckQDWc6qouwaieICMtUx9KvjgU2wHws8AXmY4EvMB8LLARhAcICV1khwgKyQiArRFg4FsICHAvMgDoWWAjCgkZQqlVlH60Nz6gKccxsxdvZDfK2FOI2jgVkhUBWCDgWwsKxEBb4AHUssBDKDdCYA10T4v5r4v5GKw5cpWMtXKUDZIVAVoiwcCyEBTgWGAJ1LLAQhAUIC9zAdYVAVghkhQireUjhWOADw63v086x+CO0+SSHotN7wpp1CmGZ71eXD6SOT/fF9OoVQ6HxfnW5PyWebD+V0qtbTPQz3a8i7ZHsU+/QSOUrzMeC5fiVoysR+8xcmqwQPKszRKKR3FL40y+ldMoKEZbRxD4ynTeq8fTemE6ORVZoOJnB9p4PCDHx470PEmOBd4T7HjiVFOOdz1bqKuD5WDiW+aR/u+Hs1m7NOoVjmU/HJ9+vna5wLDuSw1pl92BjLIRlLcHer5Ch0FqoY4EvUHmH5QVYOBb4QPJYsvYLXFcIy+DGUHQoo2G/mDZjuF8N9a1LH308pl3H2iJ3aZCOcPb0Zfjt/pdF6IsXDw5Uv9Z1naEQluhXlw84s/zuXCUrBC/jq34nJYz1nh3XLSuk8m5wneFYdOdCwJK+XRVmBVt5J8Yyl4E/vZR4zVma+ObUuqqXP3wdYcGSmG17Zt+P2oQYP/NKd/WrgeqKGMtown03B5NiYk1PN+UG8HQ0/Pk3zhx6/BX9dIVjmc7DPek6fhXs92ORFZqfHNYpuwebFSIsa+EqHfAFKu/gC8zHAl/Qcj6W4ryAD8JCV+CHsMgErcgK9RMWuiIrXC6LTk1WCz9QmolZ4aS2wpIMiyY7FldCgy+OJRAW+ADXFYIfBHyxYWv96ApM5spMEscCzxl/9c1NSYQFXutqzbO7z41kEBZ4ysSaqW7xSPvvUwgLvIyvOme7hTjXO7cquD4wg9TCcfCw853vXZOZmdEnERZ4RGbmxK784vGrO4L6Hhou/7KONvWv537iLN34bP/3BMICj/ju9y987cUBIZJb+14WCAs849sH/3HhcFvXR/uD0xUxlqWkj3Zu7g7ypqsIy1Lk2AauKwTvUbe5XyH4AldCgy8wH6tZydi8cwgrMK7MXEFY4DkTq948/B9fY6xAd487UwTlVyNT3emHMmH/3oGrdJrTr3q6RYfwc8YUV+k0o1+NTnVnn/rmzvjoWIHuIX8rDMSv7st9H+3A4V3PH/LrTYL9nncKpEHUGWYufXzhc/vLHTEr9xFhBUFyZMPDzsLwxnZLRwSEFYxnDd6zLTZ/t8F+WyMNyg2BEO4bGcqEhyN++hV/K2xGYjujR9KXfR0Hmd3QpMgxf+MrHKtJUbf9ja9wLMCxwByYjwUWgrAAYYGrGAthgX1ZIcKyFuZjAY4FOBbCanKoY4GFICxAWOAG6lhAVghkhQgLx0JYgGOBIVDHAgtBWICwwA3UsYCsEMgKERaOhbAAxwJDoI4FFoKwAGGBG6hjAVkhkBUiLBwLYQGOBYZAHQssBGEBwgI3UMcCskIgK2yMslueFL56W2UffA236Y4V1UVYqriIqixwLF2+5714qwBuGmADwdaxQjVdSuFZ4GGMVaqxeddSxFvgpbBkyTPDoqlwLx3wJysU2glLcVZsyAo1GwqzY58keLfBsQKtY3G/QmIsYixwA/OxwEIQFiAscBVjISzwJStEWOAHXKUDOBbgWAiryaGOBRaCsABhgRuoYwFZIZAVIiwcC2EBjgWGQB0LLARhAcICN1DHArJCICtEWDgWwgIcCwyBOhZYCMIChAVuoI4FZIVAVoiwcCyEBTgWGAJ1LLAQhAUIC9xAHQvICoGsEGHhWAgLcCwwBOpYYCEICxAWuIE6FpAVAlkhwsKxEBbgWGAI1LHAQhAWICxwA3UsICsEskKEhWMhLMCxwBCCrWOFOAGwJJQQMvckcksIC7zQlcw9cppSkqGwaejyW1dCKmIsskJiLPAoK1yZ6F0RYzWbY0VX5G1krQiLodBmx1qxd6oVayEsa5n0XUu1nIqhEJatLFlcqZJYi2wkrwRwSe2hUCmlX1cVPXHVk65AexKq51I4FVmh546FpsgK/RkKwQbHCvTd6wXvSmoVS4B7Pvb3lU0TG4ixStvqE2vRE3c9mVzRXqrGhkJCd/AjxkJXsExqlxuEIjUEX4J3AO8dS5Q4lqo7+XRFA0Op0yCtR6SQ60XgY0tZN4q9CdVtrGTpkgq46/lzqUUBRI8qjKo8Nhp0o6Q3rSZ9RvErc85Ig8LSJBKTdMKUM8KfdMAXEBYgLEBY0OTULjfkJzRnQ36pQQ2+2Buoc2w06UZJb6i8A0MhICxAWAAICxAWICwAhAUICxAWAMIChAUIaxEy0f337L83ubAaj3PkwAthrdm07+bezV/ieEGDtEUaa/fgd+Z+OHZexNePzT/Wi6k7HbNtmehzF7etH4uvfyd0S3TeCa2eW2gQXz8lwu8MrL3T1taxZpbDjGPVISx6OtaWbnhv9ZavitCWIxlnrf2PorNn9apNJV/19V5H74fEdO//OrfMcJQRVj3eHRHbNt6bKW4YPy+mxVfE+UvO2vnN4gviwgVxs6TBRTHfPPrTIxhWM1I10a/qasxcg9QvXtgm3pqJi4TIPpynEzfbtxfWhLN84mZpg+GMnN0uTq5O1f6PwSYqdRS6a4scMZH6y7cyYvgxkdrjCE2UPon8cqs4uV3kfC1zPbumUpG1208s9v+CHai7O1ZNATw9dzSyduNbM0/P/W1u07whjYY+MTod3fTXa0/kHauz56x4dHS6Y9vXd/U4DdoefaMl0vt2ckf77zju9gtLLi3G+s2fX7hn9xuXxOundrc7G/67Z2RMjJ2eleJkrsXYmc/Pjk6LPzz0VNhZf332tBKTn7t+4PSrHHZiLHfXwjxx5uJ9O07XCs4dEwuQVIxTG6xjLUtYsXSmte3dcK3yROtckLuZHOpbx8kOVFjLupeOk+7V0pXIBLqXN4aiQ2uvcraDpKryno4Yv0/JrQd+8PynftbG2V05qmRTR1gqXcA4od3Y2n9LHPryMwcHON/aCSstI3mME1bWr25ln17b1/IiygpOWI3Ox4rP0/j7BDet5sZQf67S/9SFkdK+eNAj5gq5oOGJfoksBhzZ5K/68p+d8K65fyII/YVV+NTGHfvKuZizIhbW4mJhzXmh9FH2YlVz7xge6i/UGcK9vx7PfSbiRdstf8/8ouY7ZSSuyw3xxPy//FO8uCW/MbeYiCcqf6nwoqhu7tnepI5FS8b6den9q8N1epGosTea7pTljjUfY80frLIDlij8KGwveT3rFHHnUda+/Ih7e/xjH5w+XlybSE+Fyy2ruos1eqHbTlnuWIm7RbEu3d+fweKxzJGjvfk/54yPTnUX1JCo8f6Ju3dIi51qjqGw3ifSGQKW+X94QHjP4EjG8amJzoKuGnp/jXeqGYL38s9mfPHP67xRJOpHG758vsN9DwzO/0FpvExX9RLauBk7ZZFjLTbfM5EbRhLx0vNVvlYRvCaqBp7qLZ7FWal/D/auq/Qr5/2q3zNRmIah906Zx7JmNwhNk5/00Z1He7qX3P044nCNl7Mb4toGFR096YZ0ZdRONZdj6QoT/YJ2LEuFBUELiy8FAa3KDQAICxAWWEJ1uYFL4cEDuEkTMBQCwgKEBYCwAGEBwgJAWICwAGEBICxAWICwABAWICxAWADe8H9WaLyEJYO5bQAAAABJRU5ErkJggg==</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>